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ABSTRACT 
Jill Camille Rau:  The Engineering of Serpins for Vascular Application 
(Under the direction of Frank C. Church, Ph.D.) 
 
  “The Engineering of Serpins for Vascular Applications” contributes to the 
understanding of serine protease inhibitors (serpins) in cardiovascular disease, the 
relationship between their structures and activities, and the manipulations of those structures 
for the benefit of medicine.   
 Chapter 1 presents a comprehensive overview of serpins’ structure-activity 
relationships, pathophysiology and their roles in thrombosis, hemostasis and fibrinolysis.   
Chapter 2 establishes the co-localization of (pro)thrombin with heparin cofactor II (HCII) in 
the core of atherosclerotic plaques and demonstrates a positive correlation between the 
presence of HCII, (pro)thrombin or antithrombin (AT) and lesion severity.   Additionally, 
these results indicate that atheromas may act as a non-specific watershed for plasma proteins 
and should serve as a warning against assumptions that (co-)localization of protein in 
atheromas implies a pathophysiologic role in atherosclerosis.   
Chapter 3 utilizes a gain-of-function approach to examine glycosaminoglycan 
(GAG)-binding in serpins.  An α1-protease inhibitor (α1PI) mutant, α1PIPitt-GAG, containing 
five basic residues homologous to the HCII D-helix was shown to have HCII-like GAG-
accelerated thrombin inhibition. Results confirm the benefit of using a gain-of-function 
approach to the study of serpins. The finding that GAG-binding and associated functionality 
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can be added to a non-GAG binding serpin has exciting implications for the engineering of 
serpins for biomedical purposes.  
In Chapter 4, a chimeric serpin, HATpin, was engineered with intent to create a 
potent anti-thrombotic, anti-inflammatory, anti-atherogenic protein.  HATpin was designed 
to comprise 1) the reactive center loop of AT for specificity of thrombin and factor Xa  over 
activated protein C;  2) the N-terminal acidic domain of HCII to utilize thrombin exosite 1 
for specific thrombin inhibition;  3) the GAG-binding region of HCII to target it to areas of 
vascular injury; 4) on an α1PI backbone. Although HATpin was successfully created, its 
inhibitory profile failed to meet expectations.  The results from Chapter 4 illustrate our need 
for a better understanding of serpin structural domain interactions and challenge the concept 
that serpin domains are strictly modular building blocks that can be exchanged without a 
contextual effect. 
Finally, Chapter 5 outlines additional future studies that can be pursued based on 
questions that arose during the completion of this dissertation. 
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INTRODUCTION 
Vascular Pathophysiology and Serpin Engineering 
 
Implications of Cardiovascular Disease 
Cardiovascular disease (CVD) is the leading cause of death in the United States1. It 
was responsible for over 800,000 deaths, more than 33% of deaths in the U.S in 20072. 
Worldwide, CVD is responsible for more than seven million deaths each year3.   It has been 
estimated that at an average of one in three Americans have one or more types of 
cardiovascular disease (over 80 million), only 47% of whom are 60 years old or more.  The 
economic burden in the United States alone is expansive, estimated at over $400 billion 
dollars for 2008 in direct and indirect costs1.  The personal burdens are incalculable. 
 
Cardiovascular Disease Components 
CVD is an aggregate of interrelated pathological conditions affecting the 
cardiovascular system.  The Center for Disease Control has categorized the most commonly 
occurring conditions of CVD as coronary heart disease (CHD also known as coronary artery 
disease), stroke, heart failure, high blood pressure, and diseases of the arteries/peripheral 
artery disease. Eighty-six percent of all deaths from CVD are due to these causes2. CHD 
accounts for over 50% of deaths from CVD.   It is caused primarily by atherosclerosis of the 
coronary arteries.  Similarly, peripheral vascular disease can also be attributed predominantly 
to atherosclerosis, but in the peripheral arteries, commonly those of the legs and pelvis. The 
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most commonly occurring type of stroke, ischemic stroke, accounting for over 80% percent 
of strokes, is frequently caused by atherosclerosis of the carotid or cerebral arteries4.  Heart
failure and high blood pressure have numerous underlying causes, but atherosclerosis often is 
a key contributor.  Thus, understanding and combating atherosclerosis is critical to reduction 
of the devastation of CVD. 
 
Atherosclerosis Overview 
Atherosclerosis is a chronic inflammatory process affecting the innermost layer of the 
arterial wall, the intima.  While there are many contributing causes to the development of 
atherosclerosis, prevailing theory favors a combination of high plasma concentrations of low-
density lipoprotein (LDL) concentration and endothelial cell dysfunction as the principle 
initiators of atherosclerosis5,6. A very basic description of the pathogenesis of atherosclerosis 
includes the initiation of a cascade of inflammatory events by increased LDL levels that 
begins with endothelial cell activation7 in areas susceptible due to hemodynamic stress8-10. 
This induces the expression of surface receptors and adhesion molecules and which recruit 
monocytes and other inflammatory cells and facilitate their entry into the vascular intima11.  
Simultaneously, endothelial permeability to LDL is increased resulting in intimal 
accumulation of LDL7.  Bound to the extracellular matrix, LDL can be enzymatically 
modified or oxidized. The resultant LDL species, are considerably more pro-inflammatory 
than native LDL12; they release phospholipids which can activate platelets and induce smooth 
muscle cells and endothelial cells to release additional cytokines13.  These cytokines have a 
multitude of pro-inflammatory effects including the differentiation of monocytes to 
 3 
 
macrophages14.  Mature macrophages ingest the LDL creating foam cells, macrophages 
packed with lipid droplets.  This is the first histopathological identifier of an early 
atheroma15.  The foam cells and other recruited cells continue to express inflammatory 
signals, stimulating smooth muscle cell proliferation and migration.  A fibrous cap of matrix 
proteins, rich in collagen I and interspersed with smooth muscle cells, may form over the 
accumulation of foam cells which often necrose and form the lipid-rich necrotic core of a 
more advanced atheromatous plaque16.  The intima, thickened with increased cellularity and 
matrix deposition, may impinge on the vascular lumen.  Consequently, this stenosis can 
cause ischemia of the region fed by blood flow through this artery, resulting in heart attack, 
stroke and claudication.  However, this atherosclerosis is a relatively slow chronic process.  
Collateral blood flow is often able to compensate for such restrictions.  Therefore heart 
attacks and stroke are not frequently the result of arterial stenosis from atherosclerosis.  More 
commonly, at least 70% of the time, they are due to arterial blockage by a thrombus formed 
from plaque rupture or erosion of the endothelium17. 
 
Atherosclerotic Plaque Rupture 
A thin fibrous plaque and an abundance of activated inflammatory cells mark the 
plaques most vulnerable to rupture18. The persistent stimulation of accumulated 
inflammatory mast cells, T-lymphocytes and macrophages results in the secretion and 
activation of matrix metalloproteases, which degrade the integrity of the collagen rich matrix 
of the fibrous cap and induces apoptosis of smooth muscle and endothelial cells19.  Together, 
this weakens the stability at the surface of atheromatous plaque20. 
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Progressive endothelial cell dysfunction reduces the ability of the endothelium to 
properly produce nitric oxide (NO)19.  NO has many properties including, vasodilation, and 
inhibition of smooth muscle cell proliferation, platelet aggregation and leukocyte adhesion8.  
In normally functioning endothelial cells, NO is released by activation of specific receptors 
and by shear stress. In atherosclerotic conditions, which include a dysfunctional endothelium, 
intimal thickening (potentially protruding into the intima) and a thick fibrous cap with 
decreased flexibility, shear stress is increased in the region of the atheroma.  However, NO is 
not released in response.  Thus, vasodilation does not occur, the vascular lumen remains 
constricted, and inflammatory processes remain unmediated by NO.  Additionally, increased 
shear stress itself can promote local inflammation9.   
With increased shear stress at the luminal surface and inflammatory cells eroding the 
fibrous cap from the inside, the interface between the blood and the intima is diminished and 
destabilized.  When a plaque does rupture, tissue factor that is located on macrophages, lipid 
rich microparticles and smooth muscle cells within the atherosclerotic core is exposed to the 
blood18.  This initiates a series of enzymatic reactions which promote blood clotting. (See 
Chapter I for a more detailed description of coagulation.)  Ultimately, thrombin, the most 
crucial protease in coagulation is activated and a thrombus is formed. Thrombi formed from 
exposure of the lipid-rich core of advanced atheromas are up to six times greater in size than 
those formed from exposure to non-atherosclerotic vessel intima21; thus, increasing the 
likelihood of vascular occlusion and clinical events. 
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Atherosclerotic Plaque Erosion 
In some cases of sudden death from coronary thrombosis, plaque rupture or exposure 
of the lipid rich atherosclerotic core to blood has not occurred. Rather, superficial erosion of 
the endothelium results in occlusive thrombus formation.   The frequency of myocardial 
infarction and death due to atherosclerotic plaque erosion versus plaque rupture is 
controversial with percentages reported from 44%17 to only 9%22-24. Regardless, tissue factor, 
normally shielded from the blood by the endothelium, is exposed to coagulation factors, 
thrombin is generated and an occlusive thrombus forms. 
 
Non-Atherosclerotic Thrombosis: Venous Thrombosis and Atrial Fibrillation  
Thrombus formation, or thrombosis, in non-atherosclerotic vessels is also a critical 
health concern.  Venous thrombosis affects over 900,000 people in the United States each 
year and causes over 300,000 deaths25,26  Additionally, atrial fibrillation which has a 
morbidity of over 2.2 million people in the United States carries the significant risk of 
thrombosis and thromboembolism, and  itself is a leading risk factor for ischemic stroke27.  In 
both venous thrombosis and atrial fibrillation, the most significant health threat is from 
emboli separated from thrombi that travel to the lungs (from deep vein thrombosis) or the 
brain (from the atrium) resulting in the severe consequences of pulmonary embolism and 
ischemic stroke.  
The pathophysiologic mechanisms driving venous thrombosis are less understood 
than arterial thrombosis.  The established perspective on the causes of venous thrombosis has 
centered on Virchow’s triad28,29 which ascribes thromogenesis to a combination of 
hemodynamic stasis or altered blood flow, intimal injury or endothelial dysfunction, and 
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hypercoagulability.  Thrombosis in atrial fibrillation is generally attributed to the same 
causes with particular emphasis on “stasis”30.  Fibrillations of the heart alter the natural flow 
of blood through the atrium leading to intimal injury and alteration in protein expression of 
the endothelium which upsets the hemostatic balance resulting in thrombus formation in the 
atrium31.  In venous thrombosis, the inciting element is less apparent; any component of 
Virchow’s triad can lead to the other.  In the past decade however, an emphasis on 
inflammation in venous thrombosis has emerged25,32,33.   
As described above the endothelium is a producer of numerous regulatory molecules 
that modulate vascular flow, leukocyte adhesion, migration and activation. It is also 
vulnerable to the cytokines and proteases released by inflammatory cells19,34. Under normal 
conditions endothelium also produces thrombomodulin and tissue factor pathway inhibitor, 
potent anticoagulant molecules.  When distressed the endothelium releases many 
thrombogenic agents including platelet activating factor, von Willibrand factor, plasminogen 
activator inhibitor-1 (PAI-1) and factor V25.  Both locally and systemically, inflammation is 
associated with an increased risk of thrombosis35.  This is evidenced by the many conditions 
of inflammation in which there is an increased risk of thrombosis such as in sepsis and 
cancer36-38.  Thrombosis eventually occurs when an imbalance between pro-coagulant and 
anti-coagulant and also between pro-fibrinolytic and anti-fibrinolytic elements (See Chapter 
1 for more details on coagulation and fibrinolysis.) is tipped in favor of those pro-coagulant 
and antifibrinolytic. 
Therefore, pharmocotherapies aimed at the treatment of prevention of venous 
thrombosis, pulmonary embolism and thromboembolic stroke focus on re-establishing the 
balance and are either profibrinolytic or antithrombotic.  Fibrinolytics are used only acutely 
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as they associated with severe side effects39.  Antithrombotics however, are widely used and 
are the most common treatment for those at risk of venous thrombosis and atrial 
fibrillation40,41.  Ultimately they target a reduction in thrombin generation. 
 
Thrombin in vascular inflammation 
In addition to its prominent role in cardiovascular disease as the essential protease in 
thrombosis, thrombin has many pro-inflammatory functions and plays a central role in 
vascular lesion formation42,43.  It regulates inflammatory processes including leukocyte 
adhesion molecule expression on endothelium, platelet activation, leukocyte chemotaxis and 
endothelial production of pro-thrombotic factors.  Thrombin is also a potent growth factor, 
initiating endothelial, fibroblast and smooth muscle cell proliferation and upregulating other 
cytokines and growth factors35,44.  Because of its role in both atherosclerotic development 
and thrombus formation, the study of thrombin and its regulators is pertinent to the 
understanding of cardiovascular disease.  
 
Thrombin and its inhibitors in CVD 
Thrombin is a serine protease.  Its cellular effects occur largely through its cleavage 
of the G-coupled protein receptors, protease activated receptors -1 and -4 (PAR-1 and PAR-
4).  In order for thrombin to cleave PAR-1 or PAR-4, it must be in its native form with the 
active site intact. Similarly, in order to promote thrombosis, thrombin must be proteolytically 
active, maintaining its structural integrity.   
Serine protease inhibitors (serpins) are a family of proteins classified by their 
homologous structure. The majority of the family members inhibit serine proteases. Several 
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serpins are capable of inhibiting thrombin: antithrombin (AT), heparin cofactor II (HCII), 
protease nexin-1 (PN-1), plasminogen activator inhibitor (PAI-1), and protein C inhibitor 
(PCI). All of these serpins utilize a similar mechanism to inhibit thrombin (described in more 
detail in Chapter 1) in which thrombin cleaves the reactive site of the serpin forming a 
covalent bond between the molecules and releasing the serpin from its metastable state. This 
translocates thrombin to the opposite pole of the serpin, inducing a strain on the protease 
causing its inactivation. AT and HCII are particularly relevant to the inhibition of thrombin 
in cardiovascular disease.  AT is the predominant thrombin inhibitor in coagulation45, and 
HCII has been shown to be protective against atherosclerosis46-50.  
 
Serpin Engineering for Vascular Applications 
This dissertation is focused on understanding and utilizing serpins, HCII in particular, 
for the purpose of combating cardiovascular disease.  Chapter 1 provides an overview of 
serpins in hemostasis, thrombosis and fibrinolysis51. It describes their biological functions, 
mechanisms of action, key structural components, and pathophysiological consequences of 
their dysfunction. Chapter 2 focuses on the role of HCII in atherosclerosis, examining its 
presence in atherosclerotic plaques.  Chapter 3 investigates a unique gain-of-function 
approach to serpin engineering, utilizing the prototypical serpin α1-protease inhibitor, α1PI, 
as a scaffold for the addition of HCII-like structural components.  This study shows that 
HCII-like activity can be conferred upon α1PI through the mutation of specific homologous 
residues.  Chapter 4 describes the design, creation and properties of a novel serpin created 
through domain engineering.  The novel serpin named HATpin was designed to incorporate 
beneficial elements of both AT and HCII on α1PI in an attempt to create a superior thrombin 
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inhibitor to battle cardiovascular disease.  Chapter 5 discusses the major findings within the 
dissertation and describes additional directions that would be interesting for investigation 
based on this work. 
Overall, this dissertation represents the culmination of five years of work and learning. 
It illustrates the facets of serpin structure and activity and contributes to the understanding of 
serpins and their engineering for the amelioration of the burdens of cardiovascular disease. 
 
  
 
CHAPTER 1 
Serpins in Thrombosis, Hemostasis and Fibrinolysis 
Jill C. Rau‡, Lea M. Beaulieu‡, James A. Huntington and Frank C. Church 
‡These authors contributed equally to the review. (2007) J. Thromb. Haemost.  
5: Suppl. 1, 102-115. 
 
SUMMARY 
Hemostasis and fibrinolysis, the biological processes that maintain proper blood flow, 
are the consequence of a complex series of cascading enzymatic reactions. Serine proteases 
involved in these processes are regulated by feedback loops, local cofactor molecules, and 
serine protease inhibitors (serpins). The delicate balance between proteolytic and inhibitory 
reactions in hemostasis and fibrinolysis, described by the Coagulation, Protein C and 
Fibrinolytic Pathways, can be disrupted resulting in the pathological conditions of thrombosis 
or abnormal bleeding. Medicine capitalizes on the importance of serpins, using therapeutics 
to manipulate the serpin-protease reactions for the treatment and prevention of thrombosis 
and hemorrhage. Therefore, investigation of serpins, their cofactors, and their structure-
function relationships is imperative for the development of state-of-the-art pharmaceuticals 
for the selective fine-tuning of hemostasis and fibrinolysis. This review describes key serpins 
important in the regulation of these pathways: antithrombin, heparin cofactor II, protein Z-
dependent protease inhibitor, α1-protease inhibitor, protein C inhibitor, α2-antiplasmin and 
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plasminogen activator inhibitor-1. We focus on the biological function, the important 
structural elements, their known non-hemostatic roles, the pathologies related to deficiencies 
or dysfunction, and the therapeutic roles of specific serpins. 
 
INTRODUCTION 
Blood flow is maintained by the proper balance of hemostasis and fibrinolysis, an 
interdependent network of physiologic processes and succession of proteolytic reactions.  
Hemostasis, the physiologic cessation of bleeding, involves the interaction of 
vasoconstriction, platelet aggregation and coagulation. The end result of coagulation is the 
deposition of cross-linked fibrin polymers to form blood clots.  Both the Protein C and the 
Fibrinolytic Pathways are activated by the Coagulation Pathway and serve to restrict 
excessive clot formation or thrombosis.  The enzymatic reactions that propel these pathways 
are dominated by serine proteases and are subject to control by serpins and their local 
cofactors.  Dysfunction, deficiencies or over-expression of serpins can cause either abnormal 
bleeding or thrombosis. Investigations into the structure and related activities of serpins, their 
target proteases and cofactors has provided valuable information regarding both serpin-
related disease states and potential mechanisms by which medicine can manipulate serpin-
protease interactions for the treatment and prevention of thrombosis and bleeding. 
 
HEMOSTASIS 
Coagulation Pathway  
 The factors of the Coagulation Pathway generally circulate in an inactive state until 
they are activated through proteolysis by an upstream factor. While the end goal of 
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coagulation is fibrin polymerization, the most crucial feature of the Coagulation Pathway is 
the generation of thrombin (Figure 1.1).  Thrombin is responsible for cleaving fibrinogen to 
fibrin, activating fXIII to fXIIIa (which cross-links fibrin), activating platelets, and positively 
feeding back into the cycle by activating upstream factors52.  
Thrombin generation is initiated when damage to a vessel wall exposes the blood to 
tissue factor (TF) in the subendothelium53.  TF is also expressed by activated platelets and 
leukocytes54. Therefore, coagulation can also be initiated by inflammation. TF forms a 
complex with fVIIa and activates fX.  Together, fVa and fXa form the prothrombinase 
complex which then cleaves a small amount of prothrombin (fII) to thrombin (fIIa).  This 
small amount of thrombin activates platelets, fV, fVIII and fXI, feeding back into the cycle to 
increase thrombin formation.  Factor IXa, previously activated by either TF-VIIa or by fXIa 
on the platelet surface, and fVIIIa in the presence of calcium, complex on the platelet surface 
to form the platelet tenase complex.  Platelet tenase activates more fX, which with fVa, 
generates a “thrombin burst” (Figure 1.1). It is this burst of thrombin rather than the initial 
thrombin activation that is crucial for the formation of a stable hemostatic plug53. 
In addition to its role in hemostasis, thrombin regulates many pro-inflammatory 
processes including leukocyte adhesion molecule expression on the endothelium, platelet 
activation, leukocyte chemotaxis and endothelial cell production of pro-thrombotic factors55.  
Thrombin is also a potent growth factor, initiating endothelial, fibroblast and smooth muscle 
cell proliferation and up-regulating other cytokines and growth factors42.  These activities 
have been attributed to proteolytic cleavage of insulin-like growth factor binding proteins56 
and  protease activated receptors -1, -3, and -4 (PAR-1, -3, -4)57 on cell surfaces, and account 
for thrombin’s central role in atherosclerotic lesion formation43.  
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Figure 1.1.  Serpin Regulation of Coagulation, Protein C and Fibrinolytic Pathways.  Serpins and 
inhibitory functions are shown in red, thrombin activity is shown in cyan. Prothrombinase and tenase 
complexes are shown in grey boxes. Coagulation is initiated by the exposure of tissue factor to fVIIa 
shown in grey oval. The symbol  indicates degradation. Necessary cofactors, Ca++, phospholipids, 
proteins S and Z, vitronectin and GAGs are not shown to maintain the simplicity of the schematic. 
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 Coagulation is regulated predominantly by antithrombin (AT)45, tissue factor 
pathway inhibitor (TFPI)58, the Protein C Pathway59 and to a lesser extent heparin cofactor II 
(HCII)48 and protein Z-dependent protease inhibitor (ZPI)60.  Protein C inhibitor (PCI) and 
plasminogen activator inhibitor (PAI-1) may also contribute by inhibiting thrombin61,62.  
TFPI is not a member of the serpin family and so will not be discussed in this paper. 
 
Protein C Pathway  
The Protein C Pathway works in hemostasis to control thrombin formation in the area 
surrounding the clot63.  The zymogen protein C (PC) is localized to the endothelium by 
endothelial cell protein C receptor (EPCR)64. Thrombin, generated via the Coagulation 
Pathway, is localized to the endothelium by binding to the integral membrane protein, 
thrombomodulin (TM).  TM occupies exosite I on thrombin which is needed for fibrinogen 
binding and cleavage, thus reducing thrombin’s pro-coagulant activities65.  However, TM 
bound thrombin is able to cleave PC to activated protein C (APC), a serine protease, on the 
endothelial cell surface66. In the presence of protein S, APC inactivates fVa and fVIIIa67 
(Figure 1.1).  This limits further thrombin generation on the clot periphery where the 
endothelium is not damaged35. 
The Protein C Pathway is also associated with non-hemostatic functions. APC has been 
shown to be an anti-inflammatory protein68,69 and modulates gene expression70.  It also 
enhances vascular permeability by signaling through both PAR-1 and sphingosine 1-
phosphate receptor-171. Using focal ischemic stroke animal models, APC treatment restored 
blood flow, reduced infarct volume and inflammation72. These neuroprotective effects of 
APC were shown to be mediated through EPCR, PAR-173, and PAR-374.  In the PROWESS 
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Study, patients diagnosed with severe sepsis were treated with recombinant human APC, 
resulting in a mortality reduction of 19.4%75. 
The proteolytic activity of APC is regulated predominantly by protein C inhibitor 
(PCI)45.  Additionally, plasminogen activator inhibitor-1 (PAI-1)76 and α1-protease inhibitor 
(α1PI)77 have been shown to inhibit APC, although their role in the hemostasis is not well 
understood.   
 
FIBRINOLYSIS -- 
Fibrinolytic Pathway  
Fibrinolysis is the physiologic breakdown of fibrin to limit and resolve blood clots78.  
Fibrin is degraded primarily by the serine protease, plasmin, which circulates as a zymogen, 
plasminogen. In an auto-regulatory manner, fibrin serves as both the cofactor for the 
activation of plasminogen and the substrate for plasmin (Figure 1.1).  In the presence of 
fibrin, tissue plasminogen activator (tPA) cleaves plasminogen to plasmin which proteolyzes 
the fibrin. Because it is a necessary cofactor for the reaction, the degradation of fibrin limits 
further activation of plasminogen79-81. The serine protease, tPA, is synthesized and released 
by endothelial cells78.  In addition to binding fibrin, tPA binds Annexin II (AnII) and other 
receptors on endothelial cell and platelet surfaces82. Thus, plasmin generation and 
fibrinolysis are restricted to the site of thrombus formation. 
In addition to its role in fibrinolysis, plasmin has other physiologic functions as 
evidenced by its ability to degrade components of the extracellular matrix83 and activate 
matrix metalloproteases 2 and 984,85.   Plasminogen can also be converted to plasmin by the 
serine protease, urokinase plasminogen activator (uPA)83.  Urokinase-catalyzed events are 
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localized on the cell surface through the uPA receptor (uPAR).  Complex formation and 
subsequent reactions are thought to be more important during pericellular proteolysis, cell 
adhesion and migration than it is for vascular fibrinolysis78. These additional functions 
contribute to the role of the Fibrinolytic Pathway in cancer83,86,87. 
Fibrinolysis is controlled predominantly by α2-antiplasmin (α2AP)88, PAI-179,89 and 
thrombin activatable fibrinolysis inhibitor (TAFI)90.  PCI can inhibit tPA and uPA91,92, but its 
role in fibrinolysis is unclear. TAFI is not a member of the serpin family and so will not be 
discussed in this paper. 
 
SERPIN OVERVIEW 
Serpins  
  Serpins are a superfamily of proteins classified into 16 clades (A-P). The systematic 
name of each serpin is, SERPINXy where X is the clade and y is the number within the 
clade93. Serpins have been identified in the genomes of organisms representing all of the 
branches of life (Bacteria, Archaea, Eukarya and Viruses), and the genome of humans 
contains ~36 serpins94.  While serpins are named for their ability to inhibit serine proteases 
(of the chymotrypsin family) (Table 1.1), some are capable of cross-class inhibition of 
proteases from the subtilisin, papain and caspase families. In addition, some serpins utterly 
lack protease inhibitory activity and serve other roles, such as hormone transporters, 
molecular chaperones or catalysts for DNA condensation.  Serpins are typically composed of 
~400 amino acids, but can have large N-, C-terminal or internal insertion loops93. Serpins can 
also be post-translationally modified by glycosylation, sulfation, phosphorylation and 
oxidation to alter their function. In spite of a low overall primary sequence identity for the 
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Table 1.1. Second Order Rate Constants of Protease Inhibition by Serpins  
in the Presence and Absence of Cofactors.a 
SERPIN SYSTEMATIC NAME 
TARGET 
PROTEASE COFACTOR 
SECOND ORDER 
RATE k2 (M-1 s-1) 
CITATION 
AT SERPINC1 
thrombin 
-- 7.5 x 103, 1 x 104 95,96 
UFH 2 x 107, 4.7 x 107 95,97 
LMWH 5.3 x 106 97 
pentasaccharide 2 x 104 96 
fXa 
-- 2.5 x 103, 6 x 103 98 
UFH 5 x 106, 6.6 x 106 96,97 
LMWH 1.3 x 106 97 
pentasaccharide 7.5 x 105 96 
fIXa 
-- 1.3 x 102, 5 x 102 96,99 
UFH 8 x 106, 1.75 x 106 96,99 
LMWH 3.7 x 105 99 
pentasaccharide 3 x 104 96 
HCII SERPIND1 thrombin 
--  6 x 102 95 
UFH  5 x 106 95 
LMWH ~ 5 x 106 100 
dermatan sulfate 1 x 107 95 
hexasaccharide    2 x 104 101 
ZPI  SERPINA10 
fXa  -- , Ca++, PL 2.3 x 103 102 
 protein  Z, Ca
++, 
PL 6.1 x 10
5 102 
fIXa -- 2 x 10
5 103 
UFH 4 x 105 103 
PCI SERPINA5 
thrombin 
-- 1.7 x 104 104 
UFH ~2 x 105 104 
thrombomodulin 2.4 x 106 104 
APC -- 3 x 10
2 105 
UFH 5 x 104 105 
 UFH, Ca++ 2.9 x 105 106 
tPA (2-chain) -- 8 x 102 91 
 UFH 3 x 104 91 
α1PI SERPINA1 thrombin -- 4.8 x 10
1 107 
APC -- 4 x 101 108 
α1PIPittsburgh  thrombin  4.8 x 10
5 109 
APC  7 x 104 109 
α2AP SERPINF2 plasmin  2 x 107 88,110 
PAI-1 SERPINE1 
thrombin -- 7.9 x 102 62 
 UFH 1.6 x 105 111 
 vitronectin 1.9 x 105 111 
APC -- 5.7 × 102 76 
 vitronectin 1.8  × 105 76 
tPA(1- , 2-chain) -- 4 x 107, 1.5 x 108 112 
aThe rates constants indicated here are from selected references and may vary slightly under 
different experimental conditions. UHF = Unfractionated heparin, LMWH = low molecular 
weight heparin, PL = phospholipids. 
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family, serpins share a highly conserved three-dimensional fold comprised of a bundle of 9 
α-helices (A-I) and a β-sandwich composed of three β-sheets (A-C) (Figure 1.2A). It is 
useful to view a serpin in the ‘classic orientation’ to illustrate the important structural 
features (Figure 1.2A, left panel). In this view the main β-sheet A is facing and the reactive 
site loop (RSL) is on top. The RSL is typically composed of 20 amino acids running from 
P17 at the N-terminus (at the C-terminal end of strand 5A) to P3′ at the C-terminal end (using 
the nomenclature of Schechter and Berger, where residues are numbered from the scissile P1-
P1′ bond). In the normal native state of a serpin, β-sheet A is composed of five strands and 
the RSL (bridging the C-terminus of strand 5A to the N-terminus of strand 1C) is exposed. 
This state is, however, not the most stable. An astounding increase in thermodynamic 
stability (best estimate -32 kcal/mol)113 can be achieved through the incorporation of the RSL 
into β-sheet A, triggered either through extension of strand 1C (to form the so-called ‘latent’ 
state), or through proteolytic nicking anywhere near the scissile bond (the cleaved state).  The 
metastability of the native serpin is critical for its unusual mechanism of protease 
inhibition114). 
 
The Serpin Mechanism of Protease Inhibition  
 The serpin mechanism of protease inhibition has been worked out over the last 20 
years through a series of biochemical, fluorescence and structural studies. A minimalist 
kinetic scheme is composed of two steps: the formation of the encounter complex (also 
known as the Michaelis complex) where the sequence of the RSL is recognized by the 
protease as a substrate; and, the formation of a final covalent complex where the protease is 
trapped in an inactive state (Figure 1.2B). The rates of formation and dissociation of the  
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Figure 1.2. Serpin Structure and Mechanism of Protease Inhibition.  A. The shared serpin fold is 
illustrated by the structure of the prototypical native serpin α1PI. The ‘classic’ orientation shown on 
the left places the RSL (yellow) on top and the main β-sheet A (red) to the front. Sheets B and C are 
blue and orange, respectively, and helices A, D and H are colored green, cyan and magenta. The 
accessibility of the RSL is illustrated by rotating the molecule by 110° to the left along the long axis. 
It shows how the P1-P1′ (rods) scissile bond is exposed for proteolytic attack. Also clearer in this 
orientation are helices D and H which are the heparin binding helices. B. The serpin mechanism of 
protease inhibition is minimally expressed as a two step process. In the first step native serpin (ribbon 
with the P1 and P1′ residues as magenta balls, below) interacts reversibly with a protease (surface 
representation, colored according to temperature factors from blue to red) to form the Michaelis 
complex (middle). After formation of the acyl-enzyme intermediate the protease is flung to the 
opposite pole of the serpin and its catalytic architecture is destroyed, and consequently there is a loss 
of ordered structure (notice the smaller size and increase in temperature factors). 
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reversible Michaelis complex, along with colocalization in tissues, determines the specificity 
of the serpin-protease interaction115,116. While the obligate RSL-active site contacts 
contribute significantly to the formation of the Michaelis complexes, exosite interactions may 
also be involved. As with actual substrates of serine proteases, this step is followed by the 
nucleophilic attack of the peptide bond between the P1-P1′ residues by the catalytic Ser195 
of the protease. This ultimately results in the formation of a covalent ester bond between the 
P1 residue and Ser195 of the protease (acyl-enzyme intermediate), and then separation of the 
P′ residues from the active site of the protease. At this stage the serpin rapidly adopts its 
lowest energy conformation through the incorporation of the N-terminal portion of the RSL 
into β-sheet A. The tethered protease is thus flung from the top to the bottom of the serpin 
(~70Å), and the resulting pulling force exerted on the catalytic loop results in a 
conformational distortion of the protease117. The acyl-enzyme intermediate is thus trapped, 
with deacylation prevented largely due to the destruction of the oxyanion hole. Two 
structures of final complexes have been solved by X-ray crystallography118,119, with one 
showing an additional distortion of ~37% of the protease structure119. This mechanism is 
particularly well suited to tightly regulated processes such as hemostasis and fibrinolysis 
because inhibition is irreversible, and the conformational changes in the serpin and the 
protease alter cofactor interactions. An example of the physiologic relevance of the 
conformational change in the protease component of the complex is the complete destruction 
of thrombin’s exosite I in complex with serpins120. Thus, when PCI inhibits thrombin bound 
to thrombomodulin the interaction with thrombomodulin is broken, allowing the serpin-
protease complex to diffuse away so that another thrombin molecule can bind104. 
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Cofactor Interactions  
  Because serpin specificity is determined largely by the rate of formation of the 
Michaelis complex, cofactors which bind to serpins (and sometimes the protease) can 
radically alter specificity115.  Table 1.1 presents serpin second order rates of protease 
inhibition in the presence and absence of relevant cofactors. The best understood cofactor for 
serpins is the glycosaminoglycan (GAG), heparin. It binds to and activates most of the 
serpins involved in hemostasis and thrombosis121. Acceleration of protease inhibition is 
generally conferred through a template effect where the protease and the serpin bind to the 
same heparin chain. The hypothesis is that this co-occupation will limit the diffusional 
freedom from three to one dimension to increase the likelihood (rate) of encounter. In 
addition, heparin also provides a bridge between the serpin and the protease to help stabilize 
the Michaelis complex. However, heparin and other GAGs are also capable in some cases of 
altering the conformation of the serpin to permit more rapid complexation with proteases. 
The best-characterized examples are AT and HCII, whose activation by heparin is the basis 
of its therapeutic anti-coagulant effect. In the next sections we describe each of the serpins 
involved in hemostasis and fibrinolysis, their targets, the role of cofactors and available 
structural data. 
 
SERPINS IN HEMOSTASIS AND FIBRINOLYSIS 
Antithrombin – SERPINC1 
Antithrombin (AT) is a 58 kDa, 432 amino acid glycoprotein122, synthesized in the 
liver, circulating at approximately 150 μg/mL with a half-life of ~3 days123. It is the most 
important physiologic inhibitor of the coagulation pathway124.  As its name implies, 
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antithrombin inhibits thrombin.  Additionally, AT is capable of inhibiting all of the other 
proteolytic coagulation factors (e.g. factors IXa, Xa, and XIa). The predominance of its anti-
coagulant activity, however is focused on the regulation of fXa, fIXa and thrombin. 
Measurement of thrombin-AT (TAT) complex is used as a marker of hemostatic activation 
and helps diagnose thrombotic events125. Thrombin bound to fibrin, clot-bound thrombin, is 
protected from inhibition by AT126. This may explain the occurrence of rethrombosis after 
fibrinolytic therapy as clot-bound thrombin is released from the dissolving hemostatic 
plug127. 
The anti-coagulant activity of AT is dependent on its cofactor, heparin. Consisting of 
variably sulfated repeating dissacharide units, heparin can have a molecular weight ranging 
from 3 to 40 kDa128-130.  A unique pentasaccharide sequence in heparin is responsible for the 
high affinity binding to AT131. In vivo, forms of heparin relevant to AT include heparan 
sulfate found on the endothelium, and heparin released from endothelium-associated mast 
cell granules. The interaction of AT with heparan sulfate on the endothelium and 
subendothelium localizes AT activity to the vessel wall and maintains its normal, non-
thrombogenic nature123. AT is expressed as both an α-form and a β-form. α-AT represents 
90% of AT and is glycosylated at all four positions.  While comprising only 10% of AT,  β-
AT, which is not glycosylated  at one position (N135), has a higher affinity for heparin and is 
thought to exert an overall larger anti-coagulant effect132. 
Heparin utilizes two distinct mechanisms for accelerating protease inhibition by AT. 
AT undergoes a well characterized conformational change upon heparin binding, which 
expels the N-terminus of the RSL from β-sheet A (Figure 1.3A). This ‘liberation’ of the RSL 
is sufficient to confer the majority of the acceleration of fIXa and fXa inhibition, but  
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Figure 1.3. Native and Complexed Serpin Structures.  A. The native structures of important 
hemostatic and fibrinolytic serpins are shown as ribbon diagrams, colored essentially as in Fig. 2. The 
monomeric structure of AT is shown in the left panel, and is similar to that of HCII with the partial 
insertion of the N-terminal portion of the RSL. A modeled position for the N-terminal tail of HCII is 
shown in magenta although its true position is not known. For AT, HCII and PAI-1 the heparin 
binding helix (helix D) is shown in cyan, but for PCI heparin binds to helix H (blue). The increased 
size and flexibility of the RSL of PCI is also evident from this depiction.  B. Some important serpin 
complexes are shown. Using S195A proteases it was possible to obtain the structures of the AT 
Michaelis complexes with thrombin (magenta) and fXa (magenta) with their activating synthetic 
heparins (SR123781 and fondaparinux, rods). Similarly, the HCII-thrombin (blue) complex was also 
solved. The somatomedin domain of VN (magenta) binds to s1A and helix E to prevent the latent 
transition through expansion of sheet A. 
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thrombin inhibition is not appreciably affected. Recently, the structures of the AT-heparin-
protease Michaelis complexes have been solved118,133,134 revealing the interactions behind the 
allosteric and template mechanisms (Figure 1.3B). 
In addition to its anti-coagulant activity, AT has been shown to have anti-
inflammatory and anti-angiogenic functions.   These properties are independent of AT’s 
inhibitory activity. AT  regulates inflammation by signalling through heparan sulfate on 
endothelial and leukocyte cell surfaces135.  Latent and cleaved AT exert anti-angiogenic 
effects136 by binding cell surface heparan sulfate.  This blocks fibroblast growth factor-2 and 
vascular endothelial cell growth factor from forming pro-angiogenic ternary signalling 
complexes with their protein receptors and the heparan sulfate co-receptors137. 
Antithrombin in Disease - Inherited and acquired AT deficiency predisposes individuals to 
different degrees of thrombotic disease. The severity of thromophilia can be exacerbated by 
other risk factors for thrombosis. Inherited AT is classified as type I or type II. Type I 
deficiencies, which generally confer a higher thrombotic risk, are caused by genetic 
mutations that impair the synthesis and secretion of AT.  Type II deficiencies are 
caused by genetic mutations that functionally impaired AT. Variations in the degree of 
thrombophilia in inherited AT deficiencies can be attributed to homozygosity versus 
heterozygosity and where the mutation lies in the AT structure138.  An up-to-date database of 
AT mutations can be found online at  http:// 
www1.imperial.ac.uk/medicine/about/divisions/is/haemo/coag/antithrombin139.  Some 
research suggests that certain mutations predispose AT to convert to its latent form, which 
preferentially dimerizes with native β-AT. Dimerization reduces the presence of highly 
active AT monomers, thus increasing thrombogenicity140.  Concern has been raised that 
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therapeutic preparations of AT-concentrates (contain >10% latent AT) might have 
thrombotic effects. However, a recent study demonstrated that the addition of latent AT alone 
does not decrease the activity of AT in plasma141. Other mutated forms of AT do not show 
impaired activity or decreased AT levels in the standard hospital laboratory assays despite 
associated thrombophilia. In particular, the antithrombin Cambridge II (A384S) variant was 
found to be undetected by some protocols, but estimated to be the most frequent cause of 
antithrombin deficiency in Caucasian populations142. These results suggest a need for 
alternative methods for detection of AT deficiencies143.   
Antithrombin related treatements for coagulation disorders-- Therapeutic 
unfractionated heparin (UFH), derived from porcine mucosa, is one of the most commonly 
used anti-coagulant agents administered for treatment and prophylaxis of thrombotic events.  
Additionally, UFH is used to coat blood collection tubes and surgical devices to prevent 
clotting on their surfaces.  UFH’s primary mechanism of action is to accelerate AT’s 
inhibition of thrombin, fXa and fIXa.  UFH also accelerates thrombin inhibition by other 
circulating serpins. It has a very short half-life and optimal dosing of heparin is notoriously 
difficult to achieve, therefore requiring frequent monitoring144.  Still in trials, an orally 
available form of heparin, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate bound heparin 
or SNAC-heparin, has dose-dependent antithrombotic effects, and  has an efficacy 
comparable to low-molecular weight heparin in reducing venous thrombosis in patients 
undergoing hip replacement surgery145. Contraintuitively, heparin can cause a dangerous 
thrombotic condition called heparin induced thrombocytopenia (HIT).  In this autoimmune 
reaction antibodies develop against platelets146.  Currently in development stages, synthetic 
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oligosaccharide heparin mimetics show thrombin and fXa inhibition comparable to UFH 
without inducing HIT and with far fewer side effects147. 
 Low molecular weight heparin (LMWH) is a fractionated preparation of heparin 
between 1 and 10 kDa with an enriched population of high affinity pentassacharide 
sequences.  Because of the smaller average size, LMWH acts predominantly by inducing 
conformational change in AT, the mechanism which activates fXa. It has a longer half-life 
than UFH and does not need coagulation monitoring. LMWH also has significantly reduced 
risk of HIT. Multiple LMWH variants are available or in clinical trials148.   
Fondiparinux and idraparinux are synthetic pentassacharide sequences derived from 
heparin, which activate AT to specifically inhibit fXa.  Because of this the single target, the 
side effect of over-anticoagulation, bleeding, is reduced. Both have longer half-lives than 
LMWH. Additionally, neither preparation causes HIT148,149.  
 Thrombotic events due to antithrombin deficiency are treated with AT purified from 
human plasma.  A covalent AT-heparin complex is currently under preliminary 
investigations for possible use as a novel anticoagulant because unlike AT or heparin alone, 
it is able to inhibit clot-bound thrombin150. 
 
Heparin Cofactor II – SERPIND1 
Heparin cofactor II (HCII) is a 66.5 kDa 480 amino acid glycoprotein, synthesized in 
the liver, circulating at ~80 μg/mL with a half-life of 2-3 days. HCII inhibits thrombin  in the 
presence of many polyanionic molecules including the GAGs heparin and dermatan sulfate48.  
A unique hexasaccharide sequence within dermatan sulfate has been determined to be 
responsible for its high affinity binding to HCII151.  Dermatan sulfate does not accelerate any 
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other serpin activity.  HCII has a unique N-terminal extension of ~80 residues that contains 
two acidic regions, critical for its GAG-associated anti-thrombin activity152. HCII inhibits 
thrombin and clot-bound thrombin, but not other coagulation proteases48. Evidence suggests 
that HCII contributes 20-30% to thrombin inhibition in coagulation.  Neither humans nor 
mice deficient in HCII exhibit thrombophilia under normal conditions153. However, HCII 
homozygous deficient mice form occlusive thrombi faster than wild-type mice after 
photochemical vascular endothelial cell injury to the carotid artery154. Recent data suggests 
that the primary physiologic function of HCII is to inhibit thrombin’s non-hemostatic roles 
such as in the development of atherosclerosis. Elevated levels of HCII are shown to protect 
against atherosclerosis and restenosis50,155,156. 
The structure of native HCII was solved in 2002 and revealed a surprising 
resemblance to native antithrombin152, with the N-terminus of the RSL inserted into β-sheet 
A (Fig. 3). As HCII also shares a similar heparin binding site along helix D45,157, it was 
proposed that HCII underwent a similar conformational change upon heparin binding152. 
Recently, it was shown that the smallest heparin length capable of tight binding to HCII was 
14 monosaccharide unit chains, and that the majority of the acceleration effect was due to 
this allosteric change in HCII conformation100. Disappointingly, however, the native structure 
could not resolve the position of the N-terminal extension. Several mutagenesis studies 
concluded that the acidic tail is binding to the basic heparin binding site in native HCII157, 
but it is still unclear how the tail interacts with the body of HCII in the native state. From the 
structure of HCII bound to S195A thrombin152 it was clear how the tail confers specificity to 
thrombin. The tail binds to exosite I of thrombin in a manner similar to the hirudin, primarily 
through hydrophobic contacts. The tail was found sandwiched between thrombin and the 
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body of HCII, essentially providing a shared exosite (Fig. 3B). A complex allosteric 
mechanism has been proposed based on these structures, supporting biochemical studies and 
analogy to AT116,121.  
HCII related treatements for coagulation disorders - As alternatives to heparin-
based treatments, dermatan sulfate derivatives and other polyanionic molecules that act to 
accelerate HCII’s antithrombotic activity are being investigated. They are of particular 
interest for use in HIT, AT deficiency and for the inhibition of clot-bound thrombin. Two 
types of fractionated dermatan sulfate enriched for the hexasaccharide sequence (Intimatan™ 
and Desmin™) have been tested in humans158,159. Intimatan is beginning Phase I trials. Other 
HCII agonists in laboratory investigations include over-sulfated dermatan sulfate160, 
fucosylated chondroitin sulfate161 and fucoidan162. 
 
Protein Z-dependent Protease Inhibitor– SERPINA10 
Protein Z-dependent protease inhibitor (ZPI) is a 72 kDa, 444 amino acid 
glycoprotein, synthesized in the liver, circulating at ~1.5 μg/mL. In the presence of protein Z, 
phospholipids and calcium, ZPI rapidly inhibits fXa.  In the absence of cofactors, ZPI also 
inhibits factor XIa, which can be accelerated two-fold by heparin. It is thought that the major 
physiologic function of ZPI is to attenuate the coagulation response prior to the formation of 
the prothrombinase complex103. In humans, mutations in ZPI are associated with increased 
risk of venous thrombosis163-165. Additionally, reductions in protein Z plasma concentrations 
result in an aggravated thromboembolic risk in humans and mice with  fVLeiden166. 
 
 
 29 
 
Protein C Inhibitor – SERPINA5 
Protein C Inhibitor (PCI) is a 57 kDa, 387 amino acid glycoprotein167, synthesized in 
the liver, circulating at ~5 μg/mL.  It is also found in other bodily fluids including urine, 
saliva, amniotic fluid, milk, tears and seminal fluid168. PCI is a heparin-binding serpin that 
inhibits many proteases  including APC169, IIa, IIa bound to TM104 tPA and uPA170. PCI may 
have contrary anti-coagulant and pro-coagulant functions depending on the target protease 
and the presence of specific cofactors. In the presence of heparin, PCI is anti-coagulant, 
inhibiting the proteolytic cleavage of fibrinogen by thrombin.  However, in the presence of 
TM, PCI is pro-coagulant, inhibiting the activation of PC by thrombin45.   
The structures of RSL-cleaved PCI167 and of native PCI (PDB # 2HI9 and # 2OL2) (Fig. 3A) 
have now been solved, revealing a typical serpin structure with some notable differences. 
The RSL of PCI is unusually long and flexible, accounting for its broad protease specificity, 
and its heparin-binding site is found along the highly basic helix H. The effect of heparin on 
PCI activity can either be to accelerate protease inhibition (e.g. APC)171 or to abrogate it 
(tissue kallikrein)172. The position of the heparin-binding site close to the protease docking 
site may help explain this property. 
 Protein C Inhibitor in Disease - PCI is not synthesized by the liver in mice, and thus 
PCI is unlikely to play a role in hemostasis or fibrinolysis in the mouse173. Transgenic mice 
that over-express human PCI (hPCI) provide evidence of PCI’s ability to inhibit thrombin, 
APC and tPA. These mice do not exhibit symptoms of pulmonary hypertension induced by 
monocrotaline. TAT complexes are reduced compared to their wild-type counterparts 
suggesting that PCI competes with AT to inhibit thrombin.  Additionally, a decrease in free 
tPA and subsequent reduction in fibrinolysis is seen.  Finally, when APC was administered 
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for endotoxemia, hPCI-expressing transgenic mice demonstrated a reduction in the anti-
coagulant and anti-inflammatory effects of the treatment174.   Male homozygous PCI-
knockout mice were infertile due to abnormal spermatogenesis caused by loss of the Sertoli 
cell barrier175 due unregulated proteolytic activity.   
In humans, APC-PCI complex is indicative of atherosclerosis and aortic aneurysms176, an 
early indicator of myocardial infarction177 and predicts poor patient outcome after aortic 
surgery178. Additionally APC-PCI complex is increased (4-fold) in patients with fVLeiden who 
have suffered a previous venous thrombosis179.  PCI alone has been shown to be elevated in 
survivors of acute coronary events180.  
 
α1-Protease Inhibitor – SERPINA1 
α1-protease inhibitor (α1PI) – historically known as α1-antitrypsin – is a 51 kDa, 394 
amino acid glycoprotein, synthesized in the liver, circulating at ~1.3 mg/mL with a half-life 
of 4.5 days (structure shown in Figure 1.2).  Its physiologic target is neutrophil elastase181, 
however, it has also been shown to inhibit APC in a heparin-independent manner77.  In 
pediatric ischemic stroke patients, α1PI levels were significantly increased independent of 
other pro-thrombotic factors.  Authors suggest this pathology is due to APC inhibition182. 
α1PI is not thought to contribute significantly to coagulation.  However, a variant of 
the protein (α1PIPittsburgh) with a reactive site mutation (M358R) can cause a fatal bleeding 
disorder183.  The Met Æ Arg polymorphism creates a potent inhibitor of  several coagulation 
serine proteases, especially thrombin and APC, that is not dependent on heparin or other 
cofactors184.  Therapies utilizing recombinant α1PIPittsburgh were considered but abandoned 
due to side effects of promiscuous protease inhibition185,186.  
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α2-antiplasmin – SERPINF2 
α2-antiplasmin (α2AP) is a 63 kDa, 452 amino acid glycoprotein, synthesized in the 
liver, circulating at ~70 µg/ml with a half-life of 2.6 days88,187,188.  α2AP is the primary 
physiological inhibitor of plasmin, but has also been reported to inhibit other enzymes such 
as trypsin, elastase, and APC.  Homozygous deficiency of α2AP results in uncontrolled 
fibrinolysis and subsequent severe hemorrhagic tendencies187,189. While α2AP has all of the 
key structural features of the serpin family, it uniquely has both N- and C-terminal extensions 
of 42 and 55 residues, respectively88,190.  In thrombus formation, the N-terminal region of 
α2AP is cross-linked to fibrin by fXIIIa, and the C-terminal Lys binds to the Lys-binding site 
of plasmin. The rate of fibrinolysis is proportional to cross-linked α2AP. 
 
Plasminogen Activator-1 – SERPINE1 
Plasminogen activator-1 (PAI-1) is a 50 kDa, 379 amino acid glycoprotein, 
synthesized in endothelial cells, platelets and other mesenchymal cells surrounding the 
vasculature191-193.  This serpin is relatively unstable with a half-life of 1-2 hours in 
circulation194.  However, PAI-1 is found bound to the extracellular matrix protein, vitronectin 
(VN)195,196.  The PAI-1-VN complex has an enhanced half-life of 4-6 hours194.  PAI-1 
regulates both tPA and uPA and is considered the main physiological inhibitor of 
plasminogen activation78,79,89,197.  As platelets are activated following vessel injury, they 
release PAI-1 to protect the developing thrombus from premature fibrinolysis.  Later in the 
coagulation process, tPA and plasminogen/plasmin are bound to fibrin within the thrombus, 
which protects tPA from inhibition by PAI-1, resulting in plasmin generation and 
fibrinolysis78,79,89,197.   
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Several structures of PAI-1 have been solved , but, due to its rapid conversion to the 
latent form, all structures of native PAI-1 are of a stabilized quadruple mutant198-200. 
Although the structure shows a native state similar to α1PI, not AT and HCII, some 
mutagenesis studies suggest an equilibrium for wild-type PAI-1 where the native state is in 
equilibrium between α1PI-like and AT-like states201. The structure of the stabilized mutant 
bound to the somatomedin domain of VN revealed the mechanism of stabilization of the 
native state through a blocking of the expansion of β-sheet A196 (Fig. 3B). 
PAI-1 can also inhibit APC76 and thrombin62,111 in the presence of VN and/or heparin. It is 
not known to what extent these activities contribute to coagulation. Previously, it has been 
shown that APC cleaves PAI-1, inactivating the serpin202,203. Recently, it has been shown that 
PAI-1 inhibits APC and the rate of inhibition increases in the presence of vitronectin ~300-
fold76.  
Plasminogen Activator-1 in Disease - Studies show that PAI-1 levels are sensitive to 
many different pathophysiological factors and increased synthesis of PAI-1 contributes to 
numerous cardiovascular disease states.  In metabolic syndrome, both glucose and insulin 
increase PAI-1 synthesis in vascular endothelial and smooth muscle cells204.  Controlling 
hyperglycemia in type 2 diabetes results in a decrease in PAI-1 levels.  One of the clinical 
benefits of “statins” may be due to their decrease of PAI-1 expression and simultaneous 
increase of tPA expression, altering the balance of the Fibrinolytic Pathway205,206.  Circadian 
clock proteins, including CLOCK, BMAL, and CRY, regulate PAI-1 gene expression which 
may explain the increased risk of adverse cardiovascular events in the morning207. Inhibition 
of nitric oxide synthase induces PAI-1 expression, which contributes to the development of 
perivascular fibrosis208.   Increased PAI-1 levels are associated with coronary artery disease 
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and myocardial infarction.  However, studies examining the association of cardiovascular 
disease with a polymorphism within the PAI-1 promoter region (4G/5G) which increases the 
expression PAI-1 are controversial209. Stents with rapamycin and paclitaxel are used in 
interventional cardiology due to the antiproliferative effects of these drugs210,211.  These 
stents have been shown to be associated with an increased risk of thrombosis and it is 
speculated that this may be due to an up-regulation of PAI-1 by rapamycin and paclitaxel212. 
There is also strong evidence for a role of PAI-1 in cancer metastasis independent of its 
protease inhibitory activity87,213,214. 
Effectors of Plasminogen Activator Inhibitor-1 Activity and Synthesis - 
Physiological levels of PAI-1 provide crucial regulation of fibrinolysis, yet excess levels 
contribute to disease.  Numerous factors have been found that up-regulate PAI-1 expression 
and secretion, including inflammatory cytokines, angiotensin II, aldosterone, transforming 
growth factor-β, and very-low density lipoproteins89,215,216.  Monoclonal antibodies have been 
prepared against PAI-1, which express inhibitory activity by (i) preventing the formation of 
the encounter complex between PAI-1 and tPA/uPA, (ii) increasing PAI’s susceptibility to 
cleavage by target proteases, and (iii) promoting the tendency of PAI-1 to become latent and 
inactive217.  Sequence-specific catalytic DNA enzyme, short-interfering RNA structures, and 
antisense technology have all been used to down-regulate PAI-1 levels218.  Negatively 
charged organochemical compounds have been found to bind to a hydrophobic site on PAI-1 
and induce polymerization and inactivation.  Finally, several small molecules (XR5118, 
ZK4044, and PAI-039) have been developed to inhibit PAI-1 activity by either reduction of 
accessibility to the RSL, by promoting a latent-like state or by favoring a substrate-like 
conformation219-227.   
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CLOSING STATEMENT 
In this State of the Art manuscript, we have described our current knowledge of 
serpins that regulate hemostasis and fibrinolysis.  Utilizing the “suicide substrate” 
mechanism unique to serpins AT, HCII, ZPI, α1PI, PCI, α2AP and PAI-1 provide rapid and 
specific inhibition of the activated serine proteases in the Coagulation, Protein C and 
Fibrinolytic Pathways. These pathways are not single independent systems, but they 
represent a dynamic balance between pro-coagulant, anti-coagulant, pro-fibrinolytic and anti-
fibrinolytic states with serpins playing multiple and sometimes conflicting roles. While we 
have learned a considerable amount about their physiologic control, their structure, related 
activities and regulation by local cofactors, much is left to be understood. Of note, there is 
deciphering the primary physiologic roles of HCII and PCI, resolving the crystal structures of 
ZPI and α2AP, and learning more about the non-hemostatic functions of AT and PAI-1.  
Continued research with the less-studied serpins such as ZPI and α2AP will undoubtedly 
provide useful information about control of hemostasis and fibrinolysis and of serpins in 
general.  The serpins described in this paper have a multitude of functions, which under some 
circumstances contribute to disease, but which often can be maniupulated for the benefit of 
medicine.  Therefore, it is of paramount importance that we continue the investigations of 
serpins in thrombosis, hemostasis and fibrinolysis.  
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CHAPTER 2 
Heparin Cofactor II in Atherosclerotic Lesions 
 
SUMMARY 
Heparin cofactor II is a serine protease inhibitor that has been shown to be a predictor 
of decreased atherosclerosis in the elderly and protective against atherosclerosis in mice.  
HCII inhibits thrombin in vitro and HCII-thrombin complexes have been detected in human 
plasma.  Moreover, the mechanism of protection against atherosclerosis in mice was 
determined to be the inhibition of thrombin.  Despite this evidence, the presence of HCII in 
human atherosclerotic tissue has not been reported. In this study, using tissue obtained from 
the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study and the 
McLendon Clinical Laboratory, Division of Autopsy Services at the University of North 
Carolina Hospitals, we explore the local relationship between HCII and thrombin in 
atherosclerosis.  We found that HCII and (pro)thrombin are co-localized in the lipid-rich 
necrotic core of atheromas. A significant positive correlation between each protein and the 
severity of the atherosclerotic lesion was also present.  Complexed HCII and thrombin were 
not detected.  These results suggest that HCII is in a position to inhibit thrombin in 
atherosclerotic lesions where thrombin can exert a proatherogenic inflammatory response.  
However, these results should be tempered by the additional results from this and other 
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studies that indicate the presence of many circulating plasma proteins in the same region of 
the atheroma. 
 
INTRODUCTION 
Heparin cofactor II (HCII) is a unique member of the serine protease inhibitor 
(serpin) family. Although it is present in human plasma at levels over 1μM, its physiologic 
role is not yet fully understood.  In vitro, HCII is known to inhibit only thrombin, 
chymotrypsin and cathepsin G228,229.  Although one study has reported that HCII inhibits 
chymotrypsin in vivo during acute pancreatitis230, the majority of studies into HCII’s function  
have focused on its inhibition of thrombin. 
HCII, antithrombin (AT) and several other serpins that inhibit thrombin, require cofactors to 
reach physiologically relevant rates of inhibition.  HCII and AT utilize glycosaminoglycans 
(GAGs), unbranched sulfated polysaccharide chains composed of repeating disaccharide 
units, for thrombin inhibition.  While the activity of  both HCII and AT can be activated by 
the GAGs heparin and heparan sulfate, HCII is distinctive amongst the serpins in its ability to 
utilize the GAG dermatan sulfate as a cofactor45,152,231-236.  In vitro, GAGs can accelerate AT 
and HCII to similar rates of thrombin inhibition (second order rates of inhibition over 1 x107 
M-1 s-1)51. 
Despite the ability of HCII to inhibit thrombin to rates comparable to that of 
antithrombin (AT) in vitro, and the detection of HCII-thrombin complexes in human 
plasma237 evidence suggest that under normal conditions HCII does not appear to play a 
major role in the regulation of thrombosis in hemostasis.  Individuals with HCII deficiency 
do not appear to have increased risk of venous thrombosis compared to those with normal 
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HCII levels153.    There has been only one report of individuals with homozygous HCII 
deficiency, a pair of sisters who showed only 10-15% of normal plasma HCII activity and 
only 2-5% antigen238.  It was determined that their genetic mutation caused a E428K 
mutation in HCII which almost virtually abolished its hepatic secretion239.  One of these 
sisters did experience thrombotic events; however, it was determined that she had a comorbid 
AT deficiency238. 
Recently, it has been suggested that HCII acts as an adjunct to AT in hemostasis regulation in 
AT deficiency.  Tanaka et al.240 demonstrated that Intimatan, a pharmaceutical form of 
dermatan sulfate,  could be used effectively for anticoagulation when patients had deficient 
antithrombin levels indicating that HCII could be a sufficient backstop for hemostasis.  
Evidence also suggests that HCII may play a role in hemostasis during pregnancy, most 
likely in maintaining placental hemostasis241.  Heparin cofactor II and HCII-thrombin 
complex levels are elevated, during pregnancy242,243.  The placenta is abundant in dermatan 
sulfate proteoglycans241 and traces of dermatan sulfate can be found in maternal and fetal 
blood244.  Additionally, HCII levels are reduced ~50% of normal in women with 
preeclampsia245. 
One conclusion that could be drawn from this incomplete story is that complete HCII 
deficiency is embryonically lethal, that at least some HCII is required to maintain placental 
function; thus, individuals with complete HCII deficiency do not exist.  Another possibility is 
that HCII deficiency does not produce a clinical phenotype within a realm that is typically 
examined within the context of HCII plasma levels.  In 2000 He et al.246  reported the 
creation of homozygous HCII knockout mice. These mice were born with predicted 
Mendelian frequencies and had normal hemostasis when unchallenged. However, they 
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reported that these mice showed decreased time to vascular occlusion after arterial injury 
than their wildtype counterparts suggesting that HCII may play a role in response to vascular 
injury154.  More recently, another group created homozygous HCII null mice. They reported 
that complete HCII deficiency is embryonically lethal49.  This has renewed the debate 
regarding the role of HCII in placental function in pregnancy and in pathophysiology in 
general. 
Since the finding that HCII may play a role in response to vascular injury, there has 
been a flurry of research investigating the role of HCII in atherosclerosis48.  Carotid 
atherosclerosis measured by ultrasound was shown to be decreased in individuals with high 
levels of HCII50.  Furthermore, in this study, HCII was a better predictor of decreased 
atherosclerosis than high-density lipoprotein which is generally regarded as offering 
cardioprotection.  Decreased levels of HCII activity were correlated with endothelial 
dysfunction and were predictive of cardiovascular events in one study247.  However, another 
study showed no correlation between HCII and subsequent cardiovascular events248.  Two 
studies which examined restenosis after arterial stent placement, a process dominated by 
smooth muscle cell proliferation and migration that are also factors in atherogenesis,  
indicated that elevated blood concentrations of HCII were associated with decreased 
incidence of restenosis155,156.  Finally, in experiments using either homozygous HCII null 
mice or heterozygous HCII knockout mice crossed with the apolipoprotein E null mice, HCII 
was shown to protect against atherosclerosis. Furthermore, it was shown that HCII was 
acting to inhibit thrombin in and vascular remodeling after injury and in atherosclerosis47,49. 
Although HCII is thought to regulate thrombin in atherosclerosis, the presence of HCII 
within atherosclerotic lesions has not been reported. In this study we immunologically 
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probed normal artery and atherosclerotic lesions for the presence of HCII, (pro)thrombin and 
other plasma proteins.  We proceeded with the hypothesis that we would find decreased 
levels of HCII and increased levels of thrombin in atherosclerotic plaques, and the reverse in 
normal arterial wall, reasoning that less HCII would result in decreased thrombin inhibition 
and therefore more severe atheromas.  Furthermore, because dermatan sulfate, but not 
heparin was shown to be ineffective in reducing atherosclerosis in laboratory mice, we 
hypothesized that AT would be absent in the lesions47. 
 
MATERIALS AND METHODS 
Histological Samples 
Samples of human left anterior descending (LAD) coronary artery were collected, 
formalin-fixed, paraffin-embedded, cut and mounted on glass slides by the Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) Study249-253.  All subjects in this study 
were persons from the ages of 15-34 who died of external causes (accidents, homicides, 
suicides) from fifteen cooperating centers managed by the Department of Pathology at 
Louisiana State University Health Science Center.    Serial sections from 33 cases with 
varying degrees of atherosclerosis were used in this study.  For simplicity of coding, the 
cases were renumbered 1-33. Upon examination, five cases (13, 15, 20, 30, 32) were found to 
lack enough tissue for evaluation, leaving 28 cases for analysis.   
Sections of formalin-fixed, paraffin-embedded liver were obtained from the 
University of North Carolina Surgical Pathology cut into 4 μm sections and mounted on 
glass slides.  These served as positive controls slides for immunohistological staining as 
almost all of the proteins being probed are of hepatic origin.  The exception to this is maspin 
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which served as a negative control and is not synthesized by the liver.  However, a liver 
section with a maspin-positive tumor was found to serve as a positive control.  
 
Slide Preparation and Mounting  
Before staining, paraffin was dissolved and slides were rehydrated by immersion for 
three minutes each in successive baths of the following solutions: 100% xylene, 100% 
xylene, 100% xylene, 100% ethanol, 100% ethanol, 95% ethanol, 95% ethanol, 70% ethanol, 
30% ethanol, water. All water, unless otherwise specified, was distilled and deionized.  After 
staining, all slides were dehydrated by immersion for three minutes each in successive baths 
of the following solutions: 50% ethanol, 50% ethanol, 100% ethanol, 100% ethanol, 100% 
xylene, 100% xylene.  This was modified slightly for hematoxylin and eosin staining so that 
instead of 50% ethanol, slides were soaked in 95% ethanol and the time in each bath was 
extended to five minutes.  After dehydration all slides were coverslipped using 1 drop of 
Permount Mounting Media (Fisher Scientific) and air dried overnight. 
 
Hematoxylin and Eosin Staining  
For staining with hematoxylin and eosin, rehydrated slides were immersed first for 
eight minutes in filtered Mayer’s hematoxylin (Dako),  rinsed in tap water until no more dye 
was evident and then soaked in tap water for 10 minutes.  Slides were then rinsed in distilled 
and deionized water before being dipped ten times in 95% ethanol.  Slides were then 
submersed for 45 seconds in Eosin Y (Sigma) followed by 95% ethanol for five more 
minutes. 
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Antigen Retreival  
Heat-induced antigen retrieval was employed for probing the AT antigen only.  Six 
slides at a time were placed into plastic Copeland jars with a large hold drilled in the lid filled 
with Tissue Unmasking Fluid (Invitrogen).  These jars were placed into 400 mL glass beaker 
in 180 mL of distilled, deionized water and heated on highest power in a Samsung Classic 
Collection Microcooking microwave for 2.5 minutes.  The water was then exchanged for 180 
mL of fresh water and the beaker containing the Copeland jar with slides was heated again on 
highest power for 2.5 minutes to bring the internal temperature to 95° C.   The water was 
exchanged again for 180 mL of tap water and everything was permitted to cool for 20 
minutes. 
 
Immunohistochemical Staining  
 Slides were laid flat on a rack and covered with 460 μL per slide of each successive 
solution. To remove solution, slides were placed at an angle and then rinsed with PBStw1%, 
Dulbecco’s phosphate buffered saline (PBS) (Gibco) containing 1% Tween 20 (Sigma).  
Before and between incubation with each solution, slides were washed two times by being 
laid flat and covered in PBStw1% for three minutes. First, endogenous peroxidase activity was 
blocked with either HRP-Block (Dako) for five minutes or  with 3% hydrogen peroxide for 
ten minutes. Slides were then incubated for one hour in the dark with primary antibody 
diluted in PBS with either 1% ovalbumin or 1% bovine serum albumin. Table 2.1 describes 
the antibodies used, their dilutions and incubation times.  Next, slides were incubated in the 
dark with peroxidase conjugated secondary antibody appropriately matched to primary 
antibody either HRP-conjugated donkey anti-goat IgG (Serotec) or HRP labeled polymer 
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(Dako). Secondary antibodies were diluted in the same solution as their primary antibodies.  
Slides were then covered with nine drops per slide of diaminobenzidine solution (DAB) 
(DAKO) and let sit for eight minutes.  DAB staining was enhanced using a solution of 2.5% 
cobalt chloride, 2.5% nickel ammonium sulfate for eight minutes and rinsed in water.  Slides 
were counterstained for five minutes with Mayer’s Hematoxylin (Dako or Sigma), rinsed in 
tap water until no more stain was detected in the water and then immersed in tap water for 
five minutes before dehydrating and coverslipping. 
 
Table 2.1. Description of Antibody, Dilutions and Incubation Times Used in 
Immunohistological Staining.  
1° Antibody 
Clonal Raised 
in 
1° Ab 
Dilution 
1° Ab 
time 
(min) 
2° Ab 
Dilution 
2° Ab 
time 
(min) 
Anti-human HCII IgG 
--affinity purified (Affinity 
Biologicals) 
 
poly goat 1:1000 60 1:100 30 
Anti-human antithrombin IgG 
 (Diasorin) 
 
poly goat 1:500 60 1:200 20 
Anti-human (pro)thrombin* IgG 
(Dako) 
 
poly rabbit 1:2000 60 None 10 
Anti-human α1-protease inhibitor 
IgG  
(Fitzgerald Industries) 
 
poly goat 1:10,000 60 1:100 10 
Anti-human albumin IgG  
--affinity purified (Antibodies Inc) 
 
poly goat 1:1000 60 1:1000 10 
Anti-human maspin IgG 
(Pharmingen) 
poly goat 1:100 60 1:100 30 
 
Goat IgG 
 
 
goat 
 
1:1000 
 
60 
 
1:100 
 
30 
* Note: Antibodies that distinguish between human prothrombin and human thrombin are not 
commercially available. Therefore, under circumstances such as tissue staining when molecular 
weight is not detectable, the two are indistinguishable by antigen staining. 
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Lesion Classification 
One serial section from each case was stained with hematoxylin and eosin. Using this 
slide set, the severity of each atherosclerotic lesion was classified separately by three trained 
individuals. Plaque severity was rated from I to VI according to the American Heart 
Association classification system (Table 2.2)15,16. 
 
Table 2.2. American Heart Association Classification of Atherosclerotic Lesions 
Classification Description 
I 
(initial) 
Intimal thickening and isolated macrophage foam cells 
II 
(fatty streak) 
Mainly intracellular lipid accumulation 
III 
(intermediate) 
Type II changes and small extracellular lipid pools 
IV 
(atheroma) 
Type II changes and core of extracellular lipid 
V 
(fibroatheroma) 
Lipid core and fibrotic layer, or multiple lipid cores and fibrotic layers, or 
mainly calcific or mainly fibrotic 
VI 
(complicated) 
Surface defect, hematoma-hemorrhage, thrombus 
 
Staining Intensity 
The intensity of staining for each probed antigen was also independently ranked on a 
scale of 0 to 3 with 0 indicating no staining, 1 indicating weak staining, 2 indicating 
intermediate staining and 3 indicating strong staining.  Note, the reviewers vary by protein, 
but each slide set was rated by 3 reviewers.  Images were created using the Aperio 
ScanScope and Aperio ImageScope software version 9.0.  Slides were scanned using factory 
settings for immunohistochemistry.  
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Statistical Analysis 
Statistical analysis was carried out by Carolyn Deans of the University of North 
Carolina  Biometric Consulting Laboratory.  Mean scores for lesion severity and staining 
intensity was computed for each slide.  Spearman correlation coefficients, with their 
corresponding p-values, were computed to estimate the correlation between the mean scores 
for each of the probed proteins and severity of the atherosclerotic lesions.   Using the mean 
score for each protein helped to decrease the variance of scores, thereby increasing the 
chance of detecting a significant correlation when it did exist.  To support the use of the 
mean scores, intra-rater reliability was assessed using intra-class correlations. Since five 
comparisons between lesion severity and staining intensity were made, it was necessary to 
make an adjustment for multiple comparisons.  The Bonferroni-Holm method was used, 
comparing p-values for all five correlations, initially comparing the smallest p-value to 
0.05/5=0.01.  If significant, then the second-smallest p-value was compared to 0.05/4=0.125.  
If significant, the third-smallest p-value was compared to 0.05/3=0.1667, and so on for each 
of the five p-values, stopping when a non-significant result was observed.   
 
Aorta Collection and Protein Extraction  
Samples of aorta were gathered by the University of North Carolina Hospital 
McLendon Clinical Laboratory, Division of Autopsy Services.  Use of these tissues for the 
experiments described was subject to review and was preapproved by the appropriate 
individuals. Three samples each of normal or atherosclerotic aorta as determined by gross 
examination were collected from autopsy patients and numbered 1 through 6. Even-
numbered samples contained non-diseased tissue and odd-numbered samples contained 
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atherosclerotic lesions.  After washing rinsing in PBStw0.1%, tissues were submerged in 
Tissue-Tek Optimal Cutting Temperature Compound (Sakura Finetek USA), frozen in liquid 
nitrogen and stored at -80° C.  Vessels were thawed quickly and washed 3 times in 
PBStw0.1%.  The adventitia was carefully dissected and discarded to help ensure the removal 
of contamination from trapped blood and fluids.  A 5 mm2 piece was cut from each sample 
for homogenation.  Each 5 mm2 section was placed in 200 μL of modified RIPA buffer 
(50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 1% Tergitol-type NP-40, 0.25% sodium  
deoxycholate, 1% TritonX-100 pH 7.4, containing 1 Complete Protease Inhibitor tablet 
(Roche) per 50mL) on a glass plate and diced with a fresh razor blade and scalpel.  This was 
transfer to a polypropylene tube on ice containing 300 μL more of modified RIPA buffer.  
Each slurry was sonicated using a Sonicator Dismembrator (Fisher Scientific) in five one-
second bursts with 2 minute rest on ice, five times with an output power of between 10 and 
14 watts.   250 μL more of modified RIPA buffer was added to each homogenation which 
was then left on ice overnight.  Protein suspensions were centrifuged at ~20,000 x g for 20 
minutes at 4° C.  Supernatant was removed, aliquoted and stored at -80° C for future use. 
 
Immunoblot Analysis of Normal and Atherosclerotic Vessel  
Protein extracted from normal and atherosclerotic aorta, HCII, AT, prothrombin (all 
purified from human plasma as previously described254,255, α-thrombin (Haematologic 
Technologies) and serpin-thrombin complex were mixed with sample buffer containing SDS 
and heated for 10 minutes at 95° C. Serpin-thrombin complexes were made by incubating a 1 
to 1 molar ratio of serpin and thrombin with 25 μg/mL unfractionated heparin (Diosynth), for 
5 minutes at room temperature and stopping the reaction with 10 μM final concentration each 
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of the protease inhibitors, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone 
(PPACK), dansyl-Glu-Gly-Arg chloromethyl ketone (DEGR), tosyl-L-lysine chloromethyl 
ketone (TLCK), tosyl-L-phenylalanine chloromethyl ketone (TPCK) (all from Calbiochem) 
and phenylmethanesulfonyl fluoride (PMSF) (Sigma).  Denatured solutions were then 
electrophoresed through either 10% SDS-polyacrylamide gels or through 4-15% gradient 
SDS-polyacrylamide PhastGel (General Electric Healthcare).  Protein was transferred to 
Immobilon-B transfer membrane, 45 μm pore-size (Millipore) and blocked with 5% milk in 
PBS.  Membranes were then incubated with two antibodies: either goat anti-human HCII 
(affinity purified, 1:1000, Affinity Biologicals) and rabbit anti-human prothrombin (1:1000, 
Dako) or goat anti-human AT (1:1000, Diosorin) and human prothrombin (1:1000, Dako) for 
1 hour at 37° C in 5% milk in PBStw0.1%.  After washing 3 times for 10 minutes in 
PBStw0.1%, membranes were incubated in the dark for 1 hour at room temperature with Alexa 
Fluor 680 donkey anti-goat (Invitrogen) and IRDye 800CW donkey anti-rabbit (Rockland 
Immunochemicals)  fluorescent secondary antibodies. Membranes were washed two times 
for ten minutes with PBStw0.1% and one time for ten minutes with PBS.  Antigen was then 
detected using the Odyssey Infrared Imaging System (LI-COR Biosciences). 
RESULTS  
Ratings of Lesion Severity and Antigen Staining  
Atherosclerotic lesions were categorized from 1 to 5.  No category 6 lesions were 
observed. Staining of each of the circulating proteins was observed with intensity range of 0 
to 3. Mean scores for each slide are listed in Chapter 2, Supplemental Material , Table 2.S1.  
Assessment of inter-rater reliability by inter-class correlation coefficients (ICCs) results in 
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ICCs above 0.5 (Table 2.3), indicating that there is reliability among raters.  This supports 
the use of the mean scores to assess correlations between plaque severity and staining 
intensity. 
Table 2.3.  Intra-class Correlation Coefficients (ICC) to Address Intra-Rater Reliability 
Variable ICC 
Severity 0.824 
HCII 0.705 
(Pro)thrombin 0.719 
AT 0.603 
α1PI 0.725 
Albumin 0.845 
 
All of the plasma proteins probed for were found in atheromatous lesions.  Mapsin was not 
detected in vessel. Antigen staining was detected primarily in the lipid rich, necrotic core of 
the atheromas.   Images of each slide have been compiled in Supplemental Materials Figures 
2.S1-2.S7.  Figure 2.1 shows an example of serial sections of one sample, #5, immunoprobed 
for each circulating protein. This atheroma was rated with an average lesion severity of 4.67.  
Mean staining intensity for HCII = 3.00, AT = 1.67, (pro)thrombin = 3.00, α1PI = 3.00, 
albumin = 3.00  and goat IgG = 0.  
It is evident from Figure 2.1 that there is protein from all of the circulating proteins 
found in this atherosclerotic plaque.  From first examination, AT appears to have less 
staining than the other proteins.  However, due to discrepancies in the quality of antibodies 
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and the requirement to use heat-induction for antigen retrieval on this slide set, it is 
impossible to compare protein concentration across protein types in these stained vessels.  
 It is interesting to note the paucity of staining in the less atherosclerotic tissue from this 
vessel (seen in the right-most column in Figure 2.1).  There is also some detectable HCII, AT 
and albumin in the endothelial region, but not the other proteins. Furthermore, no antigen 
staining was detected in the normal region of this or any of the LAD coronary arteries used in 
this study. 
 
Relationship Between Plaque Severity and Antigen Staining 
 Statistical analysis using Spearman correlation coefficients comparing lesion severity 
and staining intensity indicates that there is a significant positive correlation between lesion 
severity and HCII staining, lesion severity and (pro)thrombin staining, and lesion severity 
and antithrombin staining (Table 2.4 ). 
 
Table 2.4. Spearman Correlation Coefficients to Estimate Correlation of Severity and Antigen 
Staining. 
 HCII (pro)thrombin AT α1PI albumin
correlation 
coefficient 
0.63378 0.80537 0.48451 0.34403 0.38671 
p-value 0.0003 <.0001 0.0090 0.4499 0.1918 
N 28 28 28 7 13 
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Since five comparisons were being made, it was necessary to make an adjustment for 
multiple comparisons.  Analysis using the Bonferroni-Holm method supported the data 
above, indicating a positive correlation between lesion severity and (pro)thrombin, HCII and 
AT, but not with α1PI and albumin (Table 2.5). 
 
Table 2.5.  Breakdown of Tests of Significance Using Bonferroni-Holm Method to Adjust for Multiple 
Comparisons 
Step Variable Observed p-value Compare to Significant? 
1 (Pro)thrombin <0.0001 0.01 YES 
2 HCII 0.0003 0.0125 YES 
3 AT 0.0090 0.01667 YES 
4 Albumin 0.1918 0.025 NO Æ Stop after this step. 
 
It is useful to note that sample sizes stained for for α1PI (n=7) and albumin (n=13) were 
smaller than those for severity, HCII, (pro)thrombin, and AT (n = 28 for each).  If α1PI and 
albumin staining are truly positively correlated with severity, then an increased sample size 
would be necessary to demonstrate this significance.  
 
Protein Extraction and Immunoblot Analysis  
Figure 2.2 shows immunoblotting on protein extracted from atherosclerotic and 
normal aorta along with purified proteins for comparison.  Panel A depicts the samples run 
on the PhastGel system, through a SDS 4-15% polyacrylamide gradient gel and probed for 
HCII (red) and (pro)thrombin (green).  Complexes and overlap between the red and green 
fluorescence emissions appear yellow.  Column 1 is Aorta 1 (atherosclerotic), column 2 is  
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Figure 2.2.  Presence of HCII, AT, thrombin and Prothrombin in homogenized atherosclerotic 
and normal aorta.  Panels A and B have been probed for HCII (red) and (pro)thrombin (green).  
Panel C has been probed for AT (red) and (pro)thrombin (green).  Complexes and overlap appear 
yellow.  The columns contain the following proteins, A1 = Aorta 1 (atherosclerotic) ; A2 = Aorta 
(normal)  2; A3  = HCII;  A4 = thrombin;  A5 = HCII-thrombin-complex;  A6 = prothrombin; 
B1, C1 = molecular weight marker;  B2, C2 = Aorta 1( atherosclerotic);  B3, C3 = Aorta 2 
(normal); B4, C4 = Aorta 3( atherosclerotic);  B5, C5 = Aorta 4 (normal); B6, C6 = Aorta 5 
(atherosclerotic);  B7, C7 = Aorta 6 (normal);  B8  = HCII; C8 = AT; B9, C9 = thrombin, C10 = 
serpin-thrombin complex. 
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Aorta 2 (normal), column 3 is human HCII, column 4 is human thrombin, column 5 is HCII-
thrombin complex, column 6 is prothrombin.  The higher molecular weight band in column 3 
is intact HCII while the lower molecular weight band is cleaved HCII. Note HCII is 
detectable in both normal and atherosclerotic tissue.  On this blot, no prothrombin or 
thrombin (complexed or not) is detectable.   
Additional studies are shown in Figure 2.2 panels B and C.  These experiments 
utilized 10% SDS-polyacrylamide gels.  Column 1 is molecular weight marker, column 2 is 
Aorta 1 (atherosclerotic), column 3 is Aorta 2 (normal), column 4 is Aorta 3 atherosclerotic), 
column 5 is Aorta 4 (normal), column 6 is Aorta 5 (atherosclerotic), column 7 is Aorta 6 
(normal), column 8 is human serpin (Panel B = HCII, Panel C = AT), column 9 is human 
thrombin, column 10 is serpin-thrombin complex.  Panel B is probed with and probed for 
HCII (red) and (pro)thrombin (green).  Panel C is probed with and probed for AT (red) and 
(pro)thrombin (green).  Complexes and overlap between the red and green fluorescence 
emissions appear yellow.  Note that Panel B has been divided between columns 8 and 9 to 
indicate that these sections of the gel were adjusted separately for color curves, brightness 
and contrast so as best to detect distinct bands within each segment.  HCII is detected in all 
the aortic sections as is AT.  Additionally, prothrombin can be detected in Aortas 1-5 and 
thrombin can be detected in Aorta 2.  While Panel A would suggest that there may be more 
HCII in normal aortic vessel than in atherosclerotic vessel, the results shown in Panel B lends 
some uncertainty to this observation.  Finally, no serpin-thrombin complex is detectable in 
the aortic sections. 
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DISCUSSION 
Somewhat at odds with our hypothesis, we detected more HCII in the more severe 
atherosclerotic lesions as evidenced by a statistically significant positive Spearman 
Correlation (Table 2.3).  However, as predicted (pro)thrombin staining exhibited a positive 
correlation between intensity and lesion severity (Table 2.3).  Both HCII and (pro)thrombin 
were detected in the same lipid-rich regions and necrotic cores of the atheromas (Figure 2.1).  
Based on this data, we developed the working hypothesis that increasing amounts of HCII 
was present in increasingly severe atheromas because there are greater amounts of thrombin 
to be inhibited in the more severe plaques. Consistent with this hypothesis is that dermatan 
sulfate found in atheromas shows decreased ability to accelerate HCII inhibition of 
thrombin256.  We reasoned therefore, that to reach the same level of thrombin inhibition, 
higher levels of HCII must be present. 
The studies which show that HCII inhibits thrombin in atherosclerosis, also indicate 
that AT, the prominent thrombin inhibitor in coagulation, is unable to fulfill this role47,49.  
Therefore, to substantiate the functional specificity of HCII in the atheromas, we probed 
adjacent sections for the presence of AT, expecting to find little there.   To our surprise, AT 
was detected in the atheromas, in the same location as HCII and (pro)thrombin (Figure 2.1).   
The AT staining was somewhat less intense in the atheromas (Figure 2.1) despite comparable 
staining intensity in the liver positive controls to those of HCII and (pro)thrombin (data not 
shown).  However, a positive correlation between staining intensity and plaque severity was 
still evident (Table 2.4).  
To further investigate the specificity of the co-localization of these thrombin-
inhibiting serpins and (pro)thrombin, we probed additional adjacent LAD coronary artery 
sections for a non-thrombin-inhibiting plasma serpin, α1-protease inhibitor; a non-serpin 
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plasma protein, albumin; and a non-circulating serpin, maspin.  Although we can find no 
evidence establishing a role for α1-protease inhibitor or albumin in the pathophysiology of 
atherosclerosis, both of these proteins were found localized in the same region as HCII, 
(pro)thrombin, and AT (Figure 2.1).  While correlations between staining intensity and 
plaque severity were not significant with albumin and α1-protease inhibitor, this could be 
due to the smaller number of slides probed. It is perhaps more important that these proteins 
can be found in the atheroma at all.  
In an attempt to determine if the (pro)thrombin in atherosclerotic lesions was 
thrombin or prothrombin and if it complexed with either the HCII or AT, we examined 
homogenized aorta by immunoblot analysis.   Results from these experiments confirmed the 
presence of HCII, AT and prothrombin in atherosclerotic tissue and also in normal vessel.  
Thrombin was only detectable in one sample of aorta and there was no indication of 
thrombin-serpin complexes present.  These results do not eliminate the possibility or even 
probability that thrombin is inhibited by HCII in the atherosclerotic vessel. It is very possible 
that complexes are cleared more quickly from the vessel, or that they are somehow less 
detectable to the antibodies used here.  
The presence in atherosclerosis of all of the circulating proteins probed for in this 
study, but not the non-circulating serpin, maspin, suggests severe atherosclerotic lesions may 
act as a watershed for plasma proteins and that the co-localization of proteins in this region 
may be non-specific. The positive correlation with plaque severity for HCII, (pro)thrombin 
and AT bolster this theory especially since the endothelium is known to show increased 
permeability with atherosclerosis19,44,257.  Many other circulating proteins, in addition to those 
reported here, have been found in the same region of human atherosclerotic lesions including 
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the apolipoproteins, apoA-I, apoB and apoE258,259, C-reactive protein260, vonWillebrand 
factor260,  and resistin261.  Sound explanations for the existence and retention of these proteins 
in atherosclerotic plaques have been presented, just as there appears to be good reason for the 
presence of thrombin and HCII.  One could even make a case for the retention of albumin in 
the plaque as it is known to bind fatty acids.  However, we are unable to rationalize the 
function of α1-protease inhibitor in the atheroma. This is not to say that none of the proteins 
found in atherosclerotic lesions influence its progression. Contrarily, we find it likely that 
many of these proteins play a role in atherosclerotic regulation or advancement.  For 
example, fibrin has been found in atherosclerotic plaques262.  While it is possible that it had 
been deposited by infiltrating macrophages, it is just as likely that all of the necessary 
coagulation factors leak into the plaque and are activated by the presence of tissue factor 
bearing cells in the atheroma.  The result would be fibrin in the atherosclerotic plaque that 
does not resemble a typical fibrin clot because platelets and red blood cells would be absent 
from the milieu.  This hypothesis also explains how thrombin could be detected in its active 
form in atherosclerotic plaques.  Thus the increased permeability of atherosclerotic lesions 
may actually be a thrombogenic factor in and of itself.   However, this study emphasizes a 
caveat that must be regarded with when considering this and other immunohistochemical 
examinations of atherosclerosis.  While presence or co-localization of any circulating 
protein(s) in atherosclerotic lesion may have functionality, it is important to consider that 
proteins found in the acellular, lipid-rich region of atheromas, may simply be the result of 
increased endothelial cell permeability may not contribute to atherogenesis or its regulation 
at all. 
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CHAPTER 2 SUPPLEMENTAL MATERIAL 
 
Table 2.S1.  Average Ranking of Plaque Severity and Stain Intensity for each Sample of 
Atherosclerotic Coronary Artery. 
Sample 
Number 
Plaque 
Severity 
HCII 
Staining 
(Pro)thrombin 
Staining 
Antithrombin 
Staining 
α1PI   
Staining 
Albumin 
Staining 
1 5.00 1.33 1.67 1.00   
2 5.33 2.67 2.67 2.00  1.00 
3 3.33 0.00 0.33 0.00  3.00 
4 4.67 2.00 0.67 0.00 3.00 3.00 
5 4.67 3.00 3.00 1.67 3.00 3.00 
6 4.67 1.00 2.00 0.67 3.00  
7 1.33 0.00 0.67 0.00   
8 5.00 0.33 2.00 0.67  2.00 
9 4.00 0.00 0.67 0.00  2.00 
10 2.00 0.00 0.33 0.00  2.00 
11 2.33 0.00 0.33 0.00   
12 2.00 0.33 0.33 0.00   
14 3.33 2.33 1.00 0.33  3.00 
16 4.00 1.33 2.00 0.67 3.00  
17 2.33 0.00 0.67 0.33   
18 4.33 1.67 1.00 0.33   
19 3.00 0.33 0.33 0.00   
21 2.00 0.33 0.67 0.33   
22 1.00 0.00 0.00 0.00   
23 3.00 0.00 1.67 1.00   
24 3.33 1.33 1.00 0.67 2.33  
25 1.67 0.67 0.33 0.00   
26 2.33 0.00 0.33 0.33   
27 2.67 0.00 0.33 0.33   
28 1.67 0.67 0.00 0.00   
29 3.00 0.00 0.33 0.00   
31 4.67 1.33 1.67 0.67 1.50 2.00 
33 5.00 1.67 2.67 1.33 3.00  
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CHAPTER 3 
Transferring Glycosaminoglycan-binding Properties of Heparin Cofactor II  
to α1-Protease InhibitorPittsburgh 
 
SUMMARY 
Glycosaminoglycans (GAGs) are important for the physiologic function of several 
serine protease inhibitors (serpins).  The structural homology of the serpin superfamily is 
such that it is possible to transfer structural components from one serpin to another and 
confer the associated specific activity.  This provides an excellent opportunity to study 
structure-activity relationships and allows for the creation of novel proteins for the 
advancement of science and medicine.  Heparin cofactor II (HCII) is a serpin whose 
physiologic role as a thrombin inhibitor is dependent upon GAGs.  Binding to GAGs is 
centered on its basic D-helix region.  The archetypal serpin, α1-protease inhibitor (α1PI), 
shows no GAG-dependent binding.  To confer GAG-binding properties, we mutated five 
residues in the D-helix of α1PIPittsburgh (α1PI reactive site variant, M358R) designated 
α1PIPitt-GAG, to corresponding positively charged amino acids from the D-helix of HCII: 
E97K/Q98R/Q105R/P106R/T102R. α1PIPitt-GAG gained both heparin and dermatan sulfate 
binding capacity and enhanced thrombin inhibitory activity.  In the presence of GAGs, rates 
of α-thrombin inhibition were enhanced up to 15 fold, showing maximal inhibition rates, 
which approached those of HCII-GAG-thrombin. Further studies indicated that the primary 
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mechanism of GAG-accelerated thrombin inhibition was the creation of a ternary complex, 
with a small contribution from a conformational change in the serpin.  These results indicate 
(i) the ability to create a novel GAG-binding serpin, (ii) that this gain-of-function approach 
can further our understanding of serpin structure-activity relationships, and (iii) that the 
engineering of serpins may prove to be a useful tool in the development of pharmaceuticals. 
 
INTRODUCTION 
Serine protease inhibitors (serpins) are a protein superfamily classified based on their 
structural homology263,264. Over 1000 serpins have been identified throughout all domains of 
life (Eukarya, Bacteria, Archaea and Viruses). Thirty-six serpins are found in the human 
genome265.  In human physiology, serpins serve a multitude of functions.  The majority of 
serpins inhibit serine proteases as their name suggests.  However, some members of the 
family inhibit cysteine proteases or caspases, and a few are non-inhibitory proteins that serve 
as hormone transporters, molecular chaperones, tumor suppressors, or catalysts for DNA 
condensation. The inhibitory human serpins regulate numerous biologic activities including 
coagulation, fibrinolysis, inflammation, reproduction and lung elasticity94. 
Serpins inhibit their target proteases with an exceptional mechanism, which is 
dependent on their unique structure116. Members of the family typically comprise around 400 
amino acids arranged into nine α-helices (labeled A-I), three β-sheets (labeled A-C) and a 
reactive center loop (RCL). Upon encounter with its target protease, the serpin’s scissile P1-
P1′ (by Schechter-Berger nomenclature) bond is cleaved.  Without this bond acting as a 
tether, the serpin shifts its conformation to its most thermodynamically stable state in which 
the N-terminal portion of the RCL is inserted into β-sheet A.  This results in the covalently 
 67 
 
bonded protease being translocated to the opposite pole of the serpin, thus disabling its 
proteolytic functionality. [For review, see116 and references cited therein.] 
While serpins’ shared tertiary structure imparts inhibitory activity, specific structural 
components confer distinct characteristics including protease specificity and cofactor 
binding121,264. “GAG-binding serpins” are a subset of serpins that bind glycosaminoglycans 
(GAGs).  GAGs are negatively charged linear complex carbohydrates found throughout the 
body both soluble and membrane bound.  Heparin, a specific GAG derived from porcine 
mucosa235, is widely used for thrombosis prevention144.  It acts predominantly by accelerating 
the inhibitory activity of antithrombin (AT) (systematic name: SERPINC1) up to 10,000 fold 
primarily against thrombin, factor Xa and factor IXa51.  Biochemical and crystallographic 
studies have determined that heparin accelerates its activity via two mechanisms depending 
on the target protease.  Heparin binding to the positively charged region centered around the 
D-helix of AT causes a conformational change extending the RCL away from the body of 
serpin putting it in a more favorable alignment for cleavage by proteases such as factor Xa266-
268.  Heparin can also bind some proteases such as thrombin creating a bridge between serpin 
and protease forming a ternary complex134.   
Another heparin binding serpin, heparin cofactor II (HCII) (systematic name: 
SERPIND1) specifically inhibits thrombin and is thought to contribute to the regulation of 
coagulation51,269,270.  HCII has an N-terminal acidic extension unique among serpins271,272 and 
also has an atypical P1 residue, a leucine272,273.  The inhibitory activity of HCII is accelerated 
up to 20,000 fold by the presence of the GAGs heparin, heparan sulfate and distinctively, 
dermatan sulfate274.  GAGs bind HCII’s positively charged D-helix region resulting in 
activation through a combination of the bridging275-279 and RCL conformational 
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mechanisms100 as well as an additional mechanism unique to HCII, whereby its N-terminal 
acidic extension is relocated allowing for it to create an additional stabilizing interaction with 
thrombin152,157,280.  
The understanding of GAG-binding serpins and their mechanisms of action has been 
of biomedical importance for over thirty years due to our ability to therapeutically 
manipulate their activity with soluble GAGs such as heparin to control pathological 
processes such as thrombosis. Traditionally, the approach to investigating GAG-binding has 
been through a loss-of-function strategy whereby candidate residues or regions are ablated or 
mutated and subsequent effects are measured.  Grasberger et al.281 illustrate that serpins 
possess a modular architecture that allows for domain substitution and transfer of activity.  
Compelled by the concept, we aspired to investigate GAG-binding through a gain-of-
function strategy, transferring GAG-binding properties to a non-GAG-binding serpin.  
Specifically, we confer GAG-binding capacity and GAG-accelerated inhibitory activity to 
the naturally occurring thrombin-inhibiting Pittsburgh variant (reactive site mutation 
M358R)183 of the non-GAG binding, prototypical serpin,  α1-protease inhibitor (α1PI)107 
(systematic name: SERPINA1).  This is achieved by mutating the residues homologous with 
those on the D-helix of HCII responsible for GAG-binding152,282.   
 
MATERIALS AND METHODS 
Mutagenesis of α1PIPittsburgh   
cDNA of  α1PIPittsburgh containing an N-terminal hexahistidine tag for purification, 7 
stabilizing mutations (F51L, T59A, T68A, A70G, M374I, S381A, K387R)283 and an 
additional mutation (C232S) to prevent dimerization284 was generously donated by the 
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Gettins laboratory (Department of Biochemistry and Molecular Genetics, University of 
Chicago, IL). Primary sequences of the D-helix from α1PIPittsburgh and HCII were aligned264 
and confirmed three-dimensionally using PyMOL version 1.0 (PDB# 1HP7285) and 
1JMO152). α1PIPittsburgh residues aligning with the five basic residues in the HCII D-helix 
were chosen for mutation to the homologous HCII residue (Figure 3.1). The following 
mutations: E97K/Q98R, Q105R/P106R, E97K/Q98R/Q105R/P106R, and 
E97K/Q98R/T102R/Q105R/P106R were introduced in the double-stranded plasmid 
α1PIPittsburgh-pQE30 following the QuikChange site-directed mutagenesis (Strategene) 
protocol, using these primers:  
GTACTTAAGGCCTTTGAGGAGGT (forward, E97K/Q98R)  
TGGAGGAGTTTCCGGAAGCCTTCATG (reverse, E97K/Q98R)  
GTATGGGAGTTGGCTCTGTCGGTC (forward, Q105R/P106R onto the E97K/Q98R 
mutant),  
CTGGCTGTCTCGCCGGTTGAGGGTATG (reverse, Q105R/P106R onto the E97K/Q98R 
mutant),  
GAGGAGGTATCCGAGTTGGCCGAG (forward, E97K/Q98R/T102R/Q105R/P106R onto 
the  E97K/Q98R/Q105R/P106R mutant),  
GAGCCGGTTGAGCCTATGGAGGAG (reverse, E97K/Q98R/T102R/Q105R/P106R onto 
the  E97K/Q98R/Q105R/P106R).  
The mutated cDNA with 5 amino acid substitutions 
(E97K/Q98R/T102R/Q105R/P106R), henceforth refered to as α1PIPitt-GAG, in the pQE30 
vector was transformed into Escherichia coli (E. coli) XL1-Blue supercompetent cells 
(Strategene) for cDNA amplification and extracted using MiniPrep Wizard (Qiagen).  
Sequencing of clones by the UNC-CH Genome Analysis Facility confirmed incorporation of 
the mutations into the α1PIPittsburgh-pQE30 construct. 
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Figure 3.1. α1PI ribbon structures with highlighted D-helix and helical wheel representations of 
α1PI, HCII and α1PIPitt-GAG. Panel A shows α1PI ribbon structure (PDB #1OPH286) in its classical 
view with D-helix highlighted. Panel B shows α1PI (PDB# 1HP7285) rotated 110 degrees around the 
x axis and zoomed in on the D-helix so that the view is through the bottom of the D-helix displaying 
the side-chains of the D-helix residues as they are seen in the helical wheel representation in Panel C.  
Hydrophobic residues are indicated by grey coloring Panels C, D and E. Positively and negatively 
charged residues are shown with plus and minus signs respectively.  Panel D illustrates the helical 
wheel representation of the HCII D-helix, while Panel E shows the helical wheel representation of 
α1PIPitt-GAG D-helix. 
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Protein Expression and Purification 
α1PIPittsburgh and α1PIPitt-GAG proteins were expressed and purified with minor 
modifications as previously reported284.  Briefly, cDNA in the pQE30 vector was 
transformed into competent SG13009  Escherichia coli (E. coli) (Qiagen) and grown inLuria-
Bertani media containing 100 μg/mL ampicillin and 25 μg/mL kanamycin to an absorbance 
at 600 nm of 0.6. Protein expression was induced using 1 mM isopropyl-β-D-
thiogalactopyranoside (Promega) at 27° C for approximately 6 hours. Cell lysate in 20 mM 
sodium phosphate, 500 mM NaCl pH 7.4 containing 20 mM imidazole was loaded onto the 
Sepharose immobilized nickel affinity column, HisTrap HP (Amersham Biosciences). The 
serpin was eluted using the same buffer containing 500 mM imidazole. EDTA was added to 
the elution to reach a final concentration of 10 mM. The protein was then dialyzed overnight 
against 20 mM Tris, 50 mM NaCl pH 8.0 for future kinetic studies or 20 mM Hepes, 0.1 % 
PEG pH 7.4 for affinity chromatography studies. Final concentrations were determined by 
absorbance at 280 nm (A280) based upon Mr = 45,100 and using an extinction coefficient of 
0.43 M-1 cm-1283.  
 
Non-Denaturing Gel Electrophoresis 
  Seven μg each of α1PIPittsburgh and α1PIPitt-GAG were electrophoresed through native 
gels containing 7.5% polyacrylamide, 375 mM Tris pH 8.0, in 25 mM Tris, 191 mM glycine 
running buffer. The gel was then stained with Coomassie Brilliant Blue R-250 (GibcoBRL) 
and destained until sufficient background was removed to visualize bands.  
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Heparin-Sepharose Affinity Chromatography 
 The relative affinity of α1PIPitt-GAG, α1PIPittsburgh, and human, plasma-derived HCII 
for heparin was determined using a FPLC apparatus.  Protein was injected onto a 1 mL 
HiTrap heparin-Sepharose column (Amersham Biosciences) and eluted using NaCl gradient 
from zero to 500 mM in Hepes buffer pH 7.4. A280 was measured for each 1 mL fraction of 
α1PIPitt-GAG and α1PIPittsburgh.  The peak elution ionic strength was determined by plotting 
A280 versus the fraction number. Alternatively, peak elution ionic strength for HCII as 
determined by dermatan sulfate activity in each 1 mL fraction (method previously 
reported287). 
 
Inhibition of Proteases in the Presence and Absence of Heparin or Dermatan Sulfate 
 Second order rates of inhibition were determined by measuring chromogenic 
development of para-nitroanaline substrate cleavage in a 96-well plate by absorbance at 
405nm using a Thermomax microplate reader from Molecular Devices for three hours in the 
presence of protease, serpin and GAG.  Proteases used included α- and γ-thrombin 
(Haematologic Technologies), R101A-thrombin [(chymotrypsinogen numbering system)288 
also designated R98A (thrombin numbering system)289 --a gift from the Leung lab at 
Stanford University School of Medicine], and activated protein C (APC) (Haematologic 
Technologies) and trypsin (Sigma) in concentrations of 200 pM, 1 nM, 400 pM, 2 nM and 1 
nM respectively. α1PIPittsburgh or α1PIPitt-GAG was employed in concentrations of 50 nM for 
thrombins and 100 nM for other proteases. HCII was used at a final concentration of 5 nM.  
In HCII assays using low concentrations of heparin (67 nM and 667 nM) or dermatan sulfate 
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(20 nM and 200 nM), only 100 pM thrombin was used. Chromogenic substrates (all purchase 
from Centerchem) included PefachromeTH (150 μM) for thrombins, PefachromePCA (300 
μM) for APC and Tos-Gly-Gly-Pro-Arg-pNA-AcOH substrate (300 mM) for trypsin.  
Finally, GAG concentrations varied from 66 nM to 133 μM for unfractionated heparin (Mr = 
15,000, Diosynth) and from 20 nM to 40 μM for dermatan sulfate (Mr = 50,000, 
Calbiochem). Solutions were made in buffer containing 20 mM Hepes, 150 mM NaCl, 0.1% 
PEG 8000, 0.05% NaN3 and 0.1% ovalbumin. Calcium chloride (2.5 mM) was included in 
APC assays. (Note, concentrations over 5 μM GAG were not tolerated by the APC assay; the 
curve of the data was altered and awkward to interpret.)    
For each heparin or dermatan sulfate concentration, complete thrombin inhibition was 
identified by a change of < 0.01 absorbance units over 5 minutes. Each data set was truncated 
at this point and resultant data was fit to the equation: abs = ((V∞ *t)+(( V0– V∞)*(1-exp(-
kobs*t)))/ kobs)+A0  where abs is the absorbance at 405 nm, t is time in seconds, V0 is the 
initial velocity of substrate cleavage and V∞  is the final (infinite) rate of substrate cleavage 
and kobs is the observed rate of complex formation110.  Second order rates of inhibition, k2, 
were calculated using the equation: k2 = kobs/ [serpin] * (1+ Km/[substrate])290 where Km is 
equal to the half-maximal rate of substrate cleavage by protease.  Km values for all 
chromogenic substrate-protease pairs were determined in our laboratory using the same 
buffers used for inhibition assays. Each condition was performed in duplicate in each 
experiment and each experiment was performed three times.  Second order rates of inhibition 
were plotted versus heparin or dermatan sulfate concentration.  The rate of thrombin 
inhibition by HCII in the absence of GAG is too slow to be determined by this assay.  It was 
determined by a previously described method291. 
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Stoichiometry of Inhibition of Protease by Serpin in the Presence and Absence of Heparin 
or Dermatan Sulfate 
 
 The stoichiometry of inhibition (SI) value for each protease-serpin pair in the 
presence and absence of heparin (6.7 μM), and for each thrombin-derivative-serpin pair in 
the presence of dermatan sulfate (20 μM), was determined by incubating 1 nM protease (α-
thrombin, γ-thrombin, R101A-thrombin, trypsin or APC) with varying concentrations of 
α1PIPittsburgh or α1PIPitt-GAG from 0.25 – 10 nM at room temperature overnight in 96 well 
plates and utilizing the same buffer as used for kinetic assays.  Chromogenic substrate (150 
μM PefachromeTH for thrombins or 100 μM PefachromePCA for APC and trypsin) was 
then added to the solutions. Residual protease activity was measured on the Thermomax by 
absorbance at 405 nm.  Residual protease activity for each concentration of serpin was 
divided by the activity in a control well containing no serpin and plotted versus serpin 
concentration (data not shown).  A straight line was fit through points at concentrations still 
possessing protease activity.  The value for the stoichiometry of inhibition was considered to 
be the x value of this line when y = 0. 
 
GAG-Binding Affinity Determined by Extrinsic Fluorescence 
 Affinity of α1PIPittsburgh, α1PIPitt-GAG, or HCII for either heparin or dermatan sulfate 
were investigated as previously reported for HCII and AT100,292.  Briefly, fluorescence 
emission spectra (400 – 500 nm) resulting from the excitation of 5 μM toluidino-2-
naphthalenesulfonic acid (TNS) at 330 nm in buffer containing 50 mM Tris, 1% PEG 8000, 
50 mM NaCl, pH 7.4 with the addition of 250 nM serpin were measured, at each titration of 
heparin, dermatan sulfate or buffer using a Perkins Elmer Instruments LS55 luminescence 
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spectrometer. Excitation slit width and emission slit width were set to 10 nm and 15 nm 
respectively. The fluorescence spectrum of TNS alone was subtracted from all TNS-serpin 
and TNS-serpin-GAG spectra. TNS-serpin fluorescence for each GAG titration was divided 
by TNS-serpin fluorescence for each buffer titration to control for dilution effect and 
machine drift.  Dissociations constant (Kd) was determined by plotting the average 
percentage change in fluorescence at 435 nm versus GAG concentration and curve-fit using 
SlideWrite Plus version 6.0 software to the equation: F/F0= j-((Fmax*([P0]+[GAG]+ Kd -(( 
[P0]+[GAG]+ Kd)^2-4*[P0]*X)^0.5))/(2*[P0])).  F/F0 is the ratio of fluorescence emission 
upon titration to initial fluorescence emission of TNS-serpin in the absence of GAG. [P0] is 
the initial concentration of serpin, set at 250 nM, and [GAG] is the heparin or dermatan 
sulfate concentration. The variable j is included to accommodate minor deviations of F/F0 in 
the absence of GAG that were introduced by mathematical controls and instrument 
variability.  The value for j never deviated more than 0.04 from 1. Fmax and Kd (calculated by 
curve fit) represent maximal fluorescent change at saturation and heparin dissociation 
constant, respectively. Each assay was performed at least twice in duplicate. 
 
RESULTS 
Alignment of α1PI and HCII D-helices 
Overlay of the crystal structures of α1PI (PDB#1OPH286) (Figure 3.1A) and HCII 
(PDB# 1JMO152) showed structural alignment of the D-helices from α1PI residue Glu 89 to 
Pro 106 with HCII residues Ile 176 to Arg 193.  Rotating α1PI backwards ~110 around the x-
axis (Figure 3.1B) showed the approximate alignment of the residues in the D-helix as they 
are represented in helical wheel projections (Figure 3.1C).  Comparison of the HCII and 
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 α1PI D-helices shows a conserved hydrophobicity along the inside of the D-helix and a 
distinct divergence of charge on the outer portion of the D-helix (Figure 3.1C & ID).  
Residues on  α1PI at the same position as the basic residues on HCII were mutated to 
become homologous with HCII. The resultant D-helix structural alignment is shown in 
Figure 3.1E.  This molecule, α1PIPitt-GAG has a net charge difference of + 6 as compared to 
α1PIPittsburgh. 
 
Expression and Purity of α1PIPittsburgh and α1PIPitt-GAG 
 Expression levels of α1PIPittsburgh were not altered by mutations in α1PIPitt-GAG and as 
expected both proteins ran as single bands with molecular weights of ~45kD on Coomassie 
Brilliant Blue R-250 stained SDS-PAGE (data not shown). In order to illustrate the 
difference in charge, these proteins were subjected to non-denaturing gel electrophoresis.  
Figure 3.2 (inset) shows that α1PIPittsburgh and α1PIPitt-GAG each ran as a single band and that 
α1PIPitt-GAG migrated farther toward the cationic pole than α1PIPitt-GAG indicating a lesser net 
positive charge α1PIPittsburgh and α1PIPitt-GAG. 
 
Heparin Binding Characterization 
In order to evaluate heparin binding capacity, the sodium chloride concentration 
required to elute α1PIPittsburgh and α1PIPitt-GAG from heparin-Sepharose was determined. Peak 
α1PIPittsburgh concentration was eluted ~200 mM NaCl, while peak α1PIPitt-GAG was eluted in 
~300 mM NaCl (Figure 3.2).  Under the same conditions, plasma HCII was eluted in ~450 
mM NaCl.  These results indicate that α1PIPitt-GAG has gained increased heparin binding 
capacity over α1PIPittsburgh, but has not achieved the heparin binding capacity of HCII. 
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Second Order Rates of Inhibition (k2) in the Presence and Absence of Heparin and 
Dermatan Sulfate 
 
Because α1PIPittsburgh readily inhibits thrombin, trypsin and APC, we calculated the 
k2’s of these proteases by both α1PIPittsburgh and α1PIPitt-GAG in the absence of GAGs in order 
to determine if the mutation affected the serpin’s activities. No substantial difference in rates 
was seen between α1PIPitt-GAG and α1PIPittsburgh for any of these protease pairs (Table 3.1). 
Upon discovering GAG accelerated thrombin inhibition (see below) we also measured the 
rates of inhibition of two additional thrombin derivatives to examine thrombin-exosite 
interactions.   Certain structural components of thrombin are important for serpin activity and 
Figure 3.2.  Gel and column chromatography of  α1PIPitt and α1PIPitt-GAG. Squares and circles show 
the elution profiles measured by absorbance at 280 nm of α1PIPittsburgh and α1PIPitt-GAG respectively 
from a HiTrap heparin-Sepharose column by NaCl gradient (dotted line and right axis). Arrow 
indicates the peak elution of HCII under similar conditions. Inset depicts the electrophoretic migration 
of purified α1PIPittsburgh (Lane 1) and α1PIPitt-GAG (Lane 2) through a non-denaturing polyacrylamide gel. 
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GAG-binding, including its active site and two electropositive areas, exosite-1 and exosite-
2293.  Exosite-1 binds the N-terminal acidic domain of HCII and exosite-2 binds heparin and 
other GAGs294-296.  Derivatives of thrombin deficient in exosite activity such as γ-thrombin, a 
proteolytically modified thrombin with reduced exosite-1 activity95,297 and a mutant thrombin 
(R101A) with reduced exosite-2 activity289,298,299, have been used to explore both serpin and 
GAG interactions.  Similarily, results showed little change for these thrombins between 
α1PIPitt-GAG and α1PIPittsburgh in the absence of GAGs (Table 3.1). 
 
Table 3.1. Second order rates of inhibition (k2) of protease by α1PIPittsburgh  or α1PIPitt-GAG  in the 
absence of GAGs.  Average values are shown  ± the standard error based on at least three independent 
assays performed in duplicate. 
k2 x 105 M-1s-1 α-thrombin γ-thrombin 
R101A-
thrombin 
APC trypsin 
α1PIPittsburgh 0.99 ± 0.17 1.18 ± 0.21 1.13 ± 0.03 0.19 ± 0.011 0.25 ± 0.009 
α1PIPitt-GAG 1.25 ± 0.14 1.28 ± 0.13 1.41 ± 0.14 0.20 ± 0.003 0.24 ± 0.008 
 
Next, we measured the k2’s in the presence of varying concentrations of heparin and 
dermatan sulfate to evaluate the ability of GAGs to alter rates of inhibition for the serpin-
protease pairs.  As expected, the inhibition of α-thrombin by HCII in the presence of GAGs 
(Figure 3.3A) was accelerated approximately 6,700 fold by 5 μM heparin and 7,500 fold by 
10 μM dermatan sulfate with diminishing rates at higher concentrations. The inhibitory 
activity of α1PIPitt-GAG was accelerated by both heparin (Figure 3.3B) and dermatan sulfate 
(Figure 3.3C) for all thrombin derivatives. In the presence of heparin, the rate enhancement 
of α-thrombin was the greatest and also took the least amount of heparin to achieve (Table 
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3.2).  This was followed by γ-thrombin, then R101A-thrombin both of which had 
increasingly reduced rates and took increasingly more heparin to achieve maximal inhibition. 
At high levels of heparin, a decrease in the rate of the inhibition of all the thrombin 
derivatives was observed. Although the fold-stimulation was reduced for dermatan sulfate as 
compared to heparin (Table 3.2), the data consistently showed a reliable pattern of 
acceleration (Figure 3.3C).  Maximal inhibition of α-thrombin was achieved at 20 μM 
dermatan sulfate and a subsequent decrease in rate was observed at increasing 
concentrations.  Maximal inhibition of γ-thrombin and R101A-thrombin were observed at the 
highest concentrations of dermatan sulfate (40 μM) utilized in these experiments. 
 
Table 3.2.  Second order rates of inhibition (k2) α1PIPitt-GAG  inhibition of thrombin derivatives in the 
prescence or absence of heparin or dermatan sulfate, and the fold acceleration at [peak 
concentration of GAG].  Average values are shown  ± the standard error based on at least three 
independent assays performed in duplicate. 
k2 x 105 M-1s-1 - GAG + heparin 
Fold 
acceleration 
[heparin] 
+ dermatan 
sulfate 
Fold 
acceleration 
[dermatan 
sulfate] 
 
α-thrombin 
 
1.25 ± 0.14 
 
19.8 ± 4.15 
 
15.8 [3.33 
μM] 
 
2.11 ± 0.23 
 
1.69 
[20.0 μM] 
 
γ-thrombin 
 
1.28 ± 0.13 
 
13.8 ± 1.57 
 
10.8 
[5.00 μM] 
 
1.83 ± 0.03 
 
1.43 
[40.0 μM] 
 
R101A-
thrombin 
 
1.41 ± 0.14 4.05 ± 0.31 2.87 [6.7 μM] 1.97 ± 0.01 1.40 [40.0 μM] 
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Figure 3.3. Second order rates of inhibition (k2) α1PIPitt,  α1PIPitt-GAG or HCII in the presence and 
absence of  heparin or dermatan sulfate.  Panel A depicts the change second order rates of inhibition 
of α-thrombin by HCII in the presence of heparin (diamonds) or dermatan sulfate (inverted triangles).  
Panels B and C illustrates the change in the second order rates of inhibition of α-thrombin (squares), 
γ-thrombin (circles) or R101A-thrombin (triangles) by α1PIPitt, (open symbols) and α1PIPitt-GAG (filled 
symbols) in the presence of increasing concentrations of heparin (Panel A) or dermatan sulfate (Panel 
B).   
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No change was observed in the inhibitory activity of thrombins by α1PIPittsburgh in the 
presence of either heparin (Figure 3.3B) or dermatan sulfate (Figure 3.3C). Likewise, neither 
inhibition of APC nor trypsin by α1PIPitt-GAG showed an enhancement in rate in the presence 
of heparin.  Rather, for all protease-serpin pairs there appeared to be a slight but steady 
decrease in the rates with increasing amount of heparin (data not shown).  
Collectively, these results confirm that not only did the D-helix mutations confer GAG 
binding to both heparin and dermatan sulfate, they also conferred an HCII-like, GAG-
accelerated pattern of thrombin inhibition that approached maximal HCII rates.  Furthermore, 
they indicate that reduction in exosite-2 activity in thrombin (the heparin binding region) has 
a profound effect on heparin-accelerated activity indicating the need for an intact exosite-2, 
or bridging of heparin to thrombin, for the majority of the acceleration seen here.  
  
Stoichiometry of Inhibition (SI) in the Presence and Absence of Heparin and Dermatan 
Sulfate  
 
Stoichiometries of inhibition of proteases by α1PIPittsburgh or α1PIPitt-GAG in the 
presence and absence of GAGs were measured to ensure that the D-helix mutations did not 
alter the substrate characteristics of α1PIPittsburgh for the proteases nor did GAGs binding to 
α1PIPitt-GAG effect the substrate capacity of the serpin.  Results shown in Table 3 indicate that 
there no substantial difference between the stoichiometry of inhibition for most of the protein 
pairs, nor do GAGs affect this relationship. The one exception is that the SI of R101A-
thrombin is somewhat lower for α1PIPitt-GAG than for α1PIPittsburgh both with and without 
heparin. However, since the drop in SI is very similar both in the absence and presence of 
heparin (1.53 and 1.78, respectively), it cannot account for the acceleration of R101A-
inhibition seen at peak heparin concentrations.  Overall, these results indicate that mutating 
 82 
 
the D-helix of α1PIPittsburgh does not increase or decrease its propensity to act as a substrate 
for these specific proteases, and that minor variations in SI values are not responsible for the 
increased rates of thrombin inhibition observed in the presence of GAGs. 
 
Table 3.3. Stoichiometry of inhibition values for α1PIPittsburgh or α1PIPit-GAG and protease in the 
presence or absence of heparin or dermatan sulfate. Average values are shown  ± the standard error 
based on at least three independent assays performed in duplicate. (N.D. = not determined). 
            NO GAG heparin dermatan sulfate 
 α1PIPittsburgh α1PIPitt-GAG α1PIPittsburgh α1PIPitt-GAG α1PIPittsburgh α1PIPitt-GAG 
α-thrombin 1.53 ± 0.07 1.74 ± 0.11 1.79 ± 0.06 2.11 ± 0.08 2.72 ± 0.11 2.61 ± 0.17 
γ-thrombin 2.58 ± 0.35 2.03 ± 0.21 2.48 ± 0.24 1.86 ± 0.06 0.88 ± 0.02 0.84 ± 0.04 
R101A-
thrombin 2.03 ± 0.08 1.33 ± 0.19 2.13 ± 0.07 1.20 ± 0.16 1.71 ± 0.13 1.73 ± 0.07 
APC 1.61 ± 0.16 1.55 ± 0.25 1.70 ± 0.19 1.63 ± 0.29 N. D. N. D. 
trypsin 1.41± 0.14 1.46± 0.06 1.32± 0.19 1.50± 0.14 N. D. N. D. 
 
 
GAG-Binding Affinity Determined by Extrinsic Fluorescence 
 Finally, we used TNS extrinsic fluorescence to examine the binding affinity of the 
α1PIPitt-GAG mutant for heparin and dermatan sulfate and to investigate their potential 
allosteric effects on the serpins.  TNS has been used to measure the GAG-binding affinity of 
serpin-GAG in instances where the introduction of GAG causes a conformational change in 
the serpin, consequently altering the TNS environment and thus its fluorescence 
spectrum100,292.  HCII-heparin is one such serpin-GAG pair100.  In the current study, the 
addition of HCII to TNS alone caused an increase in peak fluorescence emission from ~200 
to ~600 units and induced a blue shift from a peak of ~450 nm to ~440 nm.  The addition of 
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either α1PIPittsburgh or α1PIPitt-GAG to TNS produced very similar emission spectra with an 
increase to ~300 fluorescence units and a mild blue shift to ~450 nm. The titration of heparin 
to HCII-TNS caused a 48% reduction in fluorescence signal and red shift of ~5 nM, while 
the titration of dermatan sulfate to HCII-TNS resulted in a 13% drop in fluorescence signal 
and with no shift in the peak emission wavelength.  The titration of heparin to α1PIPitt-GAG 
also caused a 13% quench in fluorescence signal without a shift in peak emission 
wavelength. Titration of dermatan sulfate into α1PIPitt-GAG and titrations of either heparin or 
dermatan sulfate into α1PIPittsburgh failed to produce a systematic change in TNS-serpin 
spectra (data not shown). 
 
Figure 3.4. Change in TNS fluorescence emission at 435 nm.  Data points depict HCII (squares) or 
α1PIPitt-GAG (circles) with titration of heparin (filled symbols) or dermatan sulfate (open symbols).  
Lines are fit to the equation  F / F0 =  (j - (Fmax* ([P0] + [GAG] + Kd - (([P0] + [GAG] + Kd)^2 – 4 * 
[P0] * [GAG])^0.5)) / (2 * [P0]), where [P0] = 250 nM  and j is a variable for the accommodation of 
F/F0 ≠ 1 due to  instrument and human variability. 
 
The half-maximal binding equilibrium constant or dissociation constant, Kd,  for HCII 
and heparin was measured to be 397 nM (r2 = 0.99, Fmax = 0.48) (Figure 3.4).  This is 
consistent with previously reported Kd measured by other methods300, and while they cannot 
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be directly compared with data from O’Keefe et al.100 due to different ionicity reported for 
HCII and unfractionated heparin in that study, they are consistent with their data ranges and  
patterns.  Similarily, titration of dermatan sulfate into TNS-HCII resulted in a Kd , 814 nM (r2 
= 0.97, Fmax = 0.13) (Figure 3.4), consistent with that determined by other methods300, but 
which has not been previously reported using this method. Under these same conditions the 
Kd for α1PIPitt-GAG with heparin was calculated to be 645 nM (r2 = 0.87, Fmax = 0.13) (Figure 
3.4).    These results might be interpreted to conclude that heparin is able to induce a 
conformational change in α1PIPitt-GAG and that α1PIPitt-GAG binds heparin with slightly less 
affinity than HCII binds heparin but with better affinity than HCII binds dermatan sulfate.  
However, we should note that the increase in fluorescence emission of TNS-α1PIPitt-GAG over 
TNS alone is small.  Therefore, once background TNS is subtracted from the α1PIPitt-GAG 
fluorescence spectra, the signal-to-noise ratio is increased.  So while a consistent systematic 
quenching of fluorescence signal was observed, the noise limited the accuracy of the 
observed curve-fit. 
 
DISCUSSION 
This study illustrates three purposes for using gain-of-function manipulations in 
serpin study: 1) to determine whether specific functions can be transferred with their 
purported associated structures; 2) to isolate and examine the relationship between a structure 
and its activity; 3) to develop promising new proteins for therapeutic purposes. We 
endeavored to engineer this novel serpin primarily for the first two reasons: to determine 
whether HCII-like GAG-binding can be conferred to a non-GAG-binding serpin and explore 
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what this tells us about GAG-binding in HCII and other serpins, with the understanding that 
the manipulation of GAG-binding capacity could have therapeutic applications. 
The engineering of α1PIPitt-GAG achieved successful transfer of heparin and dermatan 
sulfate binding and associated functional characteristics, specifically, the acceleration of 
thrombin inhibition and allows for the examination of HCII GAG-binding outside the context 
of the unique HCII structure.  This gain-of-function approach is rarely employed in the study 
of serpins outside the mutation of RCL residues to alter protease specificity.  Exceptions in 
the literature include several studies with the three primary goals described above. 
Grasberger et al.281 were the first to pioneer the concept of transferring foreign functionality 
to one serpin by replacing entire structural domains with those from a different serpin.  These 
investigators substituted the thyroxine binding domain of the serpin, thyroxine binding 
globulin onto α1PI  to produce a chimeric serpin that gained thryoxine binding capacity, but 
did not lose its primary neutrophil elastase inhibitory activity.  The primary purpose of this 
experiment was to examine the modularity of serpins and determine if bifunctional serpins 
could be created from structurally homologous but functionally diverse family members.  
McCarthy et al.301 created chimeric proteins in order to investigate the functionality of a 
specific structural region in serpins.  These investigators transferred increasing percentages 
of the C-terminus of the inhibitory serpin, plasminogen activator inhibitior-2 (PAI-2) to the 
non-inhibitory serpin, ovalbumin.  Inhibitory activity observed in a chimera with 64% PAI-2, 
but was not seen in the chimera with only 35%.  They were thus able to pinpoint the 
structural differences between these chimeras to identify the critical region for inhibition.  
Finally, Sutherland et al.302 added the N-terminal extension including the acidic domain of 
HCII onto α1PIPittsburgh. They were able to investigate the role of the N-terminus outside the 
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context of the HCII molecule.  Additionally, the appendage bestowed α1PIPittsburgh the ability 
to interact with thrombin exosite-1, thus increasing its inhibition of thrombin, but having 
little effect on its inhibition of APC.  The overall result was the creation of a chimeric serpin 
with an increased ratio of thrombin to APC inhibition, which is beneficial in the development 
of potential therapeutic anticoagulants. 
The results from our study further confirm the notion that the homology of serpins 
affords not only the exchange of structural components between serpins, but also their 
associated activity. Specifically, it demonstrates that with the substitution of only 5 amino 
acids, GAG-binding can be conferred to a non-GAG binding serpin without diminishing the 
inhibitory activity of the parent protein. α1PIPitt-GAG bound heparin-Sepharose with greater 
affinity than α1PIPittsburgh and eluted in a salt concentration greater than physiologic strength.  
Additionally, heparin and dermatan sulfate were both able to accelerate α1PIPitt-GAG 
inhibition of thrombin indicating that activity was conferred along with the addition of the 
basic charges in the D-helix.  The increase in thrombin inhibition by α1PIPitt-GAG in the 
presence of dermatan sulfate is also evidence of binding and hence, indicates HCII-specific 
qualities in α1PIPitt-GAG. 
HCII shows up to 20,000 fold stimulation of thrombin inhibition in the presence of 
heparin and dermatan sulfate, while α1PIPitt-GAG demonstrated only a 15 fold increase with 
heparin and approximately two fold increase in the presence of dermatan sulfate.  The unique 
N-terminal extension of HCII is responsible for the majority of its GAG-accelerated activity.  
GAG-binding works through an allosteric mechanism whereby a global conformational 
change is induced, extending the RCL while releasing the N-terminal acidic domain to 
interact with thrombin exosite-1. Mutants of HCII with the N-terminal extension 
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truncated287,297,303 are more akin to the α1PIPitt-GAG molecule created here.  These mutants 
show 5-40 fold stimulation of thrombin inhibition in the presence of heparin and 0-3 fold 
acceleration in the presence of dermatan sulfate, ranges very like to those found in this study. 
Similarly, when exosite-1 is eliminated in thrombin (e.g., γ-thrombin), so that HCII cannot 
utilize exosite-1 binding, the remaining GAG-accelerated inhibition of the exosite-1-deficient 
thrombin is along the first order of magnitude; 3-10 fold acceleration is seen with 
heparin95,101,303,304 and ~10 fold acceleration is seen with dermatan sulfate101.   
Although α1PIPitt-GAG has no HCII- like N-terminal extension to interact with 
thrombin exosite-1, we still see a mild drop in acceleration in the presence of heparin (15 
fold to 10 fold) and dermatan sulfate (1.7 fold to 1.4 fold) from α-thrombin to γ-thrombin 
inhibition, but with no difference between the inhibition of the two thrombins in the absence 
of GAGs.  While this might be interpreted as exosite-1 involvement in GAG-binding, it is 
much more likely that there may be a small amount of non-specific GAG-binding to 
thrombin in effect for the GAG-acceleration seen in these assays or that the ablation of 
exosite-1 has an indirect effect on exosite-2305,306 binding and reflects thrombin-GAG 
binding effects rather than serpin-thrombin interactions. This is supported by the fact that a 
drop in acceleration with γ-thrombin as compared to α-thrombin inhibition in the presence of 
heparin is also seen with antithrombin304 even though the crystal structure of the ternary 
complex (AT-heparin-thrombin) shows no exosite-1 involvement118,134. 
The GAG-accelerated HCII activity reported both with N-terminal truncated HCII 
and γ-thrombin is generally attributed to the bridging mechanism, from the D-helix region to 
the protease.  Mutations in thrombin exosite-2, thrombin’s heparin and dermatan sulfate 
binding region298, shows a small reduction in  heparin accelerated activity by HCII (<10 
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fold)298,299,303.  Results with dermatan sulfate varied, showing no change between HCII peak 
rates of inhibition of exosite-2-diminished thrombin and α-thrombin298 using a quadruple 
mutation (R89E, R245E, K248E, K252E – thrombin numbering system) in exosite-2, or a ~2 
fold reduction using a single point mutation (R101A)299.  In this study, we observe a 7 fold 
reduction in heparin accelerated inhibition of R101A-thrombin and α-thrombin by α1PIPitt-
GAG, but no change in the acceleration in the presence of dermatan sulfate.  Together, the 
results indicate that the majority (~7 fold) of heparin acceleration of thrombin inhibition by 
α1PIPitt-GAG is due to bridging between the positively charged D-helix and thrombin’s 
exosite-2.   The remaining 2 fold stimulation seen in α1PIPitt-GAG in the presence of heparin 
and dermatan sulfate, cannot be accounted for by bridging or, not surprisingly, by exosite-1 
interactions. These results mimic the GAG-acceleration of HCII’s thrombin inhibition when 
exosite-1 interactions have been eliminated. 
The logical explanation for the above results is that both heparin and dermatan sulfate 
induce a conformational change in α1PIPitt-GAG that increases its thrombin inhibition 
approximately two-fold.  This is supported by the evidence that heparin titration results in a 
reduction of TNS-α1PIPitt-GAG fluorescence.  This cannot be accounted for by TNS competing 
with heparin for the positively charged D-helix as both α1PIPitt-GAG and α1PIPittsburgh showed 
the same increase and shift in peak fluorescence emission when added to TNS.  However, 
only a quenching was observed with TNS-α1PIPitt-GAG.  Titration with dermatan sulfate did 
not exhibit this same quenching.  However, while HCII-TNS showed a dramatic reduction in 
fluorescence emission with heparin titration, the same degree quenching was not observed 
with dermatan sulfate titration.  This is not to say that HCII does not undergo conformational 
change in the presence of dermatan sulfate, indeed it does.  It does demonstrate that the 
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changes in the TNS-HCII environment brought about by dermatan sulfate are different than 
those engendered by heparin. If dermatan sulfate has a similarly reduced effect on α1PIPitt-
GAG-TNS, given the maximal fluorescence change was already small, it may not be detected 
in this assay.  
 The GAG-induced conformational change that we have reasoned to account for a 
portion of the acceleration of thrombin inhibition by α1PIPitt-GAG is perplexing. Both HCII 
and AT exhibit structural modifications upon GAG-binding; their RCLs are expelled from 
insertion into β-sheet A which exposes the previously protected P1 arginine in AT267,307 and 
simultaneously liberates the N-terminal acidic domain in HCII152,303.  Because the RCL of 
α1PI is not inserted into the β-sheet A, nor does it have an N-terminal extension285, neither 
can describe the conformational change presumably occurring when GAGs bind the D-helix 
of α1PIPitt-GAG.   GAG-binding also generates new exosites on AT for factors IXa and Xa 
interaction96.  The formation of novel exosites on α1PIPitt-GAG for thrombin interface is one 
explanation which could account for both the TNS-fluorescence quenching and accelerated 
thrombin inhibition upon GAG-binding.  However, the complex and exquisite nature of 
serpin-protease interactions intimates a protracted evolutional development of their 
complementary structures.  It is quite improbable that generation of an exosite for thrombin 
would be a consequence of GAG binding to α1PIPitt-GAG.  Thrombin is not a physiological 
target-protease for α1PI, α1PI does not bind GAGs and α1PIPittsburgh is a rare variant with 
severe health consequences, thus, there is no evolutionary pressure for the development of 
GAG-induced thrombin exosites.   
One plausible GAG-induced conformational change which could be occurring in 
α1PIPitt-GAG is the elongation of the D-helix.  Antithrombin exhibits elongation of its D-helix 
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upon GAG binding that contributes to the expulsion of the RCL and translates into increased 
inhibitory activity307-309. It is undetermined whether this occurs in HCII or other GAG-
binding serpins. Thus we can only speculate that D-helix elongation could be the structural 
change that results in quenching of the TNS-α1PIPitt-GAG fluorescent signal.  Even so, it is 
unclear how this might result in increased thrombin inhibition by α1PIPitt-GAG.    
Although we are unable to provide a cogent description of the conformational change 
that may take place in α1PIPitt-GAG when it binds heparin or dermatan sulfate, we are able to 
assert that any transformation that occurs can be attributed to binding at the D-helix.   What 
is particularly interesting about this is that α1PIPitt-GAG, whose parent protein α1PI does not 
bind GAGs, harbors the ability to change its conformation when GAGs interact with its D-
helix. This speaks to the conservation of structure in serpins and the centrality of the D-helix 
region to GAG-acceleration of thrombin inhibitory serpins. Virtually all of the naturally 
occurring human serpins that inhibit thrombin utilize the D-helix for GAG-binding.  We 
hypothesize that the conserved structural environment of serpins’ D-helices fetters their 
conformational rearrangement and that engagement of the D-helix region with GAGs eases 
the constraint.  If you will, the D-helix region acts as a lock on the serpin, GAGs—the key(s).  
Binding of a GAG unlocks the serpin, permitting or promoting the other structural changes to 
take place, such as release of the N-terminus, expulsion of the RCL, generation of new 
exosites, some undetermined structural rearrangement or perhaps just facilitated insertion of 
the RCL into β-sheet A.  Using further manipulations and this same gain-of-function strategy 
could prove useful in investigating the D-helix region as potential serpin lock.  
While developing a therapeutic anticoagulant was not the goal of this study, the 
addition of GAG-binding to α1PIPittsburgh has potential usefulness for the treatment of 
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thrombosis.  The chimeric serpin created by Sutherland et al.302, which appended the N-
terminus including the acidic domain of HCII onto α1PIPittsburgh  showed 21 fold 
augmentation of thrombin inhibition with little effect on APC inhibition or stoichiometries of 
inhibition. The authors point out the benefit that such an increase in thrombin: APC 
inhibitory ratio could have if pursued as an anticoagulant.  In the presence of GAGs, α1PIPitt-
GAG achieved similar enhancement in thrombin inhibition (up to 15 fold) while no changes 
were observed in APC inhibition or stoichiometries of inhibition.   As α1PIPitt-GAG is able to 
bind both heparin and dermatan sulfate, manipulation of such a GAG-binding mutant has the 
added potential to be targeted to specific locations in the intra- and extra- vasculature where 
heparan sulfate and dermatan sulfate are found.   Finally, GAG binding is also an important 
element in the function of an array of proteins in addition to serpins including many growth 
factors (e.g., acidic and basic fibroblast growth factors, insulin-like growths factor and 
insulin-like growth factor binding proteins, EGF-like growth factors) and the heparin binding 
proteins that affect DNA synthesis.  Therefore, the ability to engineer GAG-binding and 
confer a functional benefit may be a novel and useful tool for the development of chimeric 
proteins to combat not just thrombosis, but numerous other pathologies.  
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CHAPTER 4  
Engineering of the thrombin-inhibiting chimeric serpin, HATpin 
 
SUMMARY 
In addition to its central role in thrombosis, thrombin also has pro-inflammatory 
functions that contribute to cardiovascular disease (CVD).  Interestingly, thrombin can also 
act in anti-thrombotic and anti-inflammatory capacities by activating protein C. 
Serine protease inhibitors (serpins) are a family of proteins with high structural homology, 
such that it is possible to transfer individual domains between serpins and confer related 
activity.  Heparin cofactor II (HCII) and antithrombin (AT) are serpins with unique structures 
regulating thrombin inhibition. The goal of this project was to engineer a chimeric serpin, 
HATpin, by transferring HCII and AT structural elements to α1-protease inhibitor-M358R 
(α1PIPittsburgh) that specifically inhibits the coagulant and atherogenic functions of thrombin 
without altering its Protein C activating function with purpose of creating a novel 
preventative therapy for CVD.  
The N-terminal region of HCII (comprising its unique acidic domain through its 
glycosaminoglycan-binding domain) and the reactive center loop (RCL) of AT were 
substituted onto α1PIPittsburgh.  The presence of specific structural components was confirmed 
by immunoblot.  RCL integrity was determined by visualization of HATpin-thrombin 
complex. HATpin was observed to have heparin binding capacity greater than α1PIPittsburgh 
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but less than HCII as measured by elution from a heparin column.  Inhibition of thrombin 
and activated protein C (APC) and factor Xa and their stoichiometries of inhibition by 
HATpin were measured using chromogenic assays in the presence and absence of 
glycosaminoglycans.  Results indicate that despite having all of the elements that would 
predict the creation of a superior thrombin inhibitor for anticoagulation, HATpin fell short of 
this goal.  Potential explanations for these unexpected results are provided.  
 
INTRODUCTION 
Cardiovascular Disease and Its Pharmaceutical Treatment  
 Cardiovascular disease (CVD) is responsible for the death and debilitation of 
millions of people each year and billions of dollars in healthcare costs1.  Therefore it is 
imperative that we continue to develop new and better preventative pharmaceuticals to 
diminish its devastating effects. 
Strategies for treatment and prevention of CVD are targeted at its underlying 
pathophysiologic mechanisms.  Two of the primary pathological processes causing CVD are 
atherosclerosis and thrombosis310.  Atherosclerosis is a chronic inflammatory process marked 
by a focal thickening of the arterial intima14.  Stenosis of coronary and carotid or cerebral 
blood vessels from this vascular pathology can result in acute coronary syndrome or ischemic 
stroke.  However, more often atherosclerosis leads to these conditions from rupture of the 
lesion which triggers the coagulation cascade leading to occlusive thrombi or emboli310.  
Additionally, imbalance of the elements of coagulation and fibrinolysis can lead to venous 
thrombosis and subsequent emboli with severe and sometimes fatal consequences. Thus, 
targeting atherosclerosis and thrombosis are amongst the strategies for prevention of CVD. 
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Preventative treatment guidelines for CVD are derived from the evidence of reduced 
risk in controlled trials.  Recommendations are based on individual patient’s risk factors 
which include both non-modifiable risk factors such as age, race, gender, and previous 
cardiovascular events and modifiable risk factors including atherosclerotic disease, atrial 
fibrillation, hypertension, etc.  Antithrombotic therapies comprise anti-platelet and anti-
coagulant treatments with different risk factors dictating the recommended use of either or 
both. Anti-coagulant treatment is recommended in patients with atrial fibrillation, acute 
myocardial ischemia, left ventricular thrombus, extracranial arterial dissection, cerebral 
venous sinus thrombosis, deep vein thrombosis, pulmonary embolism and certain 
hypercoagulable states4,311-314.  Anticoagulants specifically target elements of the coagulation 
cascade with the ultimate goal of attenuating the action of thrombin.   
 
Thrombin  
 Thrombin is a multifunctional serine protease.  It acts as a pro-coagulant by cleaving 
fibrinogen to fibrin and activating factor XIII, which crosslinks fibrin to form a clot. 
Thrombin also activates factors V and VIII upstream in the coagulation cascade, thus 
perpetuating its own activation. (See Chapter 1, Figure 1.1.)  Thrombin is a potent platelet 
agonist through its cleavage and activation of protease-activated receptors (PARs)44,57.  
Conversely, thrombin possesses some anti-coagulant functionality since it feeds into an auto-
regulatory loop, activating zymogen protein C to activated protein C (APC) (see below). 
Finally, thrombin has many non-hemostatic pro-inflammatory functions, which include 
cytokine-like activities that contribute to the pathological processes of atherosclerosis42.    
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Therapeutically, thrombin attenuation can be accomplished in three ways: by 
reducing the amount of active thrombin generated in the system, by directly inhibiting 
thrombin’s proteolytic activity, or by enhancing the activity of inhibitors in any part of the 
cascade.  Accordingly, there are currently three types of anticoagulation medications 
available: vitamin K antagonist (warfarin); glycosaminoglycans (unfractionated heparin 
(UFH), low molecular weight heparin (LMWH) and the heparin pentasaccharide, 
Fondaparinux); and direct thrombin inhibitors (recombinant hirudins, bivalirudin, argatroban, 
ximelagatran and dabigatran).  Vitamin K antagonists inhibit coagulation by preventing the 
synthesis of the vitamin K-dependent coagulation factors VII, IX, X, prothrombin, protein S, 
and protein C.  The glycosaminoglycans act as cofactors to accelerate antithrombin’s (AT) 
inhibition of coagulation.  UFH and LMWH accelerate the inhibition of both thrombin and 
factor Xa (an upstream coagulation factor) by AT.  LMWH has considerably more anti-
factor-Xa than anti-thrombin activity, and Fondaparinux catlayzes only AT- factor Xa.  
Finally, direct thrombin inhibitors inactivate thrombin by binding tightly to the protein 
structures in thrombin responsible for cleaving fibrinogen to fibrin310. 
 
Activated Protein C 
 While thrombin is crucial in coagulation, activated protein C (APC) another serine 
protease, is also imperative for proper hemostasis315-317.  In the presence of thrombomodulin 
(TM), a receptor found on endothelial cells, thrombin activates protein C59.  APC in turn, 
when bound to its cofactor protein S, inactivates factors Va and VIIIa upstream from 
thrombin in the coagulation cascade, thus regulating the activation of thrombin in an auto-
regulatory feedback loop.  APC also acts to reduce endothelial inflammation70.  It has been 
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proposed that through such mechanisms APC protects against ischemic stroke182.  
Recombinant APC is used to treat severe sepsis and has been shown to be effective in 
reducing mortalities318.  Currently, the use of recombinant APC as an adjunct to thrombolytic 
therapies is being investigated319,320.  Because of the protective effects of APC, an ideal 
anticoagulant would inhibit thrombin from cleaving fibrinogen and activating platelets, but 
would not inhibit it from activating protein C. Nor would it inhibit APC itself. Of the current 
anti-coagulant therapies, only LMWHs avoid inhibiting the generation of APC. 
 
Thrombin Structures  
 Therapeutic strategies for inhibition of thrombin, either directly or through 
enhancement of endogenous inhibitors requires an understanding of the structure and kinetic 
mechanisms of all of the molecules involved.  The ability of thrombin to specifically 
recognize substrates is dependent not only its active site, but also two other regions on the 
molecule.  Thrombin utilizes two electropositive areas located at opposite poles of the 
molecule.   These anion-binding regions, known as exosite 1 and exosite 2, mediate 
thrombin’s interactions with many cofactors and substrates52.   Exosite 1 is the region 
responsible for the binding of fibrinogen, fibrin321, thrombomodulin, hirudin’s acidic C-
terminal tail, and the acidic domain of HCII293,299,322  Exosite 2 binds heparin and other 
glycosaminoglycans (GAGs) to mediate reactions with GAG-binding inhibitors52,296,299.  
Many ligands bind thrombin in these regions and their spatiotemporal availability and 
relative affinities define the local thrombin function and its inhibitors.  
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Serine Protease Inhibitors  
As serine proteases, thrombin and APC are inhibited by serine protease inhibitors 
(serpins).  Serpins are a superfamily of proteins with high structural homology.  They contain 
9 α-helices, 3 β-sheets and a reactive center loop (RCL)51.  Unique sequences in the RCL 
define target protease activity while variations in the other structural domains confer cofactor 
activity.  Amongst others, three serpins, antithrombin (AT), heparin cofactor II (HCII) and 
α1-protease inhibtor (α1PI) inhibit proteases in the coagulation cascade304,323.  
Understanding how the unique structures of these serpins determine their specific function 
can help to create a novel anti-coagulant therapy. 
 
Antithrombin  
Antithrombin is the serpin most responsible for regulation of the coagulation cascade. 
The GAGs heparin or heparan sulfate are necessary to accelerate AT activity to 
physiologically relevant rates. GAG binding results in accelerated thrombin inhibition by a 
bridging mechanism from AT to thrombin exosite 2 and by causing an allosteric 
conformation change in AT that exposes its reactive center loop (RCL) for enhanced 
inhibition of factor Xa133,324,325.  The primary structure of the RCL of antithrombin is such 
that it is simultaneously a potent thrombin and factor Xa inhibitor and poor APC 
inhibitor109,326.  However, because AT-heparin utilizes exosite 2 on thrombin, which is 
available when thrombin is bound to TM, AT (in the presence of heparin) inhibits thrombin 
bound to TM (thrombin-TM).  This subsequently reduces the activation of APC. 
Furthermore, when thrombin is released rapidly from a clot through lytic therapy, it is bound 
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to fibrin at exosite, but still enzymatically active. Because AT requires heparin binding 
through exosite 2 on thrombin for inhibition, AT cannot inhibit clot-bound thrombin127.  
 
Heparin Cofactor II  
 While HCII is known to inhibit thrombin in vitro and has been found in complex 
with thrombin in vivo237, it does not appear to play a significant role in normophysiologic 
coagulation153. However, HCII is capable of inhibiting clot-bound thrombin327-329. HCII has a 
unique N-terminus which is able to bind thrombin’s exosite 1 when HCII is bound to GAGs; 
the GAG-bridging mechanism is not necessary for thrombin inhibition101. Therefore, this 
region of HCII may be important for limiting reocclusion after lytic therapy.   
Elevated HCII levels have been shown to be associated with decreased 
atherosclerosis and restenosis, while reduced levels have been associated with increased 
cardiac events50,154,156,247.  Although the inhibition of thrombin by HCII can be accelerated by 
many GAGs, dermatan sulfate exclusively accelerates the inhibition of thrombin by HCII.  
Dermatan sulfate, is abundant in vessel walls330, is increased in atherosclerotic tissue and has 
been shown to regulate the antithrombotic activity of HCII in mice after vascular injury46. 
Thus, it is the current scientific premise that HCII’s action against thrombin in atherogenesis 
is due to its unique ability to bind dermatan sulfate which targets it to the vascular intima.   
The GAG-associated acceleration of thrombin inhibition by HCII has been attributed 
to the binding of positively charged residues on and around the D-helix of HCII and to 
subsequent transposition of its N-terminal acidic domain275-279. GAG binding accelerates 
thrombin inhibition primarily by an allosteric/conformation change mechanism whereby the 
acid region of HCII binds thrombin exosite 1.  There is also a small additional acceleration 
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that can be accounted for by GAGs bridging.  Because HCII and TM both utilize exosite 1 
for binding to thrombin, and TM has a much higher binding affinity, HCII cannot inhibit 
thrombin-TM and thus has no effect on the APC system. 
 
α1-Protease Inhibitor  
 α1PI is considered the protoypical serpin107,331.  It is able to inhibit APC but is an 
extremely poor thrombin inhibitor. A naturally occurring mutation in the RCL of α1PI from 
a methionine to an arginine (M358R) (α1PIPittsburgh) increases its affinity for both thrombin 
and APC184.  The inhibitory effects of α1PIPittsburgh were so much enhanced that the variant 
resulted in the hemorrhagic death of the person in whom it was discovered183. Neither α1PI 
nor α1PIPittsburgh show any cofactor associated acceleration of thrombin inhibition.  
 
Serpin Structural Homology for Protein Engineering  
The significant homology of serpin structure makes it possible to substitute structural 
elements of one serpin for another332 and transfer the specific activity associated with the 
structural domain302,326. In this study, we designed a chimeric serpin with the goal of 
harnessing the beneficial properties of α1PIPittsburgh, AT and HCII.  The chimera was designed 
to have the following biochemical properties: 1) to possess the potent thrombin inhibition of 
α1PIPittsburgh; 2) to have the specificity of AT for thrombin and factor Xa over APC; 3) to 
have the N-terminal region of HCII which prevents it from inhibiting APC generation 
(thrombin-TM) and permits it to inhibit clot-bound thrombin; and 4) to posses the dermatan 
sulfate binding capability of HCII.  
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HATpin Design  
Specifically, we used α1PIPittsburgh as the scaffolding on which to build our novel 
thrombin-inhibitory serpin.  α1PI is often used as the structural framework for serpin 
engineering in order to learn about structure-function relationships302,326,333. The acidic 
domain (without the D-helix, GAG binding region) of HCII has been added to α1PIPittsburgh302 
and increased thrombin inhibition.  Additionally, as seen in Chapter 3, addition of several 
basic residues to the D-helix resulted in HCII-like GAG binding of α1PIPittsburgh.   Upon the 
α1PIPittsburgh backbone, we chose to replace the N-terminus of α1PIPittsburgh for the N-terminus 
of HCII, from the acidic domain through the D-helix, in order to incorporate the GAG-
binding properties of HCII.  A component of the design of this chimeric serpin is to utilize 
endogenous GAGs to target the chimera’s activity to sites of atherosclerosis and diseased 
vascular endothelium predisposed to atherosclerosis and venous thrombosis. This region of 
HCII incorporates all of the residues that have been shown to be crucial for dermatan sulfate 
and heparin binding as well as the N-terminal extension which binds exosite 1 of thrombin.  
This N-terminus of HCII was included to increase the thrombin specificity, facilitate the 
inhibition of clot-bound thrombin and decrease the inhibition of thrombin-TM.  Next, the 
RCL, from P7-P3´, was substituted with that of AT.  These AT residues were included 
because they have been shown to be those responsible for AT’s specificity of thrombin over 
APC and promote the inhibition of factor Xa109,326,334. Through this understanding of the 
specific activities of these serpin’s structures, we purposefully designed  the chimeric serpin, 
HATpin (Heparin cofactor II, AntiThrombin, α1-Protease INhibitor),  to possess the anti-
atherogenic and anti-reocclusion properties of HCII and the anti-coagulant properties of 
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Visualization System and  published crystal structures of HCII152 and α1PI335.  HCII residues 
1-51 have been shown to be inconsequential to its ability to inhibit thrombin in the presence 
or absence of GAGs101,287.  Furthermore, expression and purification of HCII from 
Escherichia coli (E. coli) is notoriously finicky.  Therefore, to reduce extraneous HCII 
sequence, we substituted only from the beginning of the acidic domain of HCII (residue 52) 
through the end of its D-helix (residue 193) for the N-terminus of α1PIPittsburgh (residue 4) 
through the end of its D-helix (residue 106).  α1PIPittsburgh cDNA containing an N-terminal 
hexahistidine tag for purification, 7 stabilizing mutations (F51L, T59A, T68A, A70G, 
M374I, S381A, K387R)283 and a cysteine to serine (C232S) mutation to prevent 
dimerization284  in the pQE30 vector (Strategene) was generously donated by the Gettins 
laboratory (Department of Biochemistry and Molecular Genetics, University of Chicago, IL). 
These mutations affect the heat stability of the α1PIPittsburgh protein without altering its 
inhibitory properties283.  HCII cDNA in the pVL1392 vector (BD Biosciences Pharmingen) 
was a gift from the Tollefsen Laboratory (Division of Hematology, Department of Medicine, 
Washington University School of Medicine, St. Louis, MO).  
Chimeric cDNA was created using the oligonucliotide primers purchased from 
Integrated DNA Technologies, denoted in Table 4.1, and a series of polymerase chain 
reactions (PCR) outlined in Figures 4.2a, 4.2b and 4.2c and described below.  PCR 
comprised thirty cycles each of 30 seconds at 95° C, followed by 30 seconds at 55° C and 2 
minutes at 72° C. All reactions utilized Pfu Turbo DNA polymerase (Stratagene) in 1 x 
Cloned Pfu DNA polymerase reaction buffer (Stratagene),  200μM dNTP mix (Invitrogen), 
50nM each of forward and reverse primer, and 1 μL of a 1 to 10 dilution of purified plasmid 
cDNA or purified DNA product.  
  
 
 
 
Table 4.1.  Oligonucleotide primers used in PCR reactions for engineering the chimeric serpin, HATpin. 
Primer Name Primer Sequence Direction Coverage 
Forward A GTG AGC GGA TAA CAA TTA TAA TAG ATT C 5' - 3' pQE30 vector 
Reverse A CCT CTG GAA TGG ATC CGT GAT GGT GAT GGT GAT GCG 3' - 5' HCII / pQE30 vector 
Forward B CAC GGA TCC ATT CCA GAG GGC GAG GAG 5' - 3' pQE30 vector / HCII 
Reverse B CAG CTG GAG CTG GCT GTC CCT CCT GAA GAG GCG ATG 3' - 5' α1PI / HCII 
Forward C GAC AGC CAG CTC CAG CTG ACC ACC GGC 5' - 3' α1PI 
Reverse C CCA AGC TCA GCT AAT TAA GC 3' - 5' pQE30 vector 
AT-RCL-Fwd GAA GCT GCT GGG GCC ATG GCT GTA GTG ATC GCA GGC AGA TCT CTC AAC CCC GAG GTC AAG TTC 5' - 3' 
α1PI + AT  RCL 
mutations 
AT-RCL-Rvs GAA CTT GAC CTC GGG GTT GAG AGA TCT GCC TGC GAT CAC TAC AGC CAT GGC CCC AGC AGC TTC 3' - 5' 
α1PI + AT  RCL 
mutations 
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Step 1. Obtain plasmids with 
HCII and α1PI cDNA   
Step 2. Design three sets of primers. 
Forward A: pQE30 vector
Reverse A: HCII / pQE30 vector
Forward B: pQE30 vector / HCII
Reverse B: α1PI / HCII
Forward C: α1PI
Reverse C: vector / α1PI
 
Step 3. PCR primers with α1PI 
or HCII cDNA. 
Step 4. Purify PCR products:
A, B and C.
 
pQE30 
Step 5: Join products A and B 
using forward primer A and 
reverse primer B.  
EcoRI    HindIII
α1PI
A CB
A CB
A B C
Step 6. Purify PCR product, D. D
Step 7: Join products C and D 
using forward primer A and 
reverse primer C.  
Figure 4.2a.  Protocol for Domain Engineering Using Polymerase Chain 
Reaction. Steps 1 - 7.
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Step 10. Purify digestions.
Step 9. Digest PCR product E and 
pQE30 vector with EcoRI and 
HindIII restriction enzymes. 
Step 11. Ligate PCR product and 
pQE30 vector. 
EcoRI HindIII 
pQE30 
EcoRI  HindIII
pQE30 
EcoRI    HindIII
pQE30 
EcoRI  HindIII
pQE30 
EcoRI  HindIII
+
Step 8. Purify PCR product, E.
E
E'
Steps 12 +: Transform plasmid into 
supercompetent E. coli.  Amplify 
plasmid and purify. Confirm coding 
sequence integrity using UNC Genome 
Analysis Facility. 
Figure 4.2b.  Protocol for Domain Engineering Using Polymerase Chain 
Reaction. Steps 8 - 12.
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pQE30 
EcoRI    HindIII
x Sal1
pQE30 
EcoRI    HindIII
x
Sal1
Step 13. Find two clones with mutations on
opposite sides of Sal1 restriction site.
Step 14. Digest Clone A and B with Sal1 
and HindIII.
Clone A Clone B
Step 15. Purify smaller band of Clone A, A'. 
Purify larger band of Clone B, B'.
Step 16. Ligate A' and B'.
A' B'
pQE30 
EcoRI    HindIII
Sal1
Step 17.  Transform plasmid into supercompetent 
E. coli.  Amplify plasmid and purify. Confirm 
coding sequence integrity using UNC Genome 
Facility. 
+
Step 18. Mutate reactive site loop residues of α1PIPittsburgh to AT homologous residues 
using complimentary forward and reverse primers with modifications in the α1PIPittsburgh
sequence to result in coding sequence for AT RCL. The reactive center is boxed in red.
 
   
Steps 19 + . Digest parental DNA. Transform plasmid into supercompetent E. 
coli.  Amplify plasmid and purify. Confirm coding sequence
Figure 4.2c.  Protocol for Domain Engineering Using Polymerase Chain 
Reaction. Steps 13 - 19.
 344   T  E  A  A  G  A  M  F  L  E  A  I  P  R  S  I  P  P  E  V  K  F  N   367
      ACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCAGATCTATCCCCCCCGAGGTCAAGTTCAAC 
   
 344   T  E  A  A  G  A  M  A  V  V  I  A  G  R  S  L  N  P  E  V  K  F  N   367
      ACTGAAGCTGCTGGGGCCATGGCTGTAGTGATCGCAGGCAGATCTCTCAACCCCGAGGTCAAGTTCAAC 
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Initially, three separate double stranded DNA products (A, B and C) were created 
using PCR.   The resultant PCR products (A, B and C) were subjected to electrophoresis 
through a 1.5% agarose gel.  Desired bands were evaluated by molecular weight and were 
purified using QIAquick PCR Purification Kit (Qiagen).  Product A contained vector cDNA 
which included an ECORI restriction site, the signal peptide sequence, the polyhistidine tag 
and part of the coding region for the desired HCII amino acid sequence.  Product B contained 
the entire HCII coding sequence for HCII residues 52 - 193, flanked 5' by a portion of pQE30 
vector sequence that overlapped with Product A, and 3' by coding sequence for α1PIPittsburgh 
that overlapped with that of Product C (below).  Product C comprised cDNA from 
α1PIPittsburgh coding for sequence just 3' of its D-helix through its C-terminus and some of the 
pQE30 vector that followed (including the HINDIII restriction enzyme cleavage site).  
Purified Products A and B were joined by PCR using primers Forward A, Reverse B and 
purified Products A and B.  Product AB resulted. This was then purified and joined with 
Product C using primers Forward A and Reverse C. After purification, this product (D) was 
digested with restriction endonucleases EcoRI (New England BioLabs) and HINDIII (New 
England BioLabs).  An empty pQE30 vector was separately digested with the same enzymes 
simultaneously. The digested product and vector were each purified and then ligated together 
using T4 DNA ligase (New England BioLabs) at 37° C for 1 hour.  Calf intestinal alkaline 
phosphatase (CIAP) (Invitrogen) was included in both the digestions and the ligation to 
prevent circularization of the cDNA.  The ligation mixture was transformed into XL1-Blue 
supercompetent E.coli (Strategene) for plasmid amplification.  The cDNA from thirteen 
individual E. coli colonies was extracted using Wizard® Plus SV Minipreps DNA 
Purification System (Promega), and cDNA sequences were determined by the UNC Genome 
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Analysis Facility. Each of these colonies exhibited at least one point-mutation in its cDNA 
sequence.  Therefore, we devised the following strategy to circumvent the errors arising from 
the PCR. 
The cDNA of the desired chimeric serpin, HATpin, was determined to have a SAL1 
restriction endonuclease cleavage site located within the α1PIPittsburgh coding region.  We 
selected the cDNA of two sequenced clones: one contained a point mutation 5' to the SAL1 
restriction site and the other contained a point mutation 3' to the SAL1 restriction site.  We 
digested each clone with the restriction endonucleases SAL1 (New England BioLabs) and 
HINDIII (including CIAP in the mixture to prevent circularization).  The digestions were 
electrophoresed through 0.8% agarose gel and the desired fragment from each clone (without 
the point mutation) was determined based on its molecular weight.  The cDNA from these 
bands was purified from the agarose and the fragments were ligated using T4 DNA ligase 
plus CIAP.   The ligation mixture was transformed into XL1-Blue supercompetent E.coli.  
The plasmid cDNA was amplified, purified and the sequence was resolved by the UNC 
Genome Facility.   This resulted in a pQE30 plasmid containing the desired cDNA sequence 
for an intermediate chimeric protein containing a polyhistadine tag, the HCII acidic domain 
through the HCII D-helix and α1PIPittsburgh from 3' of its D-helix through its N-terminus. 
 
Substitution of the RCL of AT onto the Intermediate Chimeric cDNA  
Multiple basepair mutagenesis using PCR was directed to the coding sequence for P7 
– P3' (residues 352 - 361) of the intermediate chimeric sequence.  The primers for this 
reaction were designed to incorporate as much complementary sequence as possible, with 
mutations only to the basepairs needed to code for the AT RCL between P7-P3' (residues 387 
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– 396).  The primers used, AT-RCL-Fwd and AT-RCL-Rvs, are reported in Table 4.1.  The 
PCR mix contained the same proportions of ingredients as listed above.  The thermocycling 
conditions for this mutagenesis comprised 18 cycles, each consisting of 30 seconds at 95° C, 
followed by 1 minute at 55° C and 10 minutes at 68° C.  Thereafter, parental cDNA was 
digested with Dpn1 restriction enzyme (Strategene).  The resultant product was transformed 
into XL1-Blue supercompetent E. coli.  Amplified plasmid was purified and its cDNA 
sequence was the confirmed (through the UNC Genome Analysis Facility) to be the complete 
HATpin coding sequence, without mutation, in the pQE30 vector. 
 
Protein Expression and Purification 
 The HATpin protein was expressed and purified with modifications as using methods 
previously reported284.  Briefly, cDNA in the pQE30 vector was transformed into competent 
SG13009 E. coli (Qiagen) and grown in Luria-Bertani media containing 100 μg/mL 
ampicillin and 25 μg/mL kanamycin to an absorbance at 600 nm of 0.6. Protein expression 
was induced using 1 mM isopropyl-β-D-thiogalactopyranoside (Promega) at 22° C for 
approximately 8 hours. Cells were pelleted by centrifugation ~ 10,000 x g at 4° C for 20 
minutes.  Pellets were resuspended in 20 mM MES (2-(N-morpholino)ethanesulfonic acid), 
500 mM NaCl. 0.1% PEG-8000 and 0.05% NaN3, pH 6.0 and frozen at -80° C. Thawed cells 
were lysed using sonication (Sonicator Dismembrator, Fisher Scientific) in 30 second bursts 
with 15 seconds rest for a total of 3 minutes of sonication at an output of ~10-15 watts.  Cell 
debris and insoluble contaminants were eliminated by centrifugation at 10,000 x g for 20 
minutes at 4° C.  Imidazole was added to a final concentration of 20 mM and the cell lysate 
solution was filtered through a 0.45 μm nylon filter disc (Whatman).  This was loaded onto 
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the Sepharose immobilized nickel affinity column, HisTrap HP (Amersham Biosciences). 
HATpin was eluted using the same buffer as above, containing 500 mM imidazole.  EDTA 
was added to the elution to reach a final concentration of 10 mM. The protein was then 
dialyzed overnight against 20 mM Hepes, 50 mM NaCl, 0.1% PEG-8000, 0.05% NaN3, pH 
7.6 for future kinetic studies or 20 mM Hepes, 0.1 % PEG pH, 7.4 for affinity 
chromatography studies.   HATpin concentration was initially estimated by absorbance at 
280 nm (A280) based upon Mr = 50,000 and using an extinction coefficient of 0.46 M-1 cm-1.  
These values were determined by entering the amino acid sequence of HATpin into the 
Peptide Property Calculator on the Northwestern University Medical School Basic Sciences 
website: http://www.basic.northwestern.edu/biotools/proteincalc.html. The principles 
underlying the calculations made have been published in the peer–reviewed journal, 
Analytical Biochemistry336. 
 
Verification of Structural Components of HATpin  
 In order to confirm the presence of each of the structural components of HATpin’s 
parent serpins in the expressed and purified HATpin protein, it was probed for antigenic 
activity of polyhistidine, HCII, α1PI and AT.  HATpin, human plasma HCII  and AT 
(purified as previously described254) and recombinant human α1PIPittsburgh (purified as 
described in Chapter 3) were electrophoresed through a 4-15% gradient SDS-polyacrylamide 
PhastGel (General Electric Healthcare) and transferred to Immobilon-B transfer membrane, 
45 μm pore-size (Millipore) on the PhastGel System.  Membranes were blocked for one hour 
at room temperature with 5% milk powder (Carnation) in Dulbecco’s phosphate buffered 
saline (PBS) (Gibco) containing 0.1% Tween 20 (Sigma) (PBStw0.1%) and then incubated in 
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the same solution for one hour at 37° C with the primary antibodies, either affinity purified 
goat anti-human HCII IgG polyclonal antibody (1:1000, Affinity Biologicals), goat anti-
human α1PI IgG polyclonal antibody (1:1000, Fitzgerald Industries), or goat anti-human AT 
IgG polyclonal antibody (1:100, Diasorin).  The membranes were then washed three times 
for 10 minutes each with PBStw0.1% and incubated for one hour with the secondary antibody, 
HRP conjugated donkey anti-goat IgG (1:5000, Santa Cruz Biotechnology).  Antigen was 
detected by incubating the membranes in Pierce ECL Western Blotting Substrate (Pierce 
Biotechnology), exposing them to Kodak Scientific Processing film and developing using a 
SRX-101A tabletop film processor (Konica Minolta).  The membranes were then stripped of 
antibodies by soaking them in 7 M guanidine HCl solution with 10 mM dithiothreitol 
(Sigma) for one hour at room temperature.  The membrane was rinsed in tap water until 
opaque and the process described above was repeated with the exception that the primary 
antibody used for all membranes was monoclonal mouse anti-polyhistidine IgG (1:1000, 
Novagen) and the secondary antibody used was HRP conjugated rabbit anti-mouse IgG 
(1:5000, Sigma). 
 
Verification of HATpin-Thrombin Complex Formation   
 To confirm the integrity of the RCL and the ability of HATpin to complex with 
thrombin (Haematologic Technologies), HATpin was incubated with thrombin in the 
presence of unfractionated heparin (UFH) (Diosynth) and visualized by Coomassie Blue R-
250 (Bio-Rad Laboratories) stained 10% SDS-polyacrylamide gel along with other serpin-
thrombin complexes.  Complexes for HATpin, HCII and α1PIPittsburgh with thrombin were 
created using the same protocol used in Chapter 2, although heparin was not included in the 
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incubation with α1PIPittsburgh.  Gel electrophoresis and Coomassie staining also followed the 
technique described in Chapter 3. 
 
Heparin-Sepharose Affinity Chromatography of HATpin  
 The relative affinity of HATpin compared to plasma-derived HCII and α1PIPittsburgh 
for heparin was determined using a FPLC apparatus.  HATpin was loaded onto a 1 mL 
HiTrap heparin-Sepharose column (Amersham Biosciences) and eluted using NaCl gradient 
from zero to 500 mM in Hepes buffer pH 7.4.  Peak elution ionic strength was determined by 
the inhibition of thrombin (in the presence of 100 μg/mL UFH) by each 1 mL fraction.  This 
was compared to the elution profile of HCII and α1PIPittsburgh as determined in Chapter 3.  
 
Determination of HATpin Protein Concentration  
 For the above studies, HATpin concentration was estimated by absorbance at 280 
nm, and the quantity of protein loaded onto each gel was based accordingly. In examining the 
gels and blots generated by these studies, we noted that our HATpin stock appeared of a 
considerably smaller concentration than originally estimated. Thus, we re-evaluated the 
concentration of HATpin by another method.  Using the Odyssey Infrared Imaging System 
(LI-COR) the band intensity of HATpin was compared to serial dilutions of a known 
concentration of α1PIPittsburgh on an immunoblot probed with polyclonal anti-human α1PI 
IgG (Fitzgerald Industries) and detected with donkey anti-goat Alexa Fluor 680 secondary 
antibody (Invitrogen). Immunoblots were generated using the PhastGel system and the 
method described in Chapter 2.  A standard curve of α1PIPittsburgh was generated and HATpin 
concentration was calculated based on the relative intensity of its band on the immunoblot. 
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Inhibition of Serine Proteases in the Presence and Absence of GAGs  
 To determine if HATpin has the postulated inhibitory profile, we measured its 
second order rates of inhibition against α-thrombin, γ-thrombin (Haematologic 
Technologies), factor Xa and APC (Haematologic Technologies) in the presence and absence 
of UFH, low molecular weight heparin (LMWH) (Calbiochem), and / or dermatan sulfate 
(Calbiochem).  In a 96-well plate 20 nM HATpin along with increasing concentrations of 
GAG was incubated with 1nM protease for varying lengths of time. The reaction was 
quenched by the addition of para-nitroaniline chromogenic substrate. Remaining protease 
activity was measured by the development of substrate cleavage product assessed by the 
change in absorbance at 405 nm.  The rate of substrate cleavage was plotted against the 
incubation time in seconds and fit to the equation:  A = A0 * e (–kt), where A is activity as 
determined by substrate cleavage, A0 is the activity at time zero, t is time in seconds and k is 
the observed rate of protease inhibition.  Second order rates of inhibition (k2) were 
determined by dividing k by HATpin concentration.  GAG concentrations used ranged from 
0 to 1000 μg/mL for UFH and dermatan sulfate and from 0 to 2000 μg/mL for LMWH.  The 
estimated molecular weight for UFH, dermatan sulfate and LMWH used to determine their 
molarity was Mr = 15,000, 50,000 and 3,700 respectively.  The following chromogenic 
substrates were used in a final concentration of 150 μM each: Pefachrome TH (Pentapharm) 
for α-thrombin and γ-thrombin, Pefachrome PCa (Pentapharm) and Pefachrome FXa 
(Pentapharm). 
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Stoichiometries of Inhibition of Serine Proteases in the Presence and Absence of GAGs  
 To evaluate if the second order rates of inhibition were being affected by alteration in 
the protein structure making it a substrate rather than inhibitor of the serine proteases, the 
stoichiometries of inhibition for each of the serine proteases with HATpin was determined in 
the presence and absence of UFH, dermatan sulfate, and LMWH.  Increasing concentrations 
of HATpin were incubated for 12 hours at room temperature with 1 nM α-thrombin, γ-
thrombin, factor Xa or 2 nM APC in the presence of either no GAG, UFH (25 μg/mL for α-
thrombin and  γ-thrombin or  500 μg/mL for factor Xa and APC), dermatan sulfate (1000 
μg/mL for α-thrombin and γ-thrombin) or LMWH (125 μg/mL for factor Xa).  Remaining 
protease activity was evaluated by chromogenic substrate cleavage as described above.  The 
ratio of substrate cleavage in the presence of each HATpin concentration to substrate 
cleavage in the absence of HATpin was plotted against HATpin concentration.  The 
intersection with the x-axis of a line fit to data points with remaining protease activity 
indicated the value of the stoichiometry of inhibition.  
 
RESULTS  
Immunoblot Analysis of the Structural Components of HATpin  
Figure 4.3 depicts immunoblot analysis of the antigenic activity of HATpin. Panel A 
depicts Fermentas PageRuler Plus Prestain Protein Ladder.  In each of the Panels B, C, and 
D, HATpin is depicted in the left lane, HCII in the center lane and α1PIPittsburgh in the right 
lane.  Panel B clearly shows a single band of HATpin protein migrating between 35 and 55 
kDa with polyhistidien antigenic activity.  HCII and α1PIPittsburgh serve as negative and 
positive controls respectively; HCII was purified from human plasma and therefore has no  
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polyhistidine tag while the recombinant α1PIPittsburgh does contain a polyhistidine tag.  Panel 
C shows multiple bands with HCII antigenic activity in the HATpin lane.  The top band 
indicates a molecular weight of just over 55 kDa.  The second band which has the most 
antigenic activity, appears in the same location as the single HATpin band in Panel B.  
 
 
 
 
  
 
Because Panel B depicts the exact same transfer membrane stripped and reprobed, it is 
certain that this second HATpin band in the left lane of Panel C, corresponds with the single 
band of HATpin in Panel B.  Two additional bands with  molecular weight below 35 kDa 
exhibit HCII antigenic activity in the HATpin preparation.  HCII is depicted in the center 
lane of Panel C.  The lower molecular weight band is cleaved HCII.  The right lane of Panel 
C contains α1PIPittsburgh  and therefore no band is evident when probing for HCII antigen.  
Panel D depicts the serpins probed for α1PI antigenic activity.  HATpin exhibits α1PI 
antigenic activity and again runs as a single band with a molecular weight of between 35 and 
Figure 4.3   Immunoblots of HATpin compared with HCII and α1PIPittsburgh.   Panel A shows the 
molecular weight ladder from the original transfer membrane. Panel B shows protein bands with 
poly-histidine antigenic activity.  Panel C shows protein bands with HCII antigenic activity.  Panel D 
shows protein bands with α1PI antigenic activity.  Note that Panel D shows the same transfer 
membrane as Panel C, but stripped and reprobed. Furthermore, the transfer membrane depicted in 
Panel B was also stripped and reprobed for α1PI antigenic activity and the resultant blot was 
indistinguishable to that shown in Panel D.   
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55 kDa in the same location as the prominent bands in Panels B and C.  As expected, HCII 
does not show α1PI antigenic activity, while α1PIPittsburgh does.  The immunoblot probed for 
AT antigenic activity is not shown.  HATpin was not visualized on this blot.  This is not 
unexpected as HATpin only possesses a ten residue sequence unique to AT and it is probable 
that this region does not make up an epitope for the AT antibody. 
 
Formation of HATpin-Thrombin Complex  
In order to confirm the integrity of the RCL of HATpin and and visualize its potential 
interaction with thrombin, HATpin-thrombin complex was formed and compared with HCII, 
α1PIPittsburgh and their thrombin complexes using Coomasie Blue stained SDS-PAGE (Figure 
4.4).  Lane 1 contains Fermentas PageRuler Plus Prestain Protein Ladder.  Lane 2 depicts 
HATpin as a single band migrating between 35 kDa and 55 kDa and at the same location as 
α1PIPittsburgh (MW = 45.1 kDa) shown in Lane 3.  Lane 4 shows the formation of HATpin-
thrombin complex migrating just below the 70 kDa marker.  In this lane the band 
corresponding to HATpin is not evident, indicating the consumption of HATpin in complex 
formation.  Thrombin (MW = 36.6 kDa) that is not complexed to HATpin can be visualized 
as the lowest band in Lane 3 and compared to thrombin alone in Lane 6.  Lanes 5 and 7 show 
HCII and HCII-thrombin complex respectively.  Lane 8 depicts α1PIPittsburgh complex with 
thrombin.   These results indicate that like HCII and α1PIPittsburgh, HATpin is able to form 
stable complex with thrombin. This also indicates that the RCL HATpin has maintained its 
integrity through the protein expression and purification procedures.   
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Heparin-Sepharose Binding Affinity   
HATpin eluted from heparin-Sepharose with ~ 250 mM NaCl (Figure 4.5).  This is 
slightly higher than α1PIPittsburgh eluted under the same conditions (~200 nM NaCl), but less 
than the NaCl concentration at which HCII eluted from the column (~ 450 nM).  While this 
data suggests that HATpin had not gained the full heparin binding capacity of HCII, it has 
improved heparin binding capacity over α1PIPittsburgh.   
  
 
 
 
 
 
Determination of HATpin concentration by immunoblot band comparison to α1PIPittsburgh  
Figure 4.5   Elution of HATpin and HCII from HiTrap heparin-Sepharose column.  Closed circles 
(●) represent HATpin. Open circles (○) represent HCII.  The star (*) indicates the NaCl elution of 
α1PIPittsburgh determined in Chapter 3 by absorbance at 280 nm. 
Figure 4.4   Coomassie Blue Stained SDS-Polyacrylamide Gel. Depicts molecular weight marker 
in column 1, HATpin in column 2, HATpin-thrombin complex in column 3, α1PIPittsburgh 4, HCII in 
column 5, thrombin in column 6, HCII-thrombin complex in column 7 and α1PIPittsburgh-thrombin 
complex column 8.  
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 Determination of HATpin Concentration by Immunoblot Band Comparison to 
α1PIPittsburgh   
 
Based on concentration estimations determined by A280 , the same quantity of total 
protein was loaded into Lanes 2 and 4 of the Coomassie Blue stained gel depicted by Figure 
4.4.  The band intensity suggests that there is far less HATpin present (Lane 2) than there is 
α1PIPittsburgh (Lane 4).  An explanation for this that is supported by Figure 4.3, is that there 
are multiple protein bands (Panel C) in the HATpin preparation that are not visualized by 
Coomassie Blue staining.  These proteins and proteins parts will have contributed to the total 
protein estimation by A280.  Therefore, to more accurately determine the concentration of 
HATpin, we compared the intensity of the antigenic activity of HATpin to that of 
α1PIPittsburgh on immunoblot.  Figure 4.6, Lanes 1 – 5, depict serial dilutions of 750 nM, 
500nM, 200 nM, 100 nM and 50 nM of α1PIPittsburgh, respectively.  Lane 6 contains HATpin. 
The intensity of the major bands in Lanes 1 - 6 was evaluated by the Odyssey Infrared 
Imaging System to emit 317.8, 266.0, 168.9, 127.5, 84.8 and 136.1 infrared units. 
 
 
 
 
Figure 4.6   Determination of HATpin concentration by immunoblot and standard curve with 
α1PIPittsburgh. Columns 1-5 contain serial dilutions α1PIPittsburgh (750 nM, 500 nM, 200 nM, 100 nM 
and 50 nM, respectively).  Column 6 contains HATpin, determined by fluorescence intensity to be 
116 nM. 
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A plot of infrared intensity of a1PI versus concentration fit the equation I = 406.8 * 
conc/ (242 + conc),  where I is infrared intensity and conc is nM of serpin.  Substituting the 
value of 136.1 infrared units for I and solving for conc resulted in the concentration of 115.8 
nM  for the HATpin, over four times less than estimated by A280. This measurement of 
HATpin concentration permits the more accurate evaluation of its kinetic inhibitory 
properties. 
 
Inhibition of Serine Proteases in the Presence and Absence of GAGs  
The goal of this project was to engineer a serpin with the GAG-binding 
characteristics and thrombin specificity of both HCII and AT, that was able to inhibit factor 
Xa, but was a poor APC inhibitor.  To evaluate these properties, we measured the inhibition 
of α-thrombin, γ-thrombin, factor Xa and APC in the presence and absence of UFH, 
dermatan sulfate and LMWH.   HATpin inhibits α-thrombin and γ-thrombin in the absence 
of heparin at the respectable second order rates (k2) of  1.89  x 105 M-1 s-1 and 1.19  x 105 M-1 
s-1,  respectively.  Similar to AT and HCII, the rates of α-thrombin and γ-thrombin inhibition 
by HATpin exhibit a heparin template curve with increasing concentrations of UFH.  The 
second order rate constants of inhibition increased at moderate concentrations and decreasing 
with high concentrations (Figure 4.7). However, the peak acceleration is less than two-fold 
(Table 4.2), so the heparin acceleration is considerably diminished compared to either HCII 
or AT with UFH.  Furthermore, if the acidic domain of HATpin was contributing to thrombin 
inhibition in the same way that it does with HCII, we would expect to see a reduction in the 
fold-acceleration of heparin with γ-thrombin as compared to α-thrombin which we do not 
observe. HATpin did not show accelerated thrombin inhibition in the presence of dermatan 
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sulfate.  Increasing concentrations systematically decreased HATpin’s inhibition of α-
thrombin at maximum dermatan sulfate tested (~ 40 μM) to approximately 75% of the rate of 
thrombin inhibition seen in the absence of GAGs (data not shown).  Dermatan sulfate had no 
effect on the rate of γ-thrombin inhibition by HATpin.  Factor Xa was inhibited by HATpin. 
In the absence of GAGs, factor Xa was inhibited with a k2 of ~ 3.5 x 105 M-1 s-1. This rate 
was enhanced ~ 2-fold by the presence of either UFH or LWMH (Table 4.2), but required 
more heparin than the peak acceleration of α- or γ-thrombin by HATpin (Figure 4.7).  
HATpin inhibited APC with a second order rate of inhibition of 4.6 x 104 M-1 s-1. UFH did 
not accelerate this inhibition. Rather, the rate of APC inhibition decreased with increasing 
UFH concentrations to 41% of it inhibition of APC in the absence of GAGs. 
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Figure 4.7 Inhibition of serine proteases by HATpin in the presence of GAGs.  Closed symbols 
represent data with UFH and open symbols represent data with LMWH. Red circles (●) show 
inhibition of α-thrombin, blue squares (■) show inhibition of γ-thrombin, green triangles (▲,U) 
show inhibition of factor Xa, and purple diamonds (♦) show inhibition of APC. 
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Table 4.2 Acceleration of HATpin Inhibition of Serine Proteases by Unfractionated and Low 
Molecular Weight Heparin.  
 
 
 
k2 (M-1 s-1) 
no GAG 
k2 (M-1 s-1) 
at peak 
fold 
acceleration 
[GAG] 
(μM) 
α-thrombin  (UFH) 1.89E+05 2.41E+05 1.3 3.33 
γ-thrombin (UFH) 1.11E+05 1.46E+05 1.3 6.67 
factor Xa  (UFH) 2.96E+04 7.25E+04 2.4 33.3 
factor Xa  (LMWH) 4.11E+04 9.32E+04 2.3 66.7 
     
 
Stoichiometries of Inhibition of Serine Proteases in the Presence and Absence of GAGs  
 In order to determine whether the structural combinations we engineered on HATpin 
had caused it to become a substrate for any of the serine proteases of interest, either in the 
presence or absence of GAGs,  we determined the stoichiometries of inhibition.  Results are 
shown in Table 4.3.  The stoichiometries of inhibition for HATpin with all of the serine 
proteases measured is either with or without GAG is close to 4 except for γ-thrombin which 
is nearer 3.   GAGs did not affect the stoichiometries. This data suggests that HATpin is 
acting to some degree as a substrate for these serine proteases. 
 
Table 4.3 Stoichiometries of inhibition for HATpin with serine proteases in the presence and absence 
of GAGs. 
GAG α-thrombin γ-thrombin factor Xa APC 
None 4.0 3.3 4.3 3.7 
heparin 4.2 3.0 3.8 4.1 
dermatan sulfate 4.0 3.1   
low molecular weight heparin   3.8  
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DISCUSSION  
 The overall goal of this project was to create a novel serpin, a chimera with structural 
elements from HCII, AT, and α1PI, with specifically enhanced protease inhibitory activities 
in the presence of GAGs.  After much effort, the recombinant protein, HATpin, was 
successfully created, expressed, purified, and characterized.  The expected unique inhibitory 
properties of HATpin were never realized, and while the results showed it to be a formidable 
protease inhibitor in its own right, the unique selectivity for thrombin and factor Xa, and not 
for APC, in the presence of either heparin or dermatan sulfate were not apparent.  We discuss 
the evidence for having successfully engineered HATpin and we present a logical 
supposition for the deviation of its inhibitory profile from that which was anticipated. 
The results indicate that while HATpin has heparin binding capacity and is able to 
inhibit thrombin and factor Xa, it does not fit the inhibitory profile for which it was designed.   
HATpin possesses a D-helix homologous to HCII.  This was included so that the inhibition 
of thrombin would be accelerated by both heparin and dermatan sulfate. Based on the results 
presented in Chapter 3, we expected that the incorporation of the D-helix of HCII would 
allow for heparin acceleration of α-thrombin inhibition of no less than 15-fold.  Additionally, 
it was presumed that including the entire D-helix sequence and other critical heparin binding 
residues such as Lys173279, Arg106 and Lys101337 that heparin binding and therefore 
HATpin activation, would increase compared to the mutant made in Chapter 3.  This was not 
the case.  Furthermore, while the ability of HATpin to bind Heparin-Sepharose as a function 
of ionic strength was increased over α1PI, it was still less able to bind heparin compared to 
both α1PIPitt-GAG (See Chapter 3.) and HCII.  Moreover, HATpin shows no dermatan sulfate 
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accelerated activity at all; dermatan sulfate causes the rate of HATpin inhibition of thrombin 
to decrease. 
The N-terminal acidic domain of HCII was included to increase HATpin’s specificity 
for thrombin and specifically, to utilize thrombin’s exosite 1.  Results from the inhibition of 
HATpin with α− and γ-thrombins suggest little difference in the inhibition of the proteases in 
the absence of GAGs and no difference in the acceleration by UFH. This would suggest that 
the N-terminal acidic domain is not free, even in the presence of UFH to interact with exosite 
1 of thrombin.  The reduced interaction of HATpin with Heparin-Sepharose compared to 
HCII might also imply that the acidic domain might be more closely associated with its D-
helix region than in HCII itself . 
The RCL sequence of HATpin was designed based on a study109 which showed that 
mutating the P7 - P3' residues of α1PIPittsburgh to those of AT reduced the inhibition of APC 
over 12,000-fold, while having a miniscule effect on thrombin inhibition.   On the contrary, 
the rate of APC inhibition by HATpin is comparable to that reported for α1PIPittsburgh (Table 
4.4).  One possible explanation is the use of wild-type α1PI in the former study and the use 
of a stabilized a1-protease inhibitor cDNA coupled with the acidic and D-helix domains of 
HCII in our study.  It is possible that these different scaffolding somehow altered the 
equilibrium between the chimera and APC so as to maintain its ability to inhibit APC.  
 Such a discrepancy in the expected inhibitory profile versus actual inhibitory profile 
of HATpin, along with the protein migrating at a slightly lower molecular weight (~45 kDa) 
than predicted (~50 kDa), did prompt the question, “Did we really express and purify 
HATpin or is the protein that we purified, some cleaved or incomplete version of HATpin?” 
The evidence strongly supports that our protein is indeed HATpin.   
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 First, sequence analysis confirmed that the cDNA we synthesized coded for HATpin.  
The cDNA had been ligated into an empty vector, and therefore, any protein expressed by the 
E. coli must be some form of HATpin or an E. coli protein. Second, our purified protein 
shows anti-polyhistidine antigenic activity.  This indicates that the N-terminus is intact. 
Third, the HATpin protein reacted with antibodies directed at human proteins, specifically, 
HCII and α1PI. This confirms that the protein we have purified is indeed some version of 
HATpin, including structural elements of both HCII and α1PI.  Fourth, our protein 
complexes with, and is able to inhibit thrombin, demonstrating the structural integrity of the 
RCL.  Finally, the rates of protease inhibition measured indicate that the C-terminus is also 
intact. The RCL sequence is near (35 residues from) the C-terminus of HATpin. Although 
the apparent molecular weight of HATpin as estimated by gel mobility was ~ 45 kDa, which 
is remarkable similar to the theoretical weight of HATpin deleted after the RCL (~46 kDa), 
the residues in the C-terminus contribute to major serpin structures (the C-Sheet, the B-sheet 
and the I-helix)264. Deletion of these residues has been shown to drastically reduce serpin 
activity338,339.  Based on our kinetic data,  HATpin is a very active serpin which substantiates 
our conviction that HATpin is full-length.  Additionally, it is well documented that protein 
characteristics other than molecular weight influence migration on SDS-PAGE340,341.    
Collectively, these results establish that our protein has a full-length N-terminus, components 
of HCII and α1PI and an intact reactive site loop that is capable of inhibiting thrombin, factor 
Xa and APC.  
Confident that we expressed and purified an intact HATpin, it is interesting to 
consider its protease inhibitory profile.  HATpin is a better thrombin inhibitor in the absence 
of GAGs than both HCII and AT, and only slightly less active than α1PIPittsburgh (Table  4.4).  
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Moreover, it is a better inhibitor of factor Xa than HCII, α1PIPittsburgh and AT in the absence 
of GAGs.  Nonetheless, HATpin falls short of its desired profile primarily in two realms, 
GAG-accelerated activity and APC inhibition.  Despite the presence of the entire region of 
HCII that has been identified as critical for both heparin and dermatan sulfate binding, 
HATpin is miserly in its response to GAGs.   
 
Table 4. 4. Comparison of second order rates of inhibition of serine proteases by HATpin and other 
serpins in the presence and absence of GAGs.  Rates for HATpin are gathered from this study.  Other 
rates, unless specified have been extracted Chapter 1, Table 1.151. 
Protease GAG 
Serpin 
HATpin α1PIPittsburgh HCII AT 
α – 
thrombin 
- 1.89 E+05 4.8E+05 6 E+02 1 E+04 
UFH 2.41 E+05  5 E+06 2 E+07 
dermatan sulfate   1 E+07 5.3 E+06 
factor Xa 
- 3.54 E+04 1.07 E+04‡ 0229* 6 E+03 
UFH 7.25 E+04  1.7 E+02229** 6.6 E+06 
LMWH 9.32 E+04   1.3 E+06 
APC - 4.69 E+04 3.54 E+04 4.4 E+01229* 0.014 E+01342 
* at 37° C. ‡ J. Rau data not published. 
 
The D-helix-based α1PIPittsburgh mutant, α1PIPitt-GAG (See Chapter 3.) showed 15-fold 
acceleration of thrombin inhibition with heparin with some evidence of conformational 
change. In a different study, Sutherland et al.302 fused the N-terminal extension of HCII onto 
α1PIPittsburgh and saw a 21-fold increase in thrombin inhibition. We postulated that the 
addition of the entire N-terminal acidic domain along with the HCII heparin binding region 
would result in at least the additive if not multiplicative acceleration of thrombin inhibition in 
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the presence of heparin. It seems that the interaction of these elements (and perhaps the RCL 
sequence) has eliminated the benefits of both structural elements when placed together on a 
serpin without their native additional components.  
 The spatial relationship of the acidic domain of HCII has not been confirmed by 
crystallography152.  However, based on molecular biological and biochemical experiments 
with HCII, it has been proposed that negatively charged residues of the acidic domain 
interact with the positively charged residues in and around the D-helix.  In authentic HCII 
this is a powerful combination that triggers an allosteric mechanism when GAGs bind to the 
D-helix, releasing the N-terminal acidic domain for the binding of thrombin exosite 1.  We 
speculated that a similar relationship would exist in HATpin.  However, HATpin may not 
contain necessary structural elements of HCII  that facilitate this mechanism, perhaps 
maintaining a stronger ionic interaction between acidic domain and its D-helix region than in 
HCII.  We conjecture that the acidic domain of HATpin may have tighter or more substantial 
interactions with the D-helix which limit its heparin binding and also restrict its full 
molecular flexibility. This would explain its reduced protease inhibitory profile and also its 
GAG-binding properties. 
The APC inhibition by HATpin in the face of the P7-P3' RCL substitutions is 
puzzling.  Hopkins et al.109 originally substituted the RCL of AT from P7-P3' into 
 α1PIPittsburgh and showed over 12,000-fold reduction in APC inhibition.  However, 
Sutherland et al.343 substituted the P7-P2' onto a  α1PIPittsburgh mutant containing the N-
terminus of HCII through the acidic domain, and observed only a 140-fold decrease in APC 
activity. While still a large reduction in APC inhibition, it is closer to our results than those 
of Hopkins et al.109 We speculate that that the acidic region itself has an influence on the 
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difference in altered rates for APC inhibition compared to the substitution of  RCL onto 
 α1PIPittsburgh with no acidic domain.   We therefore reason that not only the HCII acidic 
domain, but also the additional HCII structure in HATpin, acts to reduce the effect of the 
mutated RCL resulting in the negligible reduction in APC activity that we observed. 
 Overall, the inhibitory profile of HATpin indicates that there is still much to be 
learned about the structure-activity relationships in serpins.  While substitution of one 
domain or small stretches of amino acids for another between molecules is sometimes 
successful, replacement of large portions may distort either or both the donor and recipient 
proteins to the end that the domains do not function as expected. It would be interesting to 
continue to pursue the reasons why HATpin failed to meet its inhibitory potential, and 
continue to assess both the strategy and the process used to engineer this chimera.  It would 
likely provide us more knowledge about HCII, AT, α1PI and serpin engineering in general.  
In closing, one must consider that it may be best to embrace the adage reaffirmed by HATpin 
and the strategy to improve on serpin activity, “Mother,” Mother Nature that is, “knows 
best.”  
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CHAPTER 4 SUPPLEMENTAL MATERIAL 
 
 
   1 atgagaggatcgcatcaccatcaccatcacggatccattccagagggcgaggaggacgac 60 
   1  M  R  G  S  H  H  H  H  H  H  G  S  I  P  E  G  E  E  D  D 20 
  61 gactatctggacctggagaagatattcagtgaagacgacgactacatcgacatcgtcgac  120 
  21   D  Y  L  D  L  E  K  I  F  S  E  D  D  D  Y  I  D  I  V  D  40 
 121 agtctgtcagtttccccgacagactctgatgtgagtgctgggaacatcctccagcttttt  180   
  41  S  L  S  V  S  P  T  D  S  D  V  S  A  G  N  I  L  Q  L  F   60 
 181 catggcaagagccggatccagcgtcttaacatcctcaacgccaagttcgctttcaacctc  240 
  61  H  G  K  S  R  I  Q  R  L  N  I  L  N  A  K  F  A  F  N  L   80 
 241 taccgagtgctgaaagaccaggtcaacactttcgataacatcttcatagcacccgttggc  300 
  81  Y  R  V  L  K  D  Q  V  N  T  F  D  N  I  F  I  A  P  V  G   100 
 301 atttctactgcgatgggtatgatttccttaggcctgaagggagagacccatgaacaagtg  360   
 101  I  S  T  A  M  G  M  I  S  L  G  L  K  G  E  T  H  E  Q  V   120 
 361  cactcgattttgcattttaaagactttgttaatgctagcagcaagtatgaaatcacgacc 420  
 121   H  S  I  L  H  F  K  D  F  V  N  A  S  S  K  Y  E  I  T  T  140  
 421  attcataatctcttccgtaagctgactcatcgcctcttcaggagggacagccagctccag  480 
 141   I  H  N  L  F  R  K  L  T  H  R  L  F  R  R  D  S  Q  L  Q  160 
 481  ctgaccaccggcaatggcctgttcctcagcgagggcctgaagctagtggataagtttttg  540 
 161   L  T  T  G  N  G  L  F  L  S  E  G  L  K  L  V  D  K  F  L  180 
 541  gaggatgttaaaaagttgtaccactcagaagccttcactgtcaacttcggggacaccgaa   600 
 181   E  D  V  K  K  L  Y  H  S  E  A  F  T  V  N  F  G  D  T  E  200 
 601  gaggccaagaaacagatcaacgattacgtggagaagggtactcaagggaaaattgtggat   660  
 201   E  A  K  K  Q  I  N  D  Y  V  E  K  G  T  Q  G  K  I  V  D  220 
 661  ttggtcaaggagcttgacagagacacagtttttgctctggtgaattacatcttctttaaa   720 
 221   L  V  K  E  L  D  R  D  T  V  F  A  L  V  N  Y  I  F  F  K  200 
 721  ggcaaatgggagagaccctttgaagtcaaggacaccgaggaagaggacttccacgtggac  780  
 241   G  K  W  E  R  P  F  E  V  K  D  T  E  E  E  D  F  H  V  D  260 
 781  caggtgaccaccgtgaaggtgcctatgatgaagcgtttaggcatgtttaacatccagcac  840 
 261  Q  V  T  T  V  K  V  P  M  M  K  R  L  G  M  F  N  I  Q  H  280 
 841 agcaagaagctgtccagctgggtgctgctgatgaaatacctgggcaatgccaccgccatc   900 
 281   S  K  K  L  S  S  W  V  L  L  M  K  Y  L  G  N  A  T  A  I  300 
 901  ttcttcctgcctgatgaggggaaactacagcacctggaaaatgaactcacccacgatatc  960 
 301   F  F  L  P  D  E  G  K  L  Q  H  L  E  N  E  L  T  H  D  I  320 
 961  atcaccaagttcctggaaaatgaagacagaaggtctgccagcttacatttacccaaactg  1020 
 321  I  T  K  F  L  E  N  E  D  R  R  S  A  S  L  H  L  P  K  L  340 
1021  tccattactggaacctatgatctgaagagcgtcctgggtcaactgggcatcactaaggtc  1080 
 341  S  I  T  G  T  Y  D  L  K  S  V  L  G  Q  L  G  I  T  K  V   360 
1081  ttcagcaatggggctgacctctccggggtcacagaggaggcacccctgaagctctccaag  1140 
 361   F  S  N  G  A  D  L  S  G  V  T  E  E  A  P  L  K  L  S  K  380 
1141  gccgtgcataaggctgtgctgaccatcgacgagaaagggactgaagctgctggggccatg  1200 
 381   A  V  H  K  A  V  L  T  I  D  E  K  G  T  E  A  A  G  A  M  400 
1201  gctgtagtgatcgcaggcagatctctcaaccccgaggtcaagttcaacaaaccctttgtc  1260 
 401   A  V  V  I  A  G  R  S  L  N  P  E  V  K  F  N  K  P  F  V  420 
1261  ttcttaattattgaccaaaataccaaggctcccctcttcatgggaagagtggtgaatccc  1320 
 421  F  L  I  I  D  Q  N  T  K  A  P  L  F  M  G  R  V  V  N  P  440 
1321  acccaaaaataa 
 441  T  Q  K  - 
 
 
Figure 4. S1.  cDNA for coding region of HATpin with corresponding amino acid sequence.  
pQE30 vector sequence is in black. Homologous HCII sequence (residues 13 - 155) is in red. 
Homologous α1PIPittsburgh sequence (residues 156 - 400 and 411 - 442) is in blue.  Homologous AT 
sequence (residues 401 - 410) is in green. 
  
CHAPTER 5 
Future Directions  
 
 "The important thing in science is not so much to obtain new facts as to discover new 
ways of thinking about them."  Sir William Bragg 
 
 "The most exciting phrase to hear in science, the one that heralds new discoveries, is 
not "Eureka!" (I found it!) but "That's funny..." Isaac Asimov 
 
 Science has the habit of creating as many questions as it answers and the science 
performed for this dissertation is no exception.  This Chapter recapitulates the overall 
findings of this dissertation and presents future directions that would be useful to perpetuate 
the science described in the preceding Chapters. 
 
Immunologic Detection of Plasma Proteins in Normal and Atherosclerotic Vessels   
Chapter 2 asked the questions, “Is heparin cofactor II (HCII) present in 
atherosclerotic lesions, does it co-localize with thrombin and is there a relationship between 
these proteins and the severity of the atherosclerosis?”  The results of immunohistochemical 
and immunoblot analyses indicated that HCII is present in atherosclerotic lesions, and it co-
localizes with (pro)thrombin in lipid-rich regions and necrotic cores of the atheromas. A 
positive correlation between plaque severity and protein staining for both HCII and 
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(pro)thrombin was observed.  Interestingly, it was discovered that antithrombin (AT) is also 
present in the same location and its staining intensity was also positively correlated with 
plaque severity.  Because prior scientific evidence suggests that AT does not act in 
atherosclerosis, this result was surprising. Therefore, to further investigate the specificity of 
the presence of HCII in the atheroma, we probed for another serpin α1-protease inhibitor 
(α1PI) and another liver-derived protein of similar molecular weight, albumin; both of these 
proteins were present in the same location as HCII, (pro)thrombin and AT.   
A search of the literature revealed that many additional plasma proteins are reportedly 
found in the same region of the atheroma. This lead us to the hypothesis that due to increased 
permeability of the endothelium in atherosclerosis, the lipid-rich and necrotic core regions of 
atheromas act as a watershed, trapping circulating plasma proteins in the degraded matrix and 
extracellular debris.  Additionally, fibrin has been detected in atheromas.  Because fibrin is 
synthesized as a zymogen in the liver and must be generated through activation of the 
coagulation pathway, it follows that one possibility for the fibrin deposition in the 
atherosclerotic plaques is activation of the coagulation cascade. If our watershed hypothesis 
is true, this follows as coagulation factors would permeate the atheroma coming into contact 
with tissue factor that is present in the intima, and coagulation would be initiated.  This does 
suggest however, that fibrinogen, having a molecular weight of over 300 kDa can enter the 
atheroma.  Confirmation of this hypothesis would have implications for the thrombogenicity 
of non-ruptured atherosclerotic plaques and for their treatment and prevention.  
The results of Chapter 2 beget the questions “Are the clotting factors, either in their 
active or zymogen form, present in atherosclerotic lesions?” “Are additional serpins present 
in atheromas?”  To address these questions, one could probe additional sections for 
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coagulation factors, in particular factors VII(a),  X(a), and V(a) as these are directly involved 
in tissue factor binding and thrombin activation.  Regarding serpins, probing for α1-
antichymotrypsin, angiotensinogen, plasminogen activator inhibitor-type 1 and type 2, and 
protein C inhibitor might offer additional clues supporting the watershed versus specificity 
issues for serpins in atheromas.  Additionally, for the curious, one could probe for fibrinogen 
to address the question, “Does fibrinogen enter the plaque through the endothelium, or is it 
deposited as fibrin through another mechanism such as by scavenger macrophages?”  
Alternatively, fibrinogen synthesis by the inflammatory cells of the atheroma could be 
investigated by in situ hybridization and the polymerase chain reaction (PCR) applied to 
mRNA in frozen sections. 
The utility of fixed histological slides is somewhat limited.  Because of this, we 
secured fresh aortic samples containing either normal or atherosclerotic lesions for 
examination.  Protein extracted from these vessels was subjected to SDS-PAGE and analyzed 
by immunoblot, providing the opportunity to distinguish between thrombin, prothrombin and 
complexed thrombin.  Results from this study definitively showed prothrombin in all the 
samples, and thrombin in one sample.  HCII was also detected, but no HCII complex could 
be visualized.  
 The lack of serpin-protease complex detection does not indicate that HCII 
does not inhibit thrombin in atherosclerosis. Rather, it is simply an indication that HCII-
thrombin complex is undetectable using the method employed.  However, having the 
vascular tissue homogenized and the proteins solubilized provides additional opportunities to 
approach this problem. With the solubilized normal and atherosclerotic vessel one could 
perform Enzyme Linked ImmunoSorbent Assays (ELISA) probing specifically for HCII, 
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thrombin and also HCII-thrombin combinations.  This method would not be subject to total-
protein concentration that can be loaded into a gel and therefore should be more sensitive to 
antigenic detection.  Finally, the preparation of an antibody specific for the neo-antigenic 
epitope expressed by the HCII-thrombin complex would be an extraordinarily helpful reagent 
to further probe these tissues. 
 
Transfer of GAG-binding Properties to a Non-GAG -Binding Serpin 
Chapter 3 asked the questions, “Can the glycosaminoglycan (GAG)-binding 
properties of HCII be transferred to the non-GAG binding serpin, α1PI, through mutation 
residues on its D-helix to the homologous basic residues in the D-helix of HCII?” and “Can 
such gain-of-function approach to the study of serpin structure provide useful information 
that can be generalized to serpins?”  The results of this chapter indicate that HCII-like GAG-
binding properties can indeed be conferred upon the non-GAG binding serpin α1PI. 
Additionally, these results provide useful information regarding the GAG-accelerated activity 
of thrombin-inhibiting serpins.   In this study, we observed a ~15-fold acceleration of 
thrombin inhibition in the presence of unfractionated heparin (UFH) and ~ 2-fold 
acceleration in the presence of dermatan sulfate. Based on results using exosite variants of 
thrombin and extrinsic fluorescence changes, we concluded that 2-fold acceleration could be 
contributed to conformational changes in the serpin rather than bridging.  To further 
substantiate these conclusions, it would be beneficial to examine the GAG-accelerated 
inhibition of thrombin by fractionated heparins that are unable to bridge the serpin and 
thrombin to form a ternary complex. 
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 Only five residues on the D-helix of α1PI were mutated to become positively 
charged and homologous with those of HCII.  Several other residues in HCII have been 
identified as being important in GAG binding, generating the question, “Can GAG-binding 
and its acceleration of thrombin-inhibition be enhanced by the mutation of additional 
residues?”  Also, the mutated D-helix of our GAG-binding mutant, α1PIPitt-GAG, contained 
one negatively charged residue that HCII does not possess.  Thus we ask, “Does the 
remaining negatively charged residue in α1PIPitt-GAG effect the GAG-binding? Finally, we 
employed α1PIPittsburgh as the primary scaffolding for our mutations due to its rapid thrombin 
inhibition and thus ease of inhibitory measurements.  However, the rates of thrombin 
inhibition without GAG-accelerated activity are extremely fast. One must wonder whether an 
absolute maximum rate of thrombin inhibition has been reached with a 15-fold increase of 
this already rapid rate of inhibition. “Could the rate of thrombin inhibition be accelerated 
greater than ~15-fold if the baseline rates of thrombin inhibition were not so fast?”  All of 
these questions could be addressed with molecular studies much like those already performed 
in Chapter 3.  Serial mutations of residues homologous to Lys173, Arg106 and Lys101 
would provide additional information regarding the role of these residues in GAG-binding. 
Mutation of the negatively charged Glu89 in α1PI to its homologous residue in HCII (Ile) 
would inform us of the role of opposing electric charges in this region.  Would mutating the 
reactive center residue from Arg358 to Leu to make it more “HCII-like” provide another 
novel manner to study the GAG-activation process in this recombinant serpin?  Finally, 
mutating the D-helix of α1PI in the same way as we did α1PIPittsburgh, would increase our 
understanding of maximal rates of protease inhibition.  
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Creation of the Novel Chimeric Serpin, HATpin 
 Chapter 4 asked the question, “Can we engineer a chimeric serpin with the combined 
beneficial properties of HCII, AT and α1PIPittsburgh through the assembly of specific structural 
regions from each protein?”  While we were able to synthesize the cDNA, and express and 
purify the HATpin protein, its inhibitory profile disappointed. Three questions roared to mind 
when examining the data generated in this study, “Why doesn’t HATpin exhibit the expected 
inhibitory profile?”, “Could a slightly modified version of HATpin have the desired 
inhibitory activity?” and “Is the natural scaffolding of HCII with its acidic domain and 
glycosamoglycan-binding region uniquely dependent on its overall structure?”   
 We hypothesized that the acidic domain of HATpin interacts too strongly with its D-
helix and that without some unknown critical structural component of the HCII native 
structure, the acidic domain remained bound to the D-helix and impaired GAG-binding.  
Additionally, we theorized that the large amount of HCII structure somehow decreased the 
effect of the reactive center loop (RCL) mutations so that activated protein C (APC) 
inhibition was not decreased.  To test both of these hypotheses, one could engineer a serpin 
based on a combination of α1PIPitt-GAG and the acidic domain fusion protein, HAPI, created 
by Sutherland et al.302.  This protein would not contain the large amount of HCII sequence 
between the D-helix and the acidic domain that is present in HATpin.  It would only contain 
the two separate structural regions that have already been proven to separately accelerate 
thrombin inhibition.  Any deviations from anticipated inhibitory profiles could be more 
easily attributed to interaction between the two regions rather than some other unidentifiable 
structural component.  The RCL of AT could subsequently be transposed onto this protein 
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for further analysis and alternative approach to creating an ideal HATpin-like protease 
inhibitor.   
 Another consideration would be to recreate HATpin on a wild-type scaffold rather 
than the stabilized α1PI backbone.  In the creation of HATpin we generated the cDNA for an 
intermediate chimeric protein, it might be informative to examine the inhibitory profile of 
this protein compared to HATpin to see what the effect the RCL sequence mutation had on 
the protein as a unit. Finally, we have begun dialog with the UNC-CH Proteomics Core 
Facility to investigate the peptide components of HATpin and other minor products in the 
HATpin preparation in an attempt to understand the composition of HATpin, its expression 
chaperones and its degradation products. 
In conclusion, despite the many questions generated by the research carried out for 
this dissertation, the scientific investigation has proved useful not only in educating and 
training me for my future career, but also to the advancement of the understanding of serpins 
in vascular pathophysiology and their manipulation for its treatment. 
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